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Recently, remarkable progress has been made in the area of preclinical 
xenotransplantation experiments. Surprisingly, a heterotopic heart from the gene-
editing pig continued to beat for almost 2.5 years, when implanted in the monkey 
abdomen, and a pig life-supporting kidney could also function for over 1.3 years in 
monkeys. Concerning islets, islets from gene-editing pigs could work for more than 
one year in monkeys. It is noteworthy that one group reported a survival of adult wild-
type pig islets of over 600 days. On the other hand, the progress in these preclinical 
trials strongly affected not only the xenotransplantation study itself but regeneration 
studies to use pigs as a scaffold to foster human induced pluripotent stem cells.
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Preface
It is a great honor for me to edit the third version of Xenotransplantation in
IntechOpen’s Xenotransplantation – Comprehensive study. Since the second 
version, almost two years have passed. During this period, the 3rd WHO Global 
Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials
in Changsha-2018, the 14th IXA-2017 in Baltimore, and the 15th IXA-2019 in Munich
were held. This field seems to be progressing quickly. Now, in a sense, we are stand-
ing at the dawn of the age for xenotransplantation.
As the most imminent issue for clinical xenotransplantation, this version first
focused on pig islets transplantation. Several authors wrote about it from their own
point of view. The new Regulation by WHO in Changsha is discussed.
In addition, a past clinical case including the review of heart xenotransplantation is
introduced.
Concerning the progress of preclinical xenotransplantation studies during these
years, the reported maximum survival days were more prolonged in several organs, 
as indicated below.
*Heart~heterotopic/Orthotropic: 945 days/195 days
*Kidney: 499 days, *Liver: 25 days, *Lung: 31 days
**Islets: 603 days, *Cornea: 903 days
(**: reported in the past, using wild-type pigs)
On the other hand, as the technology progresses, especially the CRISPR/Cas9 sys-
tem, many new genetic engineered (GE) pigs are produced all over the world, such
as the quadripartite knockout (KO) pigs [αGal/CMAH/β4GalNT2/SLAclassI-KO],
the tripartite KO plus six genes transgenic (TG) pigs [αGal/CMAH/β4GalNT2-KO +
CD46/CD55/CD47/TBM/EPCR/HO1-TG], and [αGal/CMAH/β4GalNT2-KO +
CD46/CD55/CD47/TBM/EPCR/Lea29Y-TG]. These pigs were also introduced in the
last IXA-2019 in Munich. The data of the preclinical studies using these new GE pigs
will be reported in the next meeting and they must process the data indicated above.
In addition, chapters for bio-engineering focus on two reviews related to 3D bio-
printing and decellularization. These field have also seen much progress.
Finally, this version contains several chapters related to regeneration studies, such
as “Blastocyst complementation” and “Organogenic niche method” that present the
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Biosafety Barrier to 
Xenotransplantation
Wei Wang, Qi Liang, Wei Nie, Juan Zhang and Cheng Chen
Abstract
Biosafety barrier is most important for xenotransplantation clinical trial. 
Source animals used in xenotransplantation should be bred in a closed herd and 
raised in a well-controlled, pathogen-free environment with high standards of 
animal welfare. To ensure the source animals’ freedom from known pathogens 
under adequate biosecurity and surveillance, extensive tests must be done. 
Biosafety of DPF source pig should be proved by animal model before clinical 
trial. In addition, inclusion criteria for transplant recipients and clinical safe 
transplantation protocol should be established. Comprehensive anti-immune 
rejection treatment based on immune tolerance program can significantly 
prolong the xenograft survival and reduce the adverse impact on the immune 
system, which is suitable for clinical application. According to the clinical follow-
up plan of the xenograft recipients, the patients should come back to the hospital 
for a check at regular intervals after the transplantation. The database of clinical 
trials for xenotransplantation should be established, including specimens, paper 
documents, and electronic documents. The information and samples of xeno-
transplantation donors and recipients should be preserved for long time.
Keywords: biosafety barrier, donor animal, xenotransplantation, clinical trial
1. Introduction
The demand for a new source of organs and cells for clinical transplantation has 
been exacerbated for decades. And xenotransplantation (e.g., from pigs to human) 
could resolve this issue.
In 2008, the WHO and International Xenotransplantation Association (IXA) 
released a consensus statement on xenotransplantation from pig to human for 
clinical trials. In this statement, it proposed the criterion for biosafety of source 
animals in clinical trials. The source animals should be bred in a closed herd for the 
purpose and kept under a well-controlled and pathogen-free environment with 
complete animal welfare. Even source animals are housed in appropriate biosecurity 
and under surveillance, extensive detection must be done to ensure freedom from 
known pathogens and infectious disease.
Therefore, this chapter will draw attention to the significant biosafety barriers 
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known pathogens and infectious disease.
Therefore, this chapter will draw attention to the significant biosafety barriers 
need to be overcome before xenotransplantation from pig to human can become a 
clinical therapy.
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2. DPF source pig
The term “DPF” (Designated Pathogen Free) is used to describe animals, animal 
herds, or animal facilities that have been rigorously documented to be free of speci-
fied infectious agents and that are maintained using well-defined routines of testing 
for designated pathogens and utilizing rigorous SOPs (Standard operating proce-
dures) and practices of herd husbandry and veterinary care to assure the absence of 
the designated pathogens [1]. So far, there is no normative document specifying the 
pathogens specified in DPF pig. DPF standards are dynamic and need to be updated 
over time according to the geographical environment of the animal population 
and new pathogens emerging. Generally speaking, there are two types of pathogens 
that need to be excluded from DPF pig: (1) Pathogens that affect animal health;  
(2) Pathogens that can cause cross-species transmission.
Experts in this field met to agree on the most comprehensive list of bacteria, 
fungi, parasites and viruses that should not be present in DPF pig [2]. Endogenous 
viruses are not listed. PERV (Porcine endogenous retrovirus) is the only one endog-
enous virus we known in pigs [3]. PERV has three subgroups including PERV-A, 
PERV-B and PERV-C. In general, PERV-A and PERV-B can infect both pig and 
human cells, but PERV-C can only infect pig cells. It is noteworthy that PERV-A/C 
recombine were be found in vitro co-culture system using cells from miniature 
swine, which means PERV-C can also infect human cells in some condition [4]. 
To monitor the status of DPF pigs, the pigs’ samples including blood, serum, tissues 
and feces must be tested regularly.
The DPF pigs must be raised in biosecure barrier environment. Biosecure barrier 
facility includes many aspects.
2.1 Facility environment and building
1. The proposed DPF facility will be sited at a property to be confirmed.
2. The building will be on rural land where there are no other pig farms within 
a radius of 10 km. The grounds of the facility will be protected and planted 
with trees, and the grass mowed regularly. There are to be no other animals or 
livestock within the area boundary.
3. The building is to be fully protected by a secure fence and electric gate entry. 
The main entrance door is also to be a security door with key access and pro-
tected by security alarms 24 hours a day.
4. The facility is designed with two separate areas, outside the barrier (external) 
and within the barrier (termed “inside the barrier”).
5. The external area houses a delivery bay, storerooms for feed and bedding, staff 
lunchroom facilities, office, laundry area, external change rooms, and rooms to 
supply goods through the barrier.
6. Inside the barrier, the building is to have a HEPA (High efficiency particulate 
air) -filtered air supply and it will only contain goods that are sterile, staff who 
have showered and are wearing sterile clothes, and the pigs themselves which 
will be free of all specified diseases. There are to be two rooms holding the pig 
pens, internal gown-up areas, office, treatment room, reception room, and 
feed and bedding storerooms.
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7. There will be two rooms of animal pens, a further unit for the sow farrowing, 
and a quarantine area, all with an air lock entry. The air pressure in all  animal 
areas will be positive to the corridors (monitored by magnehelic gauges). 
Rooms will have controlled fluorescent lighting, temperature and humidity, 
and 15 to 20 air changes per hour of HEPA -filtered air.
8. Animal pens will have gates of the metal farm type, allowing pigs to see out 
and receive physical contact from other pigs and staff, with aisles between 
pens and a drain running in front of each row of pens. There will be windows 
in the walls between each pen to allow pigs to see each other.
9. Each pen will have a valve supplying filtered drinking water and individual 
stainless steel bowls for feed.
10. Music will be piped into the units by speakers set into the ceiling and serviced 
from the mezzanine level. Music will be controlled from the main office.
2.2 Facility operation
1. The DPF facility will operate as a full sterile barrier facility. Therefore, all 
goods entering the facility must be sterile and all staff should go through a 
full shower procedure and gown-up in sterile suits, boots, hats and gloves. All 
original breeding stock in the facility will be cesarean-derived, colostrum-
deprived, and hand-reared.
2. To enter the facility, staff must shower and don a complete clothing and foot-
wear and wear gloves.
3. All activities that take place will be fully documented in the SOP Manual, 
including inwards receipt of goods through the facility barrier using such 
methods as an autoclave, dunk tank, and UV pass-through hatch.
4. There will be SOP-documented regular health screening of pigs and staff.
5. A comprehensive pest control system will be used inside and outside the build-
ing and managed by a contracted pest control company. Records of all inspec-
tions will be documented.
6. Pig care and welfare are a top priority, as described above for the Invercargill  
facility.
2.3 Health monitoring of DPF pigs
All pigs are uniquely identified and individual records should be maintained, 
including animal breeding and genetic records.
1. Regular veterinary should attendance at the pig facilities ensures that the staff 
is trained in disease recognition and that the veterinarian is called immediately 
in the event of signs and symptoms of disease in any animal. The veterinarian 
should report any such incident in writing.
2. The donor herd should continue to test the porcine pathogens and parasites.
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3. All donor piglets should be necropsied by a veterinarian within 6 hours of cell 
harvesting. Any pathological changes must be noted and appropriate speci-
mens taken. The veterinarians’ report should be documented.
4. Donor piglet tissue retention samples collected include brain, heart, kidney, 
liver, lung, pancreas, and spleen. Duplicate samples are stored at 80°C in two 
separate locations.
5. Duplicate donor piglet serum retention samples are also stored in two separate 
locations.
6. In addition, duplicate final product retention samples are stored at 80°C in two 
separate locations.
7. A positive result in any of the infection monitoring tests described in this section, 
will lead to the donor animal and the batch of isolated islets being discarded.
The pigs are conveyed to the DPF breeding center. They must be disinfected in buffer 
rooms before entering inspection and quarantine where they are isolated for a month. 
After isolation the pigs give cesarean birth to the first generation of purified pigs. 
Compared to vaginal births Cesarean section can eliminate or reduce the risk of infect-
ing with pathogens from sow’s vajina. These newborns are fed in isolation under aseptic 
conditions and grow into adulthood. They are then impregnated and naturally deliver 
the second generation. After being tested for specified pathogens this second generation 
enters into a DPF area. The first generation of pigs should not be used as source pigs but 
the pigs in a second or higher generation can be used as DPF source pigs [1, 5].
3. Other biosafety issues for xenotransplantation clinical trials
Donor pigs are the basis for ensuring the biosafety of xenograft clinical trials. 
Other biosafety issues are also worthy of attention, including immunosuppression 
protocols, clinical treatment protocols, sample/data retention programs, and case-
tracking programs.
3.1  Immunosuppression and tolerance-inducing strategies for 
xenotransplantation
The principal challenges that must be faced to make xenotransplantation a clini-
cal reality, which include determining a repeatable strategy for efficient preparation 
of xenogeneic tissues and organs and tracing the potential transmission of porcine 
pathogens to human. In addition, it is necessary to overcome the rejection barrier 
with clinically practicable immunosuppression and tolerance induction strate-
gies. The application of xenotransplantation faces insurmountable immunological 
barriers, including: (1) hyperacute rejection (complement activation mediated by 
antibody) which is trigged by natural xenoreactive antibodies against Gal (1,3) and 
non-Gal antigens, (2) acute rejection of humoral xenograft which is mediated by 
antibodies that are dependent on T cells, (3) acute cellular xenograft rejection due 
to T cell mediated cellular responses.
3.1.1 Immunosuppression protocols for xenotransplantation
Continuous administration of multiple immunosuppressive drugs has been 
required and attempts to minimize immunosuppression. Immunosuppression in 
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preclinical models of xenotransplantation usually consists of B-cell and plasma cell 
therapeutics like Rituximab and Bortezomib in addition to the standard triple drug 
immunosuppression. One or more rounds of immuno-adsorption or plasmapheresis 
are essential to remove antibodies from the recipient’s circulation. These regimens 
are often associated with serious side effects such as pancytopenia and sepsis.
The xenogeneic T cell response is supposed to be similar to that of typical 
allogenic responses, even larger. Consider this challenging barrier, most success-
ful immunosuppressive therapy include a T cell depletion method like mono- or 
polyclonal anti-T cell antibodies, chemotherapeutic agents like cyclophosphamide, 
or whole body or thymic radiation therapy [6]. And anti-thymocyte globulin (ATG) 
is still the most commonly utilized option.
The engagement of TCR (T cell receptor) with foreign antigen without co-
stimulatory signal will lead to T cells unresponsive to the antigen (known as T-cell 
anergy), thereby suppressing antigen induced response. The possible mechanism 
was that the CTLA4Ig fusion protein blocked CD28/B7 co-stimulatory signaling of 
the primary pathway, which eventually induced differentiation bias of T helper cells 
(Th cells [7]). Anti-CD154 antibodies, known to be effective in blocking indirect 
pathway of allorecognition [6], is also a critical component of effective immuno-
suppressive strategies in preventing cellular rejection in pig-to-NHPs (Non-human 
primates) xenotransplantation [8] yet its clinical application is restricted due to 
high risk of thromboembolic complications [9]. However, in pig-to-NHPs models, 
immune tolerance achievement approached by utilizing co-stimulatory blocking 
agents and other immunosuppressants in long-term treatments.
The transgenic pigs expressing graft-protecting factors has been shown to 
require a less toxic immunosuppressive protocol [10] which gives another path 
to explore. Using advanced gene editing technologies, xenotransplantation from 
multitransgenic alpha-1,3-galactosyltransferase knockout pigs (GTKO pigs) has 
demonstrated marked prolongation of xenograft survival. In addition, the inci-
dence of hyperacute rejection was further reduced with organs from the GTKO pigs 
expressing one or more human complement-regulatory proteins (GTKO/hCRPs 
pigs), such as CD46, CD55, or CD59.
3.1.2 Tolerance-inducing strategies across xenogeneic immunological barriers
A better but much more complex approach is to try to achieve immunological 
tolerance to the xenograft. Three successful tolerance induction approaches have 
been explored in large animal models: the use of mixed hematopoietic chimerism 
[11, 12], T regulatory cells [13, 14] and thymic transplantation [15] . It has been 
demonstrated that tolerance is possible in humans by successful clinical applica-
tion of the mixed chimerism approach to renal transplantation [16] and by the T 
regulatory cell approach to liver allografts [17]. Despite the greater immunologic 
differences between species than within species, both mixed chimerism and thymic 
transplantation approaches have been shown to be capable of tolerizing human 
T cells to porcine xenografts in humanized mouse models [18]. Moreover, treat-
ment with in vitro expanded regulatory T cells (Treg) prevents porcine xenograft 
rejection in humanized NOD-SCID IL-2 receptor gamma null (NSG) mice by the 
suppression of the T cell-mediated graft destruction, which suggesting the feasibil-
ity of pig-to-primate xenograft tolerance.
For xenografts, the level of immunosuppressive agents needed to fully suppress 
immune responses is greater than for allografts, which would likely lead to greater 
side effects. Thus, adoption of tolerance strategies is inevitable. Even though current 
immunosuppression seems to be controlling T cell responses in long-term acceptors 
[19, 20], it appears likely that low levels of T cell-dependent antibodies [21] and 
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activation of innate responses still develop [22], potentially leading to xenograft 
loss. Tolerance induction has the potential to avoid such persistent immune reactiv-
ity and therefore overcome the antibody-mediated response as well. Although toler-
ance induction in vivo has not yet been achieved in pig-to-baboon models, recent 
results are encouraging that this goal will be attainable through genetic engineering 
of porcine donors. It may be that current and future suppressive regimens that 
fully suppress the immune system will function sufficiently to benefit rejection of 
xenograft. Regardless of application, the study of tolerance continues to provide an 
excellent way to explore the functioning and control the immune system.
3.2 Data archive for xenotransplantation clinical trials
A database of clinical trials for pig islet xenotransplantation should be estab-
lished, including specimens, paper documents, and electronic documents.
The information of xenotransplantation donors, including the number of ani-
mals, test reports, will be preserved for long time. All the samples will be prepared 
in duplicate and one for long-period preservation in −80° C refrigerator or liquid 
nitrogen tank. The information of transplant recipients and his/her spouses, such 
as name, hospital number, clinical data and patient records, will be recorded and 
maintained for long. When the patient comes to the hospital for review, the sample 
should be kept, including the following [23]: (1) all serum and plasma of the recipi-
ent and his/her spouse will be prepared in duplicate [24]; (2) storage of all samples 
at −80°C or liquid nitrogen tank for long time; (3) preservation of samples for 
post-transplant cytokine detection, pathogen detection, etc.; and (4) development 
of standard operating procedures.
3.3 Postoperative follow-up
The purpose of follow-up after xenotransplantation is to monitor the occur-
rence of rejection and adverse events. The goal of patient management is to 
improve their understanding of the disease, actively participate in and achieve 
partial self-management, improve compliance and achieve long-term survival and 
higher quality of life.
Postoperative follow-up of biosafety of clinical trials of recipients and spouses 
include: time-point, biosafety assays and treatment plan. (1) The patient and their 
spouses was reviewed 1 month before surgery, 1 month, 3 months, 6 months, 
12 months, 2 years, 3 years, 4 years, and 5 years after xenotransplantation, and the 
sample in duplicate was kept. (2) Biosafety assays include fungal, bacterial, para-
sitic, viral, nucleic acid, cytokine and lymphocyte population detection. (3) If the 
biosafety assays are negative, the patient continues the symptomatic treatment, but 
if positive, then quarantine and treatment, personal protection and report to CDC 
(Centers for Disease Control and Prevention).
The medical record about postoperative follow-up of a xenograft recipient 
must contain the following information including the recipient’s health status, 
all xenograft-related information, such as: (1) the contact information system of 
xenograft recipients. (2) If there is an infection related to xenotransplantation, or 
the pathogen from xenogeneic origin is identified, the health department of local 
government and the NHFPC(National health and family planning commission) 
shall be notified promptly. (3) The institution must have a reliable specimen and 
data preservation system and a complete information reporting system with the 
competent department. (4) The protocol must clearly address how patients are 
monitored for efficacy, biosafety, and period, including the draft clinical follow-up 
plan of xenotransplantation recipients.
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4. Conclusions
Source donor pigs fulfilling the Designated Pathogen-Free (DPF) status have 
been available from a closed colony by GMP(Good Manufacturing Practice) 
rigorous routines, operational SOPs and rigorous data retention. Above all are very 
important for the operation of GMP barrier facility for biosafety of DPF source 
pig. A list of designated pathogens has been excluded from the DPF donor pig by 
long-term monitoring program of microbiological surveillance and pathological 
diagnosis. In addition, the consistently known DPF animals should be bred, grown 
and developed normally in the closed colony.
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Islet transplantation is an effective treatment for insulin-dependent diabetes, 
but the shortage of donors is a problem. To overcome this, porcine islets have been 
widely studied as an alternative source. This chapter focuses on recent advances in 
porcine islet transplantation, placing particular emphasis on new transgenic pig 
models, islet encapsulation, and biological safety. Genetic modifications aimed 
at reducing the immunogenicity of islet cells to prolong graft survival or improve 
insulin secretory function have been reported. Microencapsulation and macro-
encapsulation of porcine islets may be able to control rejection with little or no 
immunosuppression. Also, the risk of porcine endogenous retrovirus infection is 
considered low because several clinical and preclinical studies have found no such 
evidence. Appropriate pathogen screening, animal selection, and microbiological 
and quality control measures should improve the safety and efficacy of porcine islet 
transplantation in future clinical trials.
Keywords: xenotransplantation, islet transplantation, porcine islet
1. Introduction
The islet transplantation protocol used for patients with type 1 diabetes, pub-
lished by a team of researchers at the University of Alberta in 2000, was called the 
Edmonton Protocol and became the starting point for clinical islet transplantation 
[1]. The characteristics of the Edmonton Protocol were that multiple transplants 
were performed using multiple donors to transplant sufficient amounts of islets, 
no steroids were used for immunosuppression, and transplants were performed as 
soon as possible after islet isolation.
Clinical results were reported 5 years after the Edmonton Protocol was 
announced [2], and several problems were identified. For example, the insulin-
free status is not sustained for a long time, the probability of being able to 
obtain islets of sufficient quality and quantity for transplantation even with 
islet isolation is about 50%, and there were many side effects, mainly from 
immunosuppressants.
Islet transplantation has been found to stabilize blood glucose levels and could 
prevent severe hypoglycemia, defined as hypoglycemia requiring another person’s 
assistance. Because severe hypoglycemia can be life-threatening for patients with 
type 1 diabetes, islet transplantation will likely be positioned as a measure for 
preventing severe hypoglycemia. Indeed, allogeneic islet transplantation is an estab-
lished treatment for severe hypoglycemia in Canada and other European countries. 
In addition, in 2016, a phase 3 clinical trial of allogeneic islet transplantation for 
type 1 diabetes patients with a history of severe hypoglycemia found that islet trans-
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Clinical results were reported 5 years after the Edmonton Protocol was 
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free status is not sustained for a long time, the probability of being able to 
obtain islets of sufficient quality and quantity for transplantation even with 
islet isolation is about 50%, and there were many side effects, mainly from 
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Islet transplantation has been found to stabilize blood glucose levels and could 
prevent severe hypoglycemia, defined as hypoglycemia requiring another person’s 
assistance. Because severe hypoglycemia can be life-threatening for patients with 
type 1 diabetes, islet transplantation will likely be positioned as a measure for 
preventing severe hypoglycemia. Indeed, allogeneic islet transplantation is an estab-
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type 1 diabetes patients with a history of severe hypoglycemia found that islet trans-
plantation has a preventive effect for severe hypoglycemia [3]. Therefore, allogeneic 
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islet transplantation has also come to be recognized as standard treatment for 
severe hypoglycemia in the United States. Data on allogeneic islet transplantation 
are registered in the Collaborative Islet Transplant Registry (CITR). According 
to CITR data, the C-peptide positivity rate after islet transplantation alone was 
80% after 1 year and 61% after 3 years, but the severe hypoglycemia prevention 
rate was 94 and 88%, respectively. This indicates that even if the concentration of 
C-peptide is below the lower limit of detection for a positive result (0.3 ng/ml), it 
would be effective in stabilizing blood glucose levels and preventing hypoglycemia. 
According to the data from the International Pancreas Transplant Registry, the 
pancreatic graft survival rate in simultaneous kidney and pancreas transplantation 
was 89% at 1 year and 82% at 3 years after transplantation. In other words, islet 
transplantation outperforms simultaneous pancreas and kidney transplantation 
in terms of rates of preventing severe hypoglycemia. The current status and direc-
tion of beta cell replacement therapy were discussed at a consensus meeting of the 
beta cell replacement therapy opinion leaders held at Oxford University in 2014 
[4]. According to the consensus report, there are 15–20 million patients with type 
1 diabetes worldwide, they are mostly at >20 years after onset of type 1 diabetes, 
1 in 6 patients develop hypoglycemia unawareness, and ~10% of deaths in type 1 
diabetes patients are due to hypoglycemia. It was announced that β cell replace-
ment therapy was optimal for hypoglycemia in patients with hard-to-control type 1 
diabetes. However, only 0.1% of patients with type 1 diabetes could receive beta cell 
replacement therapy due to a shortage of donors. In Japan, cardiac arrest donor islet 
transplantation [5] and living donor islet transplantation [6] have been carried out, 
but in order to fundamentally solve the donor shortage, β cell replacement therapy 
not relying on human organ donors is considered essential. Under these circum-
stances, pig organs are attracting attention as an alternative to organs from human 
donors.
2. Pancreatic islet transplantation using porcine islets
To realize successful porcine islet transplantation, exploratory clinical research 
began several decades ago. Table 1 shows an overview of the history of porcine islet 
transplantation. In the 1990s in Sweden, Groth et al. transplanted islet cells from 
fetal pigs into type 1 diabetic patients on immunosuppressants after kidney trans-
plantation [7]. Porcine C-peptide was positive for several months after transplanta-
tion, which indicated that porcine islets were successfully engrafted in the human 
body. Yet, no clinical effect such as a decrease in the amount of insulin injection 
was observed. In other works, Valdes et al. implanted an angioplasty device with 
newborn pig islets and Sertoli cells subcutaneously into type 1 diabetes patients 
[8]. Eleven patients received additional transplantation 6–9 months after the initial 
transplantation, and four received additional transplantation in the third year. Two 
patients achieved insulin-free status for several months after transplantation. In 
New Zealand, Elliott et al. transplanted newborn pig islets encapsulated in hydrogel 
microcapsules into the peritoneal cavity of type 1 diabetic patients. Because the 
islets were embedded in the immunoisolation capsule, no immunosuppressant was 
used. Insulin and glucagon staining of encapsulated pig islets, which were removed 
after 9.5 years of transplantation, showed that the encapsulated pig islets could be 
engrafted for a long time [9].
Thus, xenogeneic islet transplantation for type 1 diabetes patients using porcine 
islets has been performed in several clinical trials overseas. The risk of infection due 




3. Designated pathogen-free status and porcine endogenous retrovirus
Pigs for clinical use must have a designated pathogen-free (DPF) status, which 
means they are free of pathogens that can infect humans and pigs [10]. DPF status 
is achieved by delivering a piglet by cesarean section from a sow that has been con-
firmed to be free of transplacental pathogens, and after cleaning and decontamina-
tion, the piglet is placed in a biosecure barrier facility.
These facilities are defined at several levels. First, it is necessary that the facility 
itself be sited away from the pig farming facility. The breeding building must be 
completely isolated from the outside environment with an air filter, water decon-
tamination system, radiation sterilization, and autoclave for all incoming materials. 
Piglets are fed with pasteurized milk, not breast milk, and enteric bacteria are pro-
vided separately. For waste disposal, especially liquid waste, special consideration is 
necessary to avoid backflow. Staff must pass through antiseptic showers both when 
entering and exiting the facility and must change into special sterilized clothes. 
Routine health checks of personnel are also conducted. In general, all procedures 
must follow standard operative procedures. It is also important to incorporate cur-
rent good manufacturing practices in accordance with regulatory guidelines.
Nevertheless, in coculture of PK-15 pig kidney cell line (PK15 cells), and human 
fetal kidney cells 293 (HEK293 cells), infection of HEK293 cells by porcine endog-
enous retrovirus (PERV) naturally released from PK15 cells has been reported [11]. 
The problem of PERV infection via porcine xenotransplantation has emerged, 
and because PERV-A and PERV-B are integrated into all porcine genes, they are 
extremely difficult to eliminate. Thus, with regard to PERV, instead of exclusion, 
denial of infectivity and monitoring of transplanted patients and their close rela-
tives are recommended.
Year Events Ref.
1994 Groth et al. reported that fetal pig islet transplantation to diabetic patients [7]
1997 Patience et al. reported that PERV could infect human cells [11]
2005 Valdes-Gonzales et al. reported a 4-year course after transplantation of neonatal pig 
islets and Sertoli cells
[8]
2006 Dufrane et al. showed that encapsulated adult porcine islets survived in the cynomolgus 
monkey body for more than 6 months
[12]
2006 Hering et al. achieved long-term insulin-free status in diabetic monkeys by 
transplantation of wild-type adult porcine islets
[13]
2006 Cardona et al. achieved long-term insulin independence in diabetic monkeys by 
transplantation of neonatal porcine islets
[14]
2007 Elliott et al. reported that about 9.5 years after transplantation, encapsulated porcine 
islets were recovered and insulin staining was positive
[9]
2013 Wang et al. commenced neonatal porcine islet transplantation with Tregs at Central 
South University, China
—
2014 Matsumoto et al. reported porcine islet transplantation under New Zealand regulations [23]
2015 Yang et al. announced that they used CRISPR/Cas9 to inactivate all PERVs [31]
2016 Matsumoto et al. reported clinical efficacy with encapsulated pig islet transplantation [24]
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4. Pig islet transplantation experiment using nonhuman primates
Dufrane et al. demonstrated that mature pig islets embedded in alginate cap-
sules and transplanted into cynomolgus monkeys without immunosuppressants 
survived up to 6 months after transplantation [12]. Hering et al. at the University of 
Minnesota reported that wild-type (unmodified) adult porcine islets transplanted 
into the portal vein of rhesus monkeys with streptozotocin-induced diabetes mel-
litus achieved long-term insulin independence [13]. Also, Cardona et al. from the 
University of Alberta reported that wild-type newborn porcine islets transplanted 
into the portal vein of monkeys with pancreatectomy-induced diabetes resulted in 
long-term insulin-free status [14]. Recently, Park et al. reported more advances with 
modification of immunosuppressants [15]. These reports have brought great hope 
for islet transplantation using porcine islets. However, the importance of prevention 
of infections including PERV has been recognized.
5. Guidelines
While xenotransplantation holds great promise for overcoming donor shortages, 
the global problem of xenogeneic infection must be considered. Therefore, in 2008 
the World Health Organization (WHO) held a conference on xenotransplanta-
tion in Changsha, China, and presented the main points as the First WHO Global 
Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials 
[16]. This statement, referred to as the Changsha Communique, is the basis for 
xenotransplantation worldwide. The content summary is shown in Table 2.
Based on the Changsha Communique, in 2009 the International 
Xenotransplantation Association (IXA) announced a consensus statement of condi-
tions for the initiation of clinical trials of porcine islet products for type 1 diabetes 
[17]. This consensus statement consists of seven chapters and addresses the require-
ments of the Changsha Communique. Because remarkable progress has been made 
in research in this field, the statement should be updated.
Since the consensus statement for the initiation of xenogeneic islet transplan-
tation in IXA was announced in 2009, clinical findings of xenotransplantation 
including clinical xenogeneic islet transplantation in New Zealand have been 
accumulated, and the consensus statement was updated in 2016 [18]. The contents 
of the chapters are:
Chapter 1. Key ethical requirements and progress toward the definition of an 
international regulatory framework: ethical requirements and progress toward 
establishing an international regulatory framework.
Chapter 2. Source pigs: pig requirements for donor sources.
Chapter 3. Pig islet product manufacturing and release testing: manufacturing, 
quality control, and release testing.
Chapter 4. Pre-clinical efficacy and complication data required to justify a clini-
cal trial: appropriate pre-clinical trial.
Chapter 5. Strategies to prevent transmission of porcine endogenous retrovi-
ruses: concept and prevention strategy for PERV.
Chapter 6. Patient selection for pilot clinical trials of islet xenotransplantation: 
appropriate patient selection.
Chapter 7. Informed consent and xenotransplantation clinical trials: ideal 
informed consent procedure.
In particular, because PERV infection and cross-species infection did not occur 




unlikely under the adequate control of suitable donors and recipients. In addition, 
clinical data have been accumulated, infection diagnostic techniques have pro-
gressed, clinical protocols have been improved, the risk of PERV-related infection 
is better understood, DPF facilities and dietary restriction methods have advanced, 
and the role of sample archives has been clarified. As a result of these efforts, cost-
effective generation of donor pigs will be possible, and it is expected that porcine 
islets will be delivered to many patients who truly need this treatment modality.
Some countries have responded to this consensus statement. In Japan, the 
Ministry of Health, Labour and Welfare also revised the “guidelines on public 
health infection problems associated with the implementation of xenotransplanta-
tion” in 2016.
1 Xenotransplantation can be used to treat serious diseases such as diabetes, heart disease, and kidney 
disease. Also, patients who cannot currently receive transplants may be able to receive transplants
2 Medical animals can provide high-quality cells, tissues, and organs. Genetically modified animals may 
further improve outcomes. Medical animals are limited to closed colonies. Breeding should be done at 
a well-controlled pathogen-free facility, with high standards for animal welfare. Medical animals are 
verified by testing for the absence of known pathogens and, moreover, must be kept free of infectious 
diseases by continuous observation
3 Xenotransplantation is a complex procedure with risk of rejection, poor graft function, and known or 
unknown infections. There is a risk of developing serious or new infections, and patients, relatives, or 
other humans and animals may be infected
4 Because of the risk to the community at large, clinical trials of xenotransplantation should be 
conducted under strict regulation. Xenotransplantation should not be performed in the absence of 
national regulations. These regulations should have legal basis and be able to prohibit nonregulatory 
transplants. Furthermore, this regulatory framework should ensure transparency to the general public 
and should include both science and ethics
5 Given the risk to the community, the benefit to the patient should be high. In particular, preclinical 
studies should be conducted using animal experiments with predictable effects to demonstrate the 
safety and efficacy recommended by the international scientific community. Proposed clinical trials 
should be assessed by the relevant regulatory authorities to minimize risk
6 Personnel responsible for clinical trials should explain the inclusion criteria in order to justify the 
clinical trial. Patient selection must be done at the patient’s own discretion based on informed consent. 
Patients and relatives must be effectively educated to ensure compliance and minimize risks to 
themselves and to society
7 Participation in xenotransplantation usually takes a long time. Samples from donor animals, patients 
before and after surgery, and all records should be kept. Patients who have had transplants need 
lifetime follow-up, and close relatives may need similar follow-up. The results of clinical trials should 
be analyzed rigorously. Patients who have undergone xenotransplantation should be registered in 
an appropriate database, which should also be able to track donor animals. At the same time, the 
patient’s privacy has to be protected. All records, data, and samples must be prepared for submission to 
regulatory authorities for a designated period
8 The health-care team must have adequate experience and an understanding of the risks to the patient, 
the health-care team itself, and the community. Because of the risk of transmission to the community, 
a system of vigilance and surveillance should be established to ensure that any infection associated 
with the xenotransplant will be identified and addressed immediately
9 There is a need to establish a system for worldwide information exchange, prevention of unregulated 
xenotransplantation, vigilance and monitoring of xenotransplantation, and response in case of 
suspected infection
10 Considering the benefits of successful xenotransplantation, from the early stages, the treatment 
should be considered widely accepted as the treatment is completed, and the public sector is 
recommended to support
Table 2. 
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patient’s privacy has to be protected. All records, data, and samples must be prepared for submission to 
regulatory authorities for a designated period
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xenotransplantation, vigilance and monitoring of xenotransplantation, and response in case of 
suspected infection
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Table 2. 
Summary of the contents of the Changsha communique.
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Recently, in response to the resumption of clinical xenotransplanta-
tion, the Third WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials was held in 2018, and the contents were 
announced as the 2018 Changsha Communique [19]. The points of the revision are:
1. Prohibition of clinical trials in countries without national regulations and 
subsequent prohibition of medical tourism to such countries
2. Emphasis on reproducible preclinical data
3. Development of quality control measures and standards for genetically modi-
fied pigs
4. Deletion of sample retention period requirements
The Communique emphasizes safety while taking into consideration the actual 
situation of clinical xenotransplantation, social conditions, and technological 
advances.
6. Encapsulation of islets
Although islet transplantation has proved to be successful for patients with type 
1 diabetes, one of the limitations is the requirement for lifelong immunosuppres-
sion. An encapsulation strategy that can prevent rejection of xenogeneic islets can 
potentially overcome this challenge (Figure 1). Such capsules have fine holes that 
allow the passage of oxygen, glucose, and insulin but not immune cells. Blocking 
immune cells allows islet transplantation without the need for immunosuppres-
sants. The capsules have been studied in various materials and sizes. There are three 
main sizes: macro, micro, and nano [20, 21]. The macro-capsule is used to seal islets 
in centimeter-order devices, which are easy to handle and can be removed and 
replaced. However, the problem is that substance permeability is low, and foreign 
body reactions are likely to occur, and the survival rate of internal cells is low. The 
microcapsule is several hundreds of micrometers to millimeters order in size, is 
Figure 1. 
Schematic representation of an encapsulated porcine islet. Pancreatic islets isolated from DPF pig are 
encapsulated with an immunoisolation hydrogel. The capsule has fine holes that allow passage of oxygen, 




made mainly of hydrogel, and contains one to several islets. It is compatible in terms 
of substance permeability and immune isolation ability. However, it is too large 
for endovascular transplantation and recovery after transplantation is difficult. 
The nano-capsule has a thin-layered surface coating enclosing pancreatic islets 
comprising a variety of polymers and therapeutic agents. The permeability is high 
but stability is an issue. In addition, a surface modification with immune-privileged 
cells is another concept of encapsulation. Each of these encapsulation techniques 
has advantages and disadvantages, but the technique is very promising.
7. Micro-encapsulated neonatal porcine islet transplantation
In 1980, Lim and Sun applied microcapsules in diabetes treatment, showing 
prolonged islet graft survival using alginate-poly-l-lysine-polyethyleneimine 
microcapsules [22]. Since then, this promising technology has been considerably 
improved.
In 2014, clinical results were reported in which neonatal porcine islets isolated 
from DPF pigs encapsulated with alginate and poly-(l)-ornithine were transplanted 
in 14 patients with type 1 diabetes [23]. The patients were divided into four groups 
according to transplantation dose, and 5000, 10,000, 15,000, and 20,000 IEQ/kg 
of encapsulated islets were transplanted intraperitoneally, respectively, according 
to body weight. No immunosuppressant was used. After transplantation, in the low-
dose groups of 5000 and 10,000 IEQ/kg, the frequency of occurrence of hypoglyce-
mia unawareness was halved compared to that before transplantation.
In 2016, the same group reported results of a clinical trial in which 5000 and 
10,000 IEQ/kg of encapsulated neonatal porcine islets were transplanted twice at 
intervals of 3 months [24]. After transplantation, HbA1c decreased significantly 
in all patients, and the frequency of occurrence of hypoglycemia unawareness was 
significantly reduced in the group that received a transplant of 10,000 IEQ/kg 
twice. Moreover, the group that received a transplant of 10,000 IEQ/kg maintained 
an average HbA1c of ≤7% over 2 years after transplantation and showed a long-term 
effect. Clinical effects have been shown in islet xenotransplantation.
8. Porcine islet transplantation combined with regulatory T cell (Treg)
A clinical trial of transplantation of neonatal porcine islets and autologous Tregs 
in type 1 diabetes patients is underway and is being conducted by Wang et al., 
Central South University, China (ClinicalTrials.gov Identifier NCT03162237). 
The transplanted dose is 10,000 IEQ/kg of islets, 2 × 106/kg of Tregs, and the 
immunosuppressants are tacrolimus, mycophenolate mofetil, and belatacept. The 
primary end point is stable blood glucose level and prevention of ketoacidosis and 
hypoglycemia and a 30% reduction in required insulin. The authors reported that 
the condition of these patients improved substantially (http://en.xy3yy.com/docu-
ment/show_12/184.html). These results are encouraging and add value to this field 
of research.
9. Gene editing and blastocyst complementation
One of the advantages of xenotransplantation is the possibility of genetic modi-
fication in the donor. Advances in gene editing, such as the CRISPR/Cas9 system, 
have facilitated editing of specific genes.
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have facilitated editing of specific genes.
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Recent advances in genetic engineering and gene editing of donor pigs may over-
come the challenge of islet rejection and improve their engraftment and ability to 
secrete insulin. The required set of genetic modifications will depend on the source 
of islets (fetal, neonatal, and adult), mode of delivery (encapsulated, free), and 
the transplantation site. Genetic modification of pigs has been developed mainly 
via deletion of one or more of the major porcine antigens such as GGTA1, CMAH, 
and β4GalNT2, and/or insertion of human complement (such as hCD46, hCD55, 
and hCD59) which suppress the coagulation reaction [25, 26], and/or knockout or 
insertion of other genes. Simultaneous knockout of two or three major pig antigens 
has been achieved, and consequently the binding of human antibodies to these cells 
is significantly reduced. Other genes include the expression of proteins that inhibit 
co-stimulation of T cells such as hCTLA4Ig [27]. The combinations of multiple gene 
editing were promising [28, 29]. Currently, the modifications being carried out in 
pigs span over 24 genes including coagulation regulatory genes, immune cell regula-
tory genes, and anti-inflammatory genes [30]. Simultaneous modification of more 
than five genes has been performed in some pigs [30]. These genetically modified 
pigs will contribute to the improvement of transplantation outcome.
The technology has also been applied to elimination of PERV, and Yang et al. of 
Harvard University reported inactivation of all PERV genomes using the CRISPR/
Cas9 system [31]. They launched a venture company called eGenesis, aiming to 
create a human friendly medical pig with the added advantage of PERV inactiva-
tion. Thus, it is considered that a medical pig suitable for islet transplantation will 
be created by gene editing technology.
Yamaguchi et al. of the University of Tokyo complemented mouse-induced plu-
ripotent stem cells (iPS), cells with blastocysts of pancreatic-deficient rats, and suc-
ceeded in inducing the rats to develop mouse pancreas [32]. The pancreas derived 
from mouse iPS, which was produced by this blastocyst complementation method, 
was the size of the rat pancreas and had a sufficient number of pancreatic islets that 
could be isolated for transplantation to the mouse. These islets were transplanted 
with small amounts of an immunosuppressant drug to diabetic mice syngeneic with 
the iPS cells to normalize blood glucose levels. In addition, this research group also 
succeeded in inducing apancreatic pigs to produce different pig-derived pancre-
ases by blastocyst complementation [33]. In the future, it may be possible to use a 
human iPS cell line to generate a medical pig for a human pancreas by blastocyst 
complementation. If the patient’s own iPS-derived pancreas can be obtained from 
a pig, it is essentially an autologous transplantation, and it thus becomes possible to 
perform islet transplantation without the need for immunosuppressants.
10. Summary
Allogeneic islet transplantation is being established as a standard treatment for 
hypoglycemia unawareness and severe hypoglycemia, but a shortage of human 
donors has become a problem. Islet xenotransplantation using DPF pigs is consid-
ered as a promising fundamental solution to the donor shortage. However, cross-
species infection, especially PERV infection, poses risks to the community, and 
discussions among key opinion leaders have been implemented by the WHO. As a 
result, the IXA Consensus Statement was published in 2016, envisioning a future 
where cost-effective delivery of islet transplants to diabetic patients is facilitated 
by medical pigs. With the risk of infection always kept in mind, cases of clinical 
islet xenotransplantation have been accumulated, and steady progress has been 
made toward a feasible, safe, and effective treatment for diabetic patients. In 
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recently publicized CRISPR/Cas9 technology and blastocyst complementation that 
could enable the creation of an individual’s pancreas in pigs could provide for safer 
and more effective islet xenotransplantation. Proper pathogen screening, animal 
selection, microbiological control, and long-term monitoring of recipients will be 
required for clinical application of porcine islet transplantation.
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Abstract
This article reviews the rationale, sources and preparation of pig islets for 
xenotransplantation. Pancreatic islet cell transplantation is an attractive alternative 
and an effective treatment option for type 1 diabetes, however, donor pancreas 
shortages prevent islet transplantation from being a widespread solution as the 
supply cannot possibly equal the demand. Porcine islet xenotransplantation has 
the potential to address these shortages, and recent preclinical and clinical trials 
show promising scientific support. Pig islets provide a readily available source for 
islet transplantation, with the recent trials in non-human primates (NHPs) dem-
onstrating their potential to reverse diabetes. The risk of zoonosis can be reduced 
by designated pathogen-free breeding of the donor pigs, but porcine endogenous 
retroviruses (PERVs) which are integrated into the genome of all pigs, are especially 
difficult to eliminate. However, clinical trials have demonstrated an absence of 
PERV transmission with a significant reduction in the number of severe hypogly-
cemic episodes and up to 30% reduction in exogenous insulin doses. A number of 
methods are currently being tested to overcome the xenograft immune rejection. 
Some of these methods include the production of various transgenic pigs to better 
xenotransplantation efficiency and the encapsulation of islets to isolate them from 
the host immune system. Furthermore, ongoing research is also shedding light on 
factors such as the age and breed of the donor pig to determine the optimal islet 
quantity and function.
Keywords: type 1 diabetes, xenotransplant, porcine islets, encapsulation, transgenic
Keypoints
• Preclinical studies show improvements in pig islet survival after transplantation.
• Clinical pig islet xenotransplantation studies prove no transmission of PERV.
• Pig islets can be successfully transplanted using encapsulation technology.
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1. Introduction to islet xeno-transplantation
Exogenous insulin is the most common treatment option for type I diabetes 
(insulin-dependent diabetes mellitus), a chronic metabolic disorder caused by the 
failure of the beta cells of pancreatic islets most often due to T-cell mediated auto 
immune reaction which result in hyperglycemia [1]. While the standard insulin 
therapy treats patients with diabetes, however, it does not cure the disease, nor 
does it prevent the development of the secondary complications leading to end 
stage organ failures along with its morbidity and mortality [2]. Technical advance-
ments in the production of exogenous insulin, better glucose monitoring system 
and optimal insulin therapy can reduce HbA1C but still has not addressed the 
issues of increasing hypoglycemic episodes in patients. Achievement of normogly-
cemia and exogenous insulin independence is the goal of diabetes treatment. The 
International Diabetes Federation (IDF) estimated the number of adults suffering 
from DM in 2017 to be 425 million: this number is expected to increase to 629 
million patients in 2040 [3]. Whole pancreas and pancreatic islet transplantation 
Figure 1. 
Trends in the number of organ donors (blue), organ transplants (green), and patients on the waiting list 
(Orange) in the US, 2003–2015. In 2003, there were 13,285 donors, 25,473 organ transplants, and 83,731 patients 
on the waiting list. By 2015, there were 15,068 donors, 30,975 organ transplants and 122,071 patients on the 
waiting list. Source: http://optn.transplant.hrsa.gov.
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are effective treatment options for diabetes by which insulin independence in 
T1D patients can be achieved [4]. Unfortunately, both whole organ and cellular 
transplantation face challenges due to a wide gap between the ever-increasing 
transplant waiting list and the supply of donor organs [5]. Data from the Organ 
Procurement and Transplant Network (OPTN) from 2003 to 2015, indicates a 
145% increase in the wait list for all organs, while donor availability increased by 
only 113% (Figure 1) [6]. Similarly, the total number of pancreases available is 
insufficient to match the need for pancreatic islet allo-transplantation [7–9].
Due to this shortage, xenotransplantation using porcine islets has emerged as a 
potential alternative source for beta cell replacement. Porcine islets have structural 
and physiological similarities to human islets. Porcine insulin (differs from human 
insulin by only one amino acid) is used to treat diabetes in clinical practice [10, 11]. 
Intact functional islets have been successfully isolated from the pig pancreas [12], 
and these islets have shown the ability to reverse diabetes when transplanted into 
NHPs [13]. This review article will present the evolution, current practices, chal-
lenges and perspectives for pig islet xenotransplantation.
2. History of islet xeno-transplantation
Xenotransplantation has been attempted for the past 300 years or so and blood 
xenotransfusion was tried as early as the seventeenth century by Jean Baptiste Denis 
[14]. This was later followed by corneal transplantations from pigs to humans and 
kidney transplantations in NHP [15, 16]. The first pancreatic xenotransplantation 
was performed by Watson et al., implanted three ovine fragments into the sub-
cutaneous plane of a diabetic patient. Though clinically significant blood glucose 
reduction was not demonstrated, the blood sugar level did decrease [17]. This 
pioneering work was followed by many experimental xenotransplantations, but 
results were mostly inconclusive [18–21]. Shumakov et al. reported 53 fetal porcine 
xenotransplants and 18 fetal bovine xenotranaplants in diabetic patients [22]. A 
century later, Groth et al. performed clinical xenotransplantation trial using fetal 
porcine islet cell-like clusters (ICCs) and provided preliminary data regarding 
the function and survival of grafts. After porcine islets were transplanted into 10 
insulin-dependent diabetic kidney-transplant patients, detectable levels of porcine 
C-peptide were identified in the urine for up to 400 days and in one case, renal graft 
biopsy showed insulin and glucagon positive cells after staining [23]. Several xeno-
transplantation studies have also been performed in NHPs [20], and have succeeded 
in reversing diabetes [24–27] and in reducing daily insulin dosage requirement [28]. 
Transplanted porcine islet grafts were also shown to survive and function in NHPs 
for longer than 6 months with immunosuppression [25, 27, 29]. The longest survival 
rate is now over 603 days according to Shin et al., [30]. Studies have also shown that 
microencapsulation of the transplanted islets and immune-isolation lead to better 
survival rate without the need for aggressive immunosuppressive therapy [26].
3. Pig islets as alternative source
The success of porcine insulin and its role in the treatment of T1D has been well 
established since its discovery in the 1920s [11, 12, 25]. The structural and physio-
logical similarities between human and pig organs, along with its unlimited supply, 
have made them an excellent translational research model [25]. Insulin extracted 
from pig islets has been used for the treatment of diabetes for decades [10, 11, 
20, 33]. Because porcine islets produce insulin patterns similar to those found in 
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insulin-dependent diabetic kidney-transplant patients, detectable levels of porcine 
C-peptide were identified in the urine for up to 400 days and in one case, renal graft 
biopsy showed insulin and glucagon positive cells after staining [23]. Several xeno-
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20, 33]. Because porcine islets produce insulin patterns similar to those found in 
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humans, and because they are readily available [20], studies strongly suggest that 
islets obtained from pigs could be a promising substitute for human islets in the 
treatment of T1D. Recent studies on genetically engineered pigs suggest that these 
pigs are more suitable for xenotransplantation. For example, alpha 1,3-galactosyl-
transferase gene knockout (GTKO) pigs, have decreased the incidence of immune-
rejection and improved compatibility between the donor and recipient [31–36].
The major advantages for using pigs as an islet source for xenotransplantation 
are as follows:
1. Ethically acceptable source.
2. The pig pancreas has structural and physiological similarities to the human 
organ.
3. Unlimited availability.
4. Easy to breed and produce large litters.
5. Rapid growth into adult organs (6 months).
6. Significantly low cost of maintenance.
7. Elective and emergent availability of the organs.
8. Low risk of zoonosis.
9. Facilities available to breed pigs under ‘clean’ conditions.
10. Obviates ‘cultural barriers’ to human organ transplant (e.g. Japan); illegal 
organ trafficking; deleterious effects on organs in brain dead patients; living 
donor organ donation.
11. Advanced and safe immunosuppression protocols.
12. Cloning and genetic modification of cells to reduce immune destruction.
13. Islet encapsulation to combat immune challenge.
Modified from Ekser et al. [5]; Cooper et al. [37, 38]; Cheng et al. [20].
4. Selection of pig and sources of pig islets
Islet quantity and quality varies with the breed of pigs. Readily available market 
pigs have shown to yield lower when compared to the well-studied breeds of pigs like 
Landrace pigs, Chicago Medical School (CMS) miniature pigs and Chinese Wuzhishan 
(WZS) miniature pigs [23, 25, 27]. Two major factors which have been studied in 
relation to the source of pig islets for xenotransplantation are the breed and age of 
the donors. Some well-studied breeds are the Landrace pigs, Chicago Medical School 
(CMS) miniature pigs, and the Chinese Wuzhishan (WZS) miniature pigs. Market 
weight pigs are easily available, but studies have shown lower yields than for other 
breeds [39]. Landrace pigs have been shown to yield large sized (>250 μm) islets with a 
high islet volume density [39, 40]. Adult Chicago Medical School (CMS) miniature pigs 
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are bred under specific pathogen-free (SPF) conditions, and contain large-sized islets. 
The yield is greater than market or other miniature pigs (9589 ± 2838 IEQ/g), making 
CMS pigs one of the best sources for obtaining islets [39, 41–45]. Another miniature 
pig, the Chinese Wuzhishan (WZS) pig has also shown an islet yield greater than that 
of market pigs [39, 46]. Though no consensus has been arrived at the optimal breed for 
the preclinical/clinical studies, these breeds has been well documented to yield better 
islets than others. Higher expression of extracellular matrix (ECM) protein in islet 
capsules makes isolation easier and German Landrace pigs have higher ECM [24].
Additionally, age [43, 44, 47–49] and size of the donor pigs [36, 50–52] are major 
factors that affect islet isolation outcomes. Some studies have also suggested that 
gender may play a role in the final islet yield [39, 53, 54]. Pig islets can be obtained 
at four distinct life-stages: embryonic, fetal, neonatal and adult [55], and Table 1 
summarizes the significance, advantages, and disadvantages of pig islets from 
Islet source Significance Advantages Disadvantages
Embryonic In the dorsal pancreatic 
primordial, strands of 
insulin positive cells are seen 
as early as week 4 [43].
From week 13, cells 
exhibiting intense 
immunoreactivity for 
insulin are distributed 
throughout the pancreas 
[43, 57].
Embryonic pancreatic tissue 
exhibit predominantly 
insulin-positive beta cells 
without evidence of alpha 
cells [43, 58].
Use of embryonic primordial 
pancreas is better than 
pluripotent stem cells as they 
do not need steering toward 
pancreatic differentiation 
and have lower risk of 
teratoma [59].
Following transplantation, 
the exocrine tissue does 
not proliferate. Hence, 
there is decreased immune 
response and inflammatory 
complications.
Pancreatic primordia 
obtained on day 28 
successfully reversed diabetes 
in rhesus monkey when 
compared to that obtained 
on day 35, which underwent 




maturation in vivo 
[43].
Poor insulin response 
post-transplantation 
due to immaturity [39, 
62–64].
Higher expression of 
alpha-1,3 galactose 





a small number of 
islets can be isolated, 
requiring large 
number of pigs which 
limits large scale 
clinical application, 
with ethical issues.
Fetal Porcine islets are isolated 
from fetuses of 60–69 days 
gestational age [36, 65].
Islets lack a definite 
shape and capsule and 
are organized in clusters 
(ICCs) [36].
These cellular clusters 
are composed of <40% 
endocrine cells (6–8% beta 
cells) with the majority 
being the cytokeratin-
positive epithelial cells [65].
Their ability to proliferate 
makes them a potential 
source of islet cells [27, 36, 
66–68].
Isolation process is very 
simple, involving digestion of 
the pancreatic tissue to free 
the islet clusters [65, 69].
No gradient purification 
necessary.
Easily scalable to provide 
clinical product.
Isolation not dependent on 
the enzyme collagenase, 
(activity is variable between 
enzyme lots).
The use of alpha 
1,3-galactosyltransferase 
GTKO strains has 
demonstrated better 
transplant outcomes than 
wild-type strains [43, 70].
Cellular culture is 
required for 5–9 days 
to form cellular 
aggregates.
Maturation of islets is 
delayed
Demands higher 
number of pigs to 
provide sufficient 
islets due to lower 
yield [27, 36, 71].
Because of their 
clustered appearance, 
it is difficult to 
separate islets from 
the surrounding 
exocrine and other 
non-islet cells [36].
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different donor life-stages. Adult pigs have been preferred for their higher yield of 
mature islet cells that have the potential to secrete insulin soon after transplanta-
tion. However, the higher costs, fragility of the islets and the difficulty in isolation 
are the disadvantages. Neonatal and fetal islets are easy and inexpensive to isolate 
but the main disadvantage is the significant delay in functioning after transplanta-
tion due to their immaturity and their high expression of Galactose-α-1,3-galactose 
(αGal), the major antigenic target for primate anti-pig antibodies [56].
Islet source Significance Advantages Disadvantages
Neonatal The neonatal period is up 
to 30 days after birth. NPIs 
are usually obtained from 
the pancreas within the first 
week of life [43].
NPIs comprise ~35% of 
endocrine cells and ~57% 
of epithelial cells—islet 
precursor cells [39, 72, 73].
Correct hyperglycaemia 
in diabetic animal models 
as the precursor cells also 
differentiate and proliferate 
into beta cells [27, 36, 39, 
74, 75].
The cellular aggregates 
are composed of <40% 
endocrine cells (20–25% 
beta cells) with majority 
being cytokeratin-positive 
epithelial cells [65].
About 10–13 days after 
birth, the ICCs begin to 
resemble adult islets [43, 57].
Isolation process is very 
simple—the process involves 
digesting pancreatic tissue 
simply to free islet clusters 
[65, 72].
No gradient purification.
Easily scalable to provide 
clinical product.
Isolation not dependent on the 
enzyme collagenase (activity 
is variable between lots).
Isolation process is less 
expensive than for adult islets.
Maintenance of neonates is 
easy and inexpensive as they 
are maintained only for few 
days postpartum.
Exhibit strong resistance to 
inflammatory and hypoxia-
induced injury.
Lower T-cell reactivity than 
adult pigs [39, 76, 77].
Potential alternative to adult 
pig islets as xenografts.
Maturation is delayed 
when compared to 
adult islets but is 
faster than for fetal 
ICCs.
Cellular culture is 
required for 5–9 days 
to form cellular 
aggregates.
Lower yield—limits 
clinical usage. Only 
50,000 aggregates can 
be obtained from a 
single pancreas when 
compared to adult.
Adult Adult pig islets (APIs) are 
the major source of islet cells 
for xenotransplantation [39, 
78–80].
APIs are well differentiated 
with distinct and intact 
capsule and vasculature 
with very few insulin 
positive cells outside these 
islets [43, 57].
Antigenicity is from 
N-linked sugars and not 
from Gal Ag [39, 43, 81–83].
The expression of Gal Ag 
decreases and becomes 
negligible as the pig reaches 
adulthood [43, 81–86].
>2 yrs. is the optimal age 
[36, 39, 50, 54, 87].




can be extracted and purified 
as a single unit [36].
Mature cells—response to 
hyperglycemia is immediate 
following transplantation 
without latency [36, 39, 43, 
87–90].
Insulin independence in 
diabetic NHPs is achieved 
when ≥10,000 IEQs are 
transplanted. (islets pooled 
from 2 to 4 adult pigs) 
[39, 80].
Do not require culturing of 
the isolated islets [65].
Islet yield is greater than for 
fetal and neonatal pigs [43, 
78, 91].
Isolation is technically 
challenging, complex 
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5. Pig islet isolation
Adult pig islet preparation is very similar to human islet isolation methods [55] 
but the digestion process is a lot more gentler as the porcine islets are extremely 
fragile. Methods of islet preparation may vary depending on the life-stage of the 
donor pancreas. Fetal pig ICCs and neonatal pig islets (NPIs) are immature cells 
and can be easily isolated by enzymatic digestion [55] but must subsequently be 
cultured prior to transplantation to promote re-aggregation of islet clusters and to 
help eliminate exocrine cells [55]. The digestion procedure for the adult pig pan-
creas is significantly different over the fetal or neonatal pancreas. Many factors, 
such as the type of donor pigs, blood exsanguination, warm ischemia time, cold 
ischemia time, enzyme lot and activity, perfusate, and the isolation-purification 
process significantly affect the final islet yield, function and viability [39, 54, 55, 
79, 95–97].
5.1 In vitro and in vivo assessment of pig islet function
In vitro studies investigating the insulin response of islets from donor pigs of 
different ages have shown that the insulin response from adult pig islets is more 
pronounced and sustained, and that they have a higher stimulation index over young 
pigs [36]. Islets from different age of donor pigs have also been compared in vivo. 
Two groups of diabetic nude mice populations were implanted with either young 
and young adult porcine islets or adult islets. One out of 11 recipients of young and 
young-adult islets achieved normoglycemia, whereas 32 out of 39 transplanted with 
adult islets became normal, the blood glucose reaching normal range within 4 weeks 
post-transplantation. Graft function was confirmed as the cause for normoglycemia, 
as all 32 mice reverted back to hyperglycemia after islet graft removal [36]. Many 
studies using NHP models have demonstrated the benefits of the pig islets as xeno-
transplants, with a potential cure for diabetes [25, 39, 98–101]. These studies have 
shown diabetes reversal with prolonged graft survival in diabetic NHPs.
5.2 Hurdles for xenotransplantation
Prevention of the transmission of porcine endogenous retrovirus (PERV) and 
immunological reactions have been the major hurdles for xenotransplantation in 
preclinical and clinical trials. Though the risks of zoonosis have been downplayed 
significantly with the introduction of genetically modified pigs, immunological 
responses like instant blood mediated inflammatory response (IBMR) dictate the 
success of the graft survival. One of the most important risk to overcome during 
xenotransplantation is the prevention of zoonosis [102]. Porcine endogenous ret-
roviruses (PERVs) are of special concern as they are found integrated with porcine 
genomes and are difficult to eliminate [102]. The degree of risk of PERV being 
able to infect the human host is unknown, but evidence has shown that PERV can 
infect human cells when co-cultured with human EK-293 cells [55, 103]. Cross-
species transmission has also been documented in pig to SCID mice xenotrans-
plantation [55, 104]. However, no evidence of transmission has been documented 
in T1D patients who received porcine islet transplants, even after prolonged 
follow-up [55, 105].
Apart from PERV, other pathogenic organisms including the herpes virus, lym-
photropic herpes virus, and cytomegalovirus can also be transmitted. [55]. Methods 
of combatting these pathogens include careful assessment and screening protocols, 
designated pathogen-free (DPF) breeding and housing of PERV gene knockout 
pigs, all of which can help minimize the risk of zoonotic infections [29]. DPF herds 
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different donor life-stages. Adult pigs have been preferred for their higher yield of 
mature islet cells that have the potential to secrete insulin soon after transplanta-
tion. However, the higher costs, fragility of the islets and the difficulty in isolation 
are the disadvantages. Neonatal and fetal islets are easy and inexpensive to isolate 
but the main disadvantage is the significant delay in functioning after transplanta-
tion due to their immaturity and their high expression of Galactose-α-1,3-galactose 
(αGal), the major antigenic target for primate anti-pig antibodies [56].
Islet source Significance Advantages Disadvantages
Neonatal The neonatal period is up 
to 30 days after birth. NPIs 
are usually obtained from 
the pancreas within the first 
week of life [43].
NPIs comprise ~35% of 
endocrine cells and ~57% 
of epithelial cells—islet 
precursor cells [39, 72, 73].
Correct hyperglycaemia 
in diabetic animal models 
as the precursor cells also 
differentiate and proliferate 
into beta cells [27, 36, 39, 
74, 75].
The cellular aggregates 
are composed of <40% 
endocrine cells (20–25% 
beta cells) with majority 
being cytokeratin-positive 
epithelial cells [65].
About 10–13 days after 
birth, the ICCs begin to 
resemble adult islets [43, 57].
Isolation process is very 
simple—the process involves 
digesting pancreatic tissue 
simply to free islet clusters 
[65, 72].
No gradient purification.
Easily scalable to provide 
clinical product.
Isolation not dependent on the 
enzyme collagenase (activity 
is variable between lots).
Isolation process is less 
expensive than for adult islets.
Maintenance of neonates is 
easy and inexpensive as they 
are maintained only for few 
days postpartum.
Exhibit strong resistance to 
inflammatory and hypoxia-
induced injury.
Lower T-cell reactivity than 
adult pigs [39, 76, 77].
Potential alternative to adult 
pig islets as xenografts.
Maturation is delayed 
when compared to 
adult islets but is 
faster than for fetal 
ICCs.
Cellular culture is 
required for 5–9 days 
to form cellular 
aggregates.
Lower yield—limits 
clinical usage. Only 
50,000 aggregates can 
be obtained from a 
single pancreas when 
compared to adult.
Adult Adult pig islets (APIs) are 
the major source of islet cells 
for xenotransplantation [39, 
78–80].
APIs are well differentiated 
with distinct and intact 
capsule and vasculature 
with very few insulin 
positive cells outside these 
islets [43, 57].
Antigenicity is from 
N-linked sugars and not 
from Gal Ag [39, 43, 81–83].
The expression of Gal Ag 
decreases and becomes 
negligible as the pig reaches 
adulthood [43, 81–86].
>2 yrs. is the optimal age 
[36, 39, 50, 54, 87].
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5. Pig islet isolation
Adult pig islet preparation is very similar to human islet isolation methods [55] 
but the digestion process is a lot more gentler as the porcine islets are extremely 
fragile. Methods of islet preparation may vary depending on the life-stage of the 
donor pancreas. Fetal pig ICCs and neonatal pig islets (NPIs) are immature cells 
and can be easily isolated by enzymatic digestion [55] but must subsequently be 
cultured prior to transplantation to promote re-aggregation of islet clusters and to 
help eliminate exocrine cells [55]. The digestion procedure for the adult pig pan-
creas is significantly different over the fetal or neonatal pancreas. Many factors, 
such as the type of donor pigs, blood exsanguination, warm ischemia time, cold 
ischemia time, enzyme lot and activity, perfusate, and the isolation-purification 
process significantly affect the final islet yield, function and viability [39, 54, 55, 
79, 95–97].
5.1 In vitro and in vivo assessment of pig islet function
In vitro studies investigating the insulin response of islets from donor pigs of 
different ages have shown that the insulin response from adult pig islets is more 
pronounced and sustained, and that they have a higher stimulation index over young 
pigs [36]. Islets from different age of donor pigs have also been compared in vivo. 
Two groups of diabetic nude mice populations were implanted with either young 
and young adult porcine islets or adult islets. One out of 11 recipients of young and 
young-adult islets achieved normoglycemia, whereas 32 out of 39 transplanted with 
adult islets became normal, the blood glucose reaching normal range within 4 weeks 
post-transplantation. Graft function was confirmed as the cause for normoglycemia, 
as all 32 mice reverted back to hyperglycemia after islet graft removal [36]. Many 
studies using NHP models have demonstrated the benefits of the pig islets as xeno-
transplants, with a potential cure for diabetes [25, 39, 98–101]. These studies have 
shown diabetes reversal with prolonged graft survival in diabetic NHPs.
5.2 Hurdles for xenotransplantation
Prevention of the transmission of porcine endogenous retrovirus (PERV) and 
immunological reactions have been the major hurdles for xenotransplantation in 
preclinical and clinical trials. Though the risks of zoonosis have been downplayed 
significantly with the introduction of genetically modified pigs, immunological 
responses like instant blood mediated inflammatory response (IBMR) dictate the 
success of the graft survival. One of the most important risk to overcome during 
xenotransplantation is the prevention of zoonosis [102]. Porcine endogenous ret-
roviruses (PERVs) are of special concern as they are found integrated with porcine 
genomes and are difficult to eliminate [102]. The degree of risk of PERV being 
able to infect the human host is unknown, but evidence has shown that PERV can 
infect human cells when co-cultured with human EK-293 cells [55, 103]. Cross-
species transmission has also been documented in pig to SCID mice xenotrans-
plantation [55, 104]. However, no evidence of transmission has been documented 
in T1D patients who received porcine islet transplants, even after prolonged 
follow-up [55, 105].
Apart from PERV, other pathogenic organisms including the herpes virus, lym-
photropic herpes virus, and cytomegalovirus can also be transmitted. [55]. Methods 
of combatting these pathogens include careful assessment and screening protocols, 
designated pathogen-free (DPF) breeding and housing of PERV gene knockout 
pigs, all of which can help minimize the risk of zoonotic infections [29]. DPF herds 
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must be free from a comprehensive and list of specified microorganisms [29, 106] 
and meticulous documentation and standard operating procedures (SOPs) must be 
implemented to maintain this status [29] including feed restrictions [29].
5.3 Immunological response
Pig islet cells express different surface proteins that play a major role in the 
immunological rejection seen following transplantation [102, 107]. Immunological 
responses are much more complex than seen in allo-transplantation [102]. Immune 
mediated inflammatory response have been brought down by significantly by 
genetic modifications as summarized in Table 2. Hyper acute rejection (HAR), 
Instant blood mediated inflammatory response (IBMIR), and cellular rejection are 
the types of responses seen in graft rejection of which IBMIR is the most crucial. 
Portal vein site provides good revascularization and drainage for islet transplanta-
tion but due to the severe complications like bleeding, thrombosis, and hepatic 
steatosis, it is no longer an optimal site [108]. Immunological issues observed during 
xenotransplantation are similar to those seen in allo-transplantation but are much 
more complex [102]. Pig islets express different types of surface proteins, and these 
play a critical role in the immunologic rejection seen following transplantation 
[107]. Multiple genetic modifications in pigs have been proposed to significantly 
reduce immune mediated inflammatory response, and these are summarized in 
Table 2.
There are four known major routes for islet cell loss following transplantation 
and these are summarized in the following sections.
5.3.1 Hyper acute rejection (HAR)
HAR occurs due to the presence of pre-existing host antibodies to surface 
proteins on the porcine islets. These surface proteins can be broadly categorized into 
Gal and non-Gal proteins [34, 38, 110]. The Gal epitope is absent in humans, apes 
and old-world monkeys but many bacteria, NHP and new world monkeys express 
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the Gal epitope abundantly. In pigs, the expression of Gal antigens decreases as they 
grow into adults [84, 102, 110, 124, 125].
As the human body is continuously exposed to micro-organisms (including 
bacteria), it develops immunity to the Gal antigen and has pre-formed, circulating 
anti-Gal antibodies [107, 126], which make up around 1% of the circulating anti-
bodies [102, 124]. Once the pigs islets are transplanted, these pre-formed anti-
bodies kill the islet cells rapidly by complement mediated destruction [107, 124] 
resulting in substantial islet loss [102, 107, 127].
Antibodies are also produced for other surface epitopes (non-Gal Ag) such as 
N-glycolylneuraminic acid (NeuGc) also known as Hanganutzu-Deicher and beta 
1,4 N-acetylgalactosaminyltransferase (B4GALNT2) [107, 128–130] which are also 
involved in complement mediated destruction of xenografts [107].
There are two known strategies for prevention of HAR. Knockout of genes 
responsible for adding the Gal epitope and other epitopes such as Neu5Gc to the 
cell surface can prevent their expression [34, 102]. Secondly, expression of comple-
ment regulatory proteins such as hCD46, hCD55 and hCD59 can be induced on the 
surface of the islet cells [102, 131]. Double knockout pigs (deficient in alpha-gal 
(GTKO) and Neu5Gc) have been produced, which has significantly reduced the 
incidence of humoral rejection [102, 132]. The Gal antigen is highly expressed 
in fetal and neonatal pig pancreas, but its expression decreases as the pigs reach 
adulthood. The use of GTKO pigs is more validated when using fetal or neonatal 
pancreas [85, 116], but is not as essential when using adult pigs [116]. However, 
increasing titres of anti-Gal IgG antibody have been noted when immunosuppres-
sion is stopped after adult pig islet transplant [30, 116], so GTKO pigs may prove 
beneficial even for islets isolated from adult pigs.
5.3.2 Instant blood mediated inflammatory reaction (IBMIR)
Following the intra-portal infusion of the pig islets, the elevated expression of 
tissue factor by the islets initiates IBMIR [39]. The IBMIR contributes to significant 
islet loss in the early post-transplant phase through a series of events involving 
simultaneous complement activation (alternative pathway) [81, 86], activation 
of intrinsic and extrinsic coagulation pathways, and platelet activation (platelet 
aggregates around the islets P6) followed by neutrophil and monocyte infiltration 
[110, 116, 133, 134]. IBMIR can result in 60–80% of islet loss in the immediate 
post-transplant period [39, 55, 110, 118, 135], but studies in NHPs have shown that 
if a sufficient number of islet cells survive, they can establish normoglycemia for 
several months [110]. Genetically modified pigs have been produced [110, 136] 
to combat IBMIR by decreasing the load of xenoantigens but it failed to provide 
long-term protection against host response [137]. Experimental studies involving 
control of complement activation by cobra venom factor, and platelet aggregation 
and coagulation by anti-platelet agents and low molecular weight heparins are not 
proven clinically safe, [138, 139]. Peritoneal cavity and omentum offer alternative 
sites for transplantation of encapsulated islets [140].
5.3.3 Cellular rejection
Cellular rejection, a CD4+ T-cell-dependent process [55, 141–143], plays a 
major role in islet destruction [39, 118, 144, 145]. Acute cellular rejection occurs 
within 24 h to 20 days post-transplant, and is characterized by a massive infiltra-
tion of macrophages and T-cells (CD4+ and CD8+cells). Two signaling pathways 
required for the full activation of T cells are the T cell receptor signaling, and the 
co-stimulatory signaling [55, 146]. Since T cell activation requires double signaling 
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must be free from a comprehensive and list of specified microorganisms [29, 106] 
and meticulous documentation and standard operating procedures (SOPs) must be 
implemented to maintain this status [29] including feed restrictions [29].
5.3 Immunological response
Pig islet cells express different surface proteins that play a major role in the 
immunological rejection seen following transplantation [102, 107]. Immunological 
responses are much more complex than seen in allo-transplantation [102]. Immune 
mediated inflammatory response have been brought down by significantly by 
genetic modifications as summarized in Table 2. Hyper acute rejection (HAR), 
Instant blood mediated inflammatory response (IBMIR), and cellular rejection are 
the types of responses seen in graft rejection of which IBMIR is the most crucial. 
Portal vein site provides good revascularization and drainage for islet transplanta-
tion but due to the severe complications like bleeding, thrombosis, and hepatic 
steatosis, it is no longer an optimal site [108]. Immunological issues observed during 
xenotransplantation are similar to those seen in allo-transplantation but are much 
more complex [102]. Pig islets express different types of surface proteins, and these 
play a critical role in the immunologic rejection seen following transplantation 
[107]. Multiple genetic modifications in pigs have been proposed to significantly 
reduce immune mediated inflammatory response, and these are summarized in 
Table 2.
There are four known major routes for islet cell loss following transplantation 
and these are summarized in the following sections.
5.3.1 Hyper acute rejection (HAR)
HAR occurs due to the presence of pre-existing host antibodies to surface 
proteins on the porcine islets. These surface proteins can be broadly categorized into 
Gal and non-Gal proteins [34, 38, 110]. The Gal epitope is absent in humans, apes 
and old-world monkeys but many bacteria, NHP and new world monkeys express 
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the Gal epitope abundantly. In pigs, the expression of Gal antigens decreases as they 
grow into adults [84, 102, 110, 124, 125].
As the human body is continuously exposed to micro-organisms (including 
bacteria), it develops immunity to the Gal antigen and has pre-formed, circulating 
anti-Gal antibodies [107, 126], which make up around 1% of the circulating anti-
bodies [102, 124]. Once the pigs islets are transplanted, these pre-formed anti-
bodies kill the islet cells rapidly by complement mediated destruction [107, 124] 
resulting in substantial islet loss [102, 107, 127].
Antibodies are also produced for other surface epitopes (non-Gal Ag) such as 
N-glycolylneuraminic acid (NeuGc) also known as Hanganutzu-Deicher and beta 
1,4 N-acetylgalactosaminyltransferase (B4GALNT2) [107, 128–130] which are also 
involved in complement mediated destruction of xenografts [107].
There are two known strategies for prevention of HAR. Knockout of genes 
responsible for adding the Gal epitope and other epitopes such as Neu5Gc to the 
cell surface can prevent their expression [34, 102]. Secondly, expression of comple-
ment regulatory proteins such as hCD46, hCD55 and hCD59 can be induced on the 
surface of the islet cells [102, 131]. Double knockout pigs (deficient in alpha-gal 
(GTKO) and Neu5Gc) have been produced, which has significantly reduced the 
incidence of humoral rejection [102, 132]. The Gal antigen is highly expressed 
in fetal and neonatal pig pancreas, but its expression decreases as the pigs reach 
adulthood. The use of GTKO pigs is more validated when using fetal or neonatal 
pancreas [85, 116], but is not as essential when using adult pigs [116]. However, 
increasing titres of anti-Gal IgG antibody have been noted when immunosuppres-
sion is stopped after adult pig islet transplant [30, 116], so GTKO pigs may prove 
beneficial even for islets isolated from adult pigs.
5.3.2 Instant blood mediated inflammatory reaction (IBMIR)
Following the intra-portal infusion of the pig islets, the elevated expression of 
tissue factor by the islets initiates IBMIR [39]. The IBMIR contributes to significant 
islet loss in the early post-transplant phase through a series of events involving 
simultaneous complement activation (alternative pathway) [81, 86], activation 
of intrinsic and extrinsic coagulation pathways, and platelet activation (platelet 
aggregates around the islets P6) followed by neutrophil and monocyte infiltration 
[110, 116, 133, 134]. IBMIR can result in 60–80% of islet loss in the immediate 
post-transplant period [39, 55, 110, 118, 135], but studies in NHPs have shown that 
if a sufficient number of islet cells survive, they can establish normoglycemia for 
several months [110]. Genetically modified pigs have been produced [110, 136] 
to combat IBMIR by decreasing the load of xenoantigens but it failed to provide 
long-term protection against host response [137]. Experimental studies involving 
control of complement activation by cobra venom factor, and platelet aggregation 
and coagulation by anti-platelet agents and low molecular weight heparins are not 
proven clinically safe, [138, 139]. Peritoneal cavity and omentum offer alternative 
sites for transplantation of encapsulated islets [140].
5.3.3 Cellular rejection
Cellular rejection, a CD4+ T-cell-dependent process [55, 141–143], plays a 
major role in islet destruction [39, 118, 144, 145]. Acute cellular rejection occurs 
within 24 h to 20 days post-transplant, and is characterized by a massive infiltra-
tion of macrophages and T-cells (CD4+ and CD8+cells). Two signaling pathways 
required for the full activation of T cells are the T cell receptor signaling, and the 
co-stimulatory signaling [55, 146]. Since T cell activation requires double signaling 
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involving TCRs and co-stimulatory molecules [39], blockade of co-stimulatory 
cell surface molecules such as CD870/86- CD28 and/or CD40L (CD154)- CD40 
have significantly improved graft survival, even without immunosuppression [39, 
147–149]. The addition of targeted immunosuppression to multi-molecular block-
ade may further increase effectiveness, and provide an even more promising option 
to prevent cellular destruction of the transplanted islets [39].
5.3.4 Islet cell revascularization
Islet revascularization is critical for the survival of transplanted pig islets. Islet 
grafts are cut off from their native vascular supply and after transplantation, are 
solely dependent on diffusion for nutrient supply, until functional revascularization 
is established with the host vasculature. This process takes place within 10–14 days 
post-transplantation [41, 49, 141].
6. Islet encapsulation approaches
Islet encapsulation provides the means for islet cell survival in the absence of 
immunosuppressive drugs. The principle of encapsulation is that transplanted 
cells are contained within an artificial compartment separated from the immune 
system by a semipermeable membrane. The capsule should protect the cells from 
potential damage caused by antibodies, complement proteins, and immune cells. 
Therefore, the capsule is often referred to as an “immunoisolation device.” As well 
as the protective mechanism provided by the capsules, islet cells within the capsules 
can also release insulin to control blood glucose levels, since this membrane enables 
small molecules to diffuse in (glucose, oxygen, and nutrients) and out (metabolic 
wastes) [39, 150–152]. Thus, the encapsulation system is also regarded as a “bio-
artificial pancreas.” The immunoisolation device or bioartificial pancreas can be 
commonly separated into two categories, intravascular and extravascular devices. 
The latter can further be divided into macroencapsulation and microencapsulation 
devices. Intravascular and extravascular classifications are based on whether or not 
it is connected directly to the blood circulation.
The macroencapsulation and microencapsulation classifications depend on 
whether it contains one or more islets in the device [153, 154]. Alginate is the most 
commonly used capsule material for microencapsulation, but other materials such 
polyethylene glycol have also been tested [153].
Although the capsule is selectively permeable, islets can be damaged due to 
hypoxia or inadequate nutrients, and slow glucose and insulin diffusion can delay 
insulin response to changing glucose levels [155]. Despite the protection offered 
from direct immune attack, islets can still be damaged by immune responses. 
Inflammatory cytokines, produced against the capsules can enter the capsule and 
damage islets. The encapsulated islets themselves may release such cytokines and 
cause self-damage [156]. Approaches investigated to overcome these problems 
include testing different sites of implantation, creating biocompatible capsules, 
and optimizing the capsule size. The use of genetically engineered pig islets within 
capsules to promote graft survival and function have also been studied [156]. 
Several clinical trials of encapsulated pig islets to improve long-term survival 
outcomes of xenografts are currently being conducted around the world [117, 157]. 
A phase I/IIa clinical study in Moscow has tested the clinical applicability of a com-
mercially available encapsulated pig islet product called Diabecell [39, 158, 159]. 
Additional phase I/IIa clinical trials are ongoing in New Zealand and Argentina. 
These trials have demonstrated an absence of PERV transmission, a significant 
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reduction in the number of severe hypoglycaemic episodes and up to 30% reduc-
tion in exogenous insulin doses [29, 160]. A 10 year follow up of another study 
involving xenotransplantation of encapsulated porcine islets into the peritoneum 
of a T1D patient has shown long-term islet survival and function, with no evidence 
of PERV infection [39, 150].
7. Regulatory aspects
Any new therapeutic substance or procedure, safety and efficacy of the drug 
substance have been inveterate before starting government approved clini-
cal trials. In line with guidance in consensus statements from the International 
Xenotransplantation Association and the WHO on xenotransplantation, geographi-
cal location will impact choice of the microbiological mitigation strategy. Risk 
management at the source would include the definition of pathogens circulating 
in the countries of origin [161], establishment of reliable detection, and screening 
methods and assessment of risk from animal feed. Given the source animals to 
be utilized will be from specific pathogen-free/designated pathogen-free or high 
hygienic herds from a single location, the pathogen risk compared with standard 
slaughter herd animals is significantly reduced. Further testing during the manu-
facturing process, that is, islet isolation and encapsulation will provide tissue 
specific data that should further confirm safety of the final product. Moreover, 
alginate encapsulation allows keeping the islets in culture for longer periods thus 
giving enough time to perform viral screening on islet products before transplanta-
tion. Other release quality controls related to islet morphology, viability, purity, 
quantity, and potency should also be established in order to guarantee that only 
well characterized and functional islet preparations are used in patients. The use of 
genetically modified donor pigs to reduce islet cells immunogenicity and improve 
their secretory function stipulates that these genetic modifications should be well 
characterized. Integration of transgene expression cassettes should be in well-
defined genomic locations, preferably in the form of a single-targeted integration 
that would ensure stable expression of the transgene across herds without affecting 
other cell functions or rendering them tumorigenic. In this context, it should be 
noted that encapsulation limits the risk of tumor cells spreading since it confines 
the cells and eliminates the need for immunosuppression meaning that in case the 
integrity of the encapsulation device would be compromised, xenogeneic pig cells 
would most probably be rejected by the host immune system. The use of nonhuman 
primates in research is subjected to very strict ethical and regulatory considerations 
but the pig-to-primate model is still considered as a gold standard for pig islet 
xenotransplantation, so that safety and efficacy data obtained using this model are 
required before initiating clinical studies [162].
8. Conclusion
Porcine islets represent an excellent alternative source to replace human islets 
in diabetic patients. Pig islets can be obtained from different life-stages (embryos 
to adults) and has several other advantages making it an indispensable resource for 
xenotransplantation. Active research have resulted in standardization of protocols, 
thereby bettering isolation outcomes. In addition, incorporation of multiple strate-
gies such as generating transgenic pigs together with developing cellular and molec-
ular therapies to sustain long-term xenograft survival have brought porcine islets 
closer to clinical applications. Despite the risk of zoonosis and other factors which 
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involving TCRs and co-stimulatory molecules [39], blockade of co-stimulatory 
cell surface molecules such as CD870/86- CD28 and/or CD40L (CD154)- CD40 
have significantly improved graft survival, even without immunosuppression [39, 
147–149]. The addition of targeted immunosuppression to multi-molecular block-
ade may further increase effectiveness, and provide an even more promising option 
to prevent cellular destruction of the transplanted islets [39].
5.3.4 Islet cell revascularization
Islet revascularization is critical for the survival of transplanted pig islets. Islet 
grafts are cut off from their native vascular supply and after transplantation, are 
solely dependent on diffusion for nutrient supply, until functional revascularization 
is established with the host vasculature. This process takes place within 10–14 days 
post-transplantation [41, 49, 141].
6. Islet encapsulation approaches
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Therefore, the capsule is often referred to as an “immunoisolation device.” As well 
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small molecules to diffuse in (glucose, oxygen, and nutrients) and out (metabolic 
wastes) [39, 150–152]. Thus, the encapsulation system is also regarded as a “bio-
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The latter can further be divided into macroencapsulation and microencapsulation 
devices. Intravascular and extravascular classifications are based on whether or not 
it is connected directly to the blood circulation.
The macroencapsulation and microencapsulation classifications depend on 
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Although the capsule is selectively permeable, islets can be damaged due to 
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Several clinical trials of encapsulated pig islets to improve long-term survival 
outcomes of xenografts are currently being conducted around the world [117, 157]. 
A phase I/IIa clinical study in Moscow has tested the clinical applicability of a com-
mercially available encapsulated pig islet product called Diabecell [39, 158, 159]. 
Additional phase I/IIa clinical trials are ongoing in New Zealand and Argentina. 
These trials have demonstrated an absence of PERV transmission, a significant 
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reduction in the number of severe hypoglycaemic episodes and up to 30% reduc-
tion in exogenous insulin doses [29, 160]. A 10 year follow up of another study 
involving xenotransplantation of encapsulated porcine islets into the peritoneum 
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of PERV infection [39, 150].
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Xenotransplantation Association and the WHO on xenotransplantation, geographi-
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management at the source would include the definition of pathogens circulating 
in the countries of origin [161], establishment of reliable detection, and screening 
methods and assessment of risk from animal feed. Given the source animals to 
be utilized will be from specific pathogen-free/designated pathogen-free or high 
hygienic herds from a single location, the pathogen risk compared with standard 
slaughter herd animals is significantly reduced. Further testing during the manu-
facturing process, that is, islet isolation and encapsulation will provide tissue 
specific data that should further confirm safety of the final product. Moreover, 
alginate encapsulation allows keeping the islets in culture for longer periods thus 
giving enough time to perform viral screening on islet products before transplanta-
tion. Other release quality controls related to islet morphology, viability, purity, 
quantity, and potency should also be established in order to guarantee that only 
well characterized and functional islet preparations are used in patients. The use of 
genetically modified donor pigs to reduce islet cells immunogenicity and improve 
their secretory function stipulates that these genetic modifications should be well 
characterized. Integration of transgene expression cassettes should be in well-
defined genomic locations, preferably in the form of a single-targeted integration 
that would ensure stable expression of the transgene across herds without affecting 
other cell functions or rendering them tumorigenic. In this context, it should be 
noted that encapsulation limits the risk of tumor cells spreading since it confines 
the cells and eliminates the need for immunosuppression meaning that in case the 
integrity of the encapsulation device would be compromised, xenogeneic pig cells 
would most probably be rejected by the host immune system. The use of nonhuman 
primates in research is subjected to very strict ethical and regulatory considerations 
but the pig-to-primate model is still considered as a gold standard for pig islet 
xenotransplantation, so that safety and efficacy data obtained using this model are 
required before initiating clinical studies [162].
8. Conclusion
Porcine islets represent an excellent alternative source to replace human islets 
in diabetic patients. Pig islets can be obtained from different life-stages (embryos 
to adults) and has several other advantages making it an indispensable resource for 
xenotransplantation. Active research have resulted in standardization of protocols, 
thereby bettering isolation outcomes. In addition, incorporation of multiple strate-
gies such as generating transgenic pigs together with developing cellular and molec-
ular therapies to sustain long-term xenograft survival have brought porcine islets 
closer to clinical applications. Despite the risk of zoonosis and other factors which 
Xenotransplantation - Comprehensive Study
36
Author details
Rajeswar Chinnuswami, Abid Hussain, Gopalakrishnan Loganathan, 
Siddharth Narayanan, Gene D. Porter and Appakalai N. Balamurugan*
Clinical Islet Cell Laboratory, Department of Surgery, Cardiovascular Innovation 
Institute, University of Louisville, Louisville, KY, United States
*Address all correspondence to: bala.appakalai@louisville.edu
contribute to islet loss post-transplantation, tremendous progress has been made 
within the field such as developing encapsulated islets to combat host immunity and 
utilizing host stem cells to aide islet revascularization. Pig islet xenotransplantation 
currently acts as a bridge between allo-transplantation and stem-cell therapies. 
With all the tremendous progress made within the field, ongoing research focuses 
on a better understanding of various factors such as donor characteristics, isolation 
procedures, microbiological safety, and immunological tolerance to improve pig 
islet yield, function and transplantation outcomes. Furthering this understanding 
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Abstract
Although surgical techniques have progressively improved in the field of con-
genital heart disease (CHD), even such as hypoplastic left heart syndrome, pediatric
heart transplantation is the most effective surgical option for complex CHD and
cardiomyopathy with severe heart failure. However, even now, donor heart avail-
ability has been poor in children. Although technologies for ventricular assist device
(VAD) have been progressing even in children, VAD cannot grow as the pediatric
recipient grows. Therefore, pediatric cardiac xenotransplantation has a great possi-
bility to save and grow children with end-stage heart failure. In this chapter, I
would like to introduce the first pediatric baboon-to-human heart transplantation
and its basic animal experiments done by Bailey’s group and the following attempts
for pediatric cardiac orthotopic xenotransplantation (rhesus monkey-to-baboon
and pig-to-primate combination).
Keywords: concordant and discordant xenogeneic orthotopic heart transplantation,
pediatric heart transplantation, clinical trial, antibody absorption, primates, pig,
goat, lamb
1. Introduction
Clinical heart transplantation (HTx) was the unambiguous goal of the laboratory
research at Stanford University in the mid-1960s [1]. They were making tremen-
dous progress in their understanding of the host immune response, and how to
control that response with drugs of that era, while at the same time avoiding lethal
infection. Then, unexpectedly, on December 3, 1967, Christiaan Barnard et al.
performed the first clinical HTx in Cape Town, South Africa [2]. Their recipient
survived only 18 days, dying of pneumonia. Nevertheless, it stirred worldwide
enthusiasm for HTx, and, more importantly, it opened the door for the Stanford
group to develop the procedure in human.
But with regard to infants, Adrian Kantrowitz at New York attempted HTx in a
newborn from an anencephalic baby just 3 days after Barnard’s first HTx [3]. The
recipient died 6 and a half hour after the procedure, and Kantrowitz never pursued
clinical HTx. In the 1970s, there have been great progresses in medical and intensive
management and surgical technology for neonates and infants with complex con-
genital heart. However, almost all neonates and infants with too complexed con-
genital anomaly, especially hypoplastic left heart syndrome (HLHS), could not
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1. Introduction
Clinical heart transplantation (HTx) was the unambiguous goal of the laboratory
research at Stanford University in the mid-1960s [1]. They were making tremen-
dous progress in their understanding of the host immune response, and how to
control that response with drugs of that era, while at the same time avoiding lethal
infection. Then, unexpectedly, on December 3, 1967, Christiaan Barnard et al.
performed the first clinical HTx in Cape Town, South Africa [2]. Their recipient
survived only 18 days, dying of pneumonia. Nevertheless, it stirred worldwide
enthusiasm for HTx, and, more importantly, it opened the door for the Stanford
group to develop the procedure in human.
But with regard to infants, Adrian Kantrowitz at New York attempted HTx in a
newborn from an anencephalic baby just 3 days after Barnard’s first HTx [3]. The
recipient died 6 and a half hour after the procedure, and Kantrowitz never pursued
clinical HTx. In the 1970s, there have been great progresses in medical and intensive
management and surgical technology for neonates and infants with complex con-
genital heart. However, almost all neonates and infants with too complexed con-
genital anomaly, especially hypoplastic left heart syndrome (HLHS), could not
survive surgery. Theoretically, these neonates, with naïve immune systems and
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uniformly lethal heart disease, should be excellent candidates for HTx that included
aortic arch reconstruction. But around for a decade since the first HTx, clinical HTx
was limited to only a handful of progressive institutions, and none was
spearheading research in neonatal HTx except a little Leonard L Bailey’s group at
Loma Linda University.
His laboratory was using neonatal goats as recipients, and, initially, goats as
donors. In 1981, the Sandoz Laboratory, a pharmaceutical house in Basal, Switzer-
land, agreed to provide them with an investigational agent called cyclosporine-A
(CsA). With CsA immunosuppression alone, they observed remarkable survival,
maturation, and reproductive capacity among goats that were orthotopically
transplanted as newborns with allografts [4]. Even recipients of cross-species grafts
from lamb to goat experienced unprecedented survival [5].
2. Lamb to goat orthotopic concordant xenoHTx
Fourteen newborn (less than 7 days old) goats underwent orthotopic HTx
with a size-matched lamb’s heart [5]. Ten goats survived longer than 24 hours
after HTx. Recipient animals received CsA 48 and 24 hours before HTx and daily
after HTx on a gradually reducing daily protocol. Recipients were also given pulse
doses of methylprednisolone (100 mg/kg) and azathioprine (3 mg/kg) once a week,
the dosage schedule being gradually reduced. Azathioprine was discontinued on
postoperative day 60. Survival among the 10 recipients was 24, 32, 44, 47, 60, 60,
78, 90, 120, and 165 days. Average survival was 72 days. Serial left ventricular
ejection fractions measured by radionuclide left ventriculography from 1 to
4 months postoperatively in four recipients averaged 50, 58, 45, and 45%. There
were no significant infections. Most animals showed mild-to-moderate subacute
and chronic graft rejection at autopsy. One host showed no gross or microscopic
graft rejection at autopsy on postoperative day 47. Tumor was not observed.
These data suggest that long-term survival may be feasible for newborn recipients
of cardiac xenografts with CsA therapy and limited supplemental
immunosuppression.
3. Attempt of a baboon-to-human orthotopic concordant xenoHTx
Neonatal and small infant heart donors were not available in the early 1980s;
hence, the Bailey’s group focused on the possibility of using immature baboons as
donors for neonates with HLHS. They purchased a panel of infant baboons and
studied them extensively for infectious diseases. They performed HLA-typing, two-
way mixed lymphocyte cultures, and ex vivo perfusion studies to assess their
compatibility with human neonates. They thought it might be possible to actually
select a “best” baboon donor for any individual baby with HLHS. They began an
arduous 14-month process of obtaining Institutional Review Board (IRB) approval
for experimental clinical trials of baboon-to-human baby concordant xenoHTx.
Sandra Nehlsen-Cannarella, a transplant immunologist and Medawar protégé, was
one of external reviewers, helped their works, and finally joined their team after the
IRB was approved in October 1984 [6].
Then, in late July of 1984, Dr. Magdi Yacoub and his team at the National Heart
Hospital in London transplanted an 11-day-old newborn with HLHS [7], but the
recipient had a complex postoperative course and died of respiratory failure on
postoperative day 4. Later that same year, in October, the Bailey’s group were
confronted with the potential to activate our IRB-approved protocol. A neonate
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with HLHS named “Baby Fae”was transplanted on October 26, 1984, with the heart
of a highly selected infant baboon [8, 9]. She lived for only 20 days, and despite
careful observations and analysis, the cause(s) of her death remains somewhat of an
enigma. She did heighten awareness, however, and her transplant led directly to the
first successful neonatal HTx, again as treatment for HLHS, in November of 1985.
That infant is now a 34-year-old man working in Las Vegas. Baby Fae’s legacy is
found among the hundreds of neonates and small infants who are living today
because of primary or secondary HTx in the world. However, donor shortage had
been still severe, and continuous experimental efforts to achieve clinical infant
xenoHTx had been performed in the Bailey’s group.
4. The immunological effects of concordant xenograft bridging to
cardiac allografting in baboon
Human neonatal xenoHTx evolved around the idea of xenograft bridging to
cardiac allografting. The important question relating to this approach was whether
the bridged recipient would develop an antibody response to the initial xenograft
that would be cross-reactive with the allograft donor. This question was initially
explored by Alonso de Begona [10] using a heterotopic HTx model from African
green monkey to juvenile baboons treated with CsA (Table 1). These 5 grafts are
rejected over a period of 5–65 days. Lymphocytotoxic xenoantibody was identified
in recipient blood samples. The rejected xenografts were removed, and the recipient
circulating xenoantibody titers were observed to peak over 24–48 hours. Using
cardiopulmonary bypass primed without blood, the immature baboon recipients
then underwent orthotopic allogeneic HTx and were treated with varying degrees
using a cyclosporine (CSA) protocol. All survived the secondary allogeneic HTx
without any evidence of hyperacute, antibody-mediated rejection. The recipients
survived 10, 58, 65, 198, and 164 days. Despite a high titer of circulating
xenoantibody in each of the host baboons, orthotopic allogeneic engraftment was
possible in all five recipients. Each was immunosuppressed with gradations of CSA-
based therapy. Survival to 5 and 6 months of the last two consecutive animals
(which were ultimately euthanized) was not unlike that expected for
Cardiac heterotopic xenograft
(African green monkey)











1 A None 11 A None 10 Severe
2 A None 5 A B 58 Moderated to
severe
3 A None 6 A B 65 Moderated to
severe
4 A + B B + C 13 A B + C 198b None
5 A + B + C None 65 A + B None 164b None




Survival of xenografts and allografts and host therapy employed in a xenograft bridge to allograft model using
an immature baboon recipient.
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allotransplanted hosts. Xenoantibody did not appear to alter acute or chronic sur-
vival of baboon recipients managed with a clinically applicable regimen of immune
regulation. The two chronic survivors had well-functioning allografts that were free
of significant rejection injury. These findings have subsequently been confirmed
and elaborated on by Michler et al. [11].
5. Rhesus monkey to baboon orthotopic concordant xenoHTx
Orthotopic concordant xenotransplantation in a juvenile primate model was
examined [12, 13]. Eighteen donor rhesus monkeys weighing 2.4–3.8 kg (mean
2.9 kg) were matched with juvenile baboons, aged 9–19 months (mean 12.7 months)
and weighing 3.2–4.8 kg (mean 3.9 kg), using ABH blood type and mixed lympho-
cyte culture. In order to examine plasma level of tacrolimus (Tac) in infant baboons
and establish immunosuppressive regimen before starting orthotopic xenoHTx
experiments [14], seven of these baboons already received two courses of 4-week
immunosuppressive therapy prior to HTx. All baboons underwent splenectomy at
the time of HTx.
Twelve animals were divided into three groups; five baboons received no
immunosuppressive therapy (Group-C). Five baboons were pretreated (Group-P)
and the other seven (Group-NP) was not pretreated. Twelve baboons received
sheep antilymphocyte globulin (ALG; IV 15 mg/kg) induction for 3 days before the
operation and 5 days after xenoHTx and oral tacrolimus (Tac; 18 mg/kg) and
intravenous methotrexate (MTX; 0.1–5 mg IV twice weekly) daily after xenoHTx.
The baboons in Group-P received two courses of 4-week immunosuppressive ther-
apy prior to xenoHTx; the first course consisted with Tac (18 mg/kg p.o. daily)
alone and the second one consisted with Tac (12 mg/kg p.o. daily) and methotrexate
(MTX; 25 mg IV weekly). Pretreated baboons had drug-free intervals for 37 days
between two courses and for 83–110 days between the second course and xenoHTx.
Intravenous methotrexate, methylprednisolone, ALG, and their combination were
used as rescue therapy (Table 2).
Baboons in group-C had a mean survival of 8 days; all died as a result of classic
severe cellular rejection. Baboons in Group-NP had a mean survival of 51.3 days
(25–75 days), and those in Group-P had a mean survival of 198 days (35–502 days).
Two in Group-NP died during rescue therapy for rejection, and three in
Group-NP and two in Group-P died of cytomegalovirus (CMV) infection. One in
Group-NP died of massive micro-pulmonary embolism. The remaining two
in Group-P died of Klebsiella pneumoniae and renal failure aggravated by
ganciclovir, respectively.
The longest surviving baboon, named Max, had been a healthy, active, growing
baboon with normal cardiac function assessed by echocardiography and left
ventriculography and coronary arteries normal in size and distribution assessed by
coronary arteriograms at 1 year after xenoHTx. After these examinations, we tried
to convert him to oral medications, and his level of immunosuppression fluctuated
widely, which led to a late, powerful rejection response. This xenograft rejection
was reversed successfully using corticosteroids and ALG. The additional bolus
immunosuppression, however, permitted the development of generalized CMV
disease and eventually bacterial sepsis from which Max (Figure 1) ultimately died.
The animal’s autopsied xenograft was almost free of cellular rejection but with mild
coronary graft atherosclerosis [15].
Management of CMV infection in this splenectomized series of baboon recipi-
ents proved to be at least as difficult as controlling the immune response toward
their cardiac xenografts. However, Tac coupled with low-dose maintenance
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methotrexate and splenectomy has produced prolonged host survival in this
xenotransplantation model. Results suggest that concordant xenotransplantation









1 6 Moderate cellular rejection None Rejection
2 7 Moderate cellular rejection None Rejection
3 8 Severe cellular rejection None Rejection
4 8 Severe cellular rejection None Rejection
5 9 Severe cellular rejection None Rejection
6 10 Severe cellular rejection None Rejection
Group-NPa
1 25 CMV infection, no rejection ALG (21) Systemic CMV
infection
2 32 CMV infection, no rejection None CMV infection
(graft)




4 53 Mild cellular rejection ALG (68) CMV infection
(lung)




6 74 Mild cellular rejection Mild
graft atherosclerosis
Upb MTX (25) Pulmonary
embolism
7 75 Mild cellular rejection ALG + MP (29, 62) During rejection
treatment
Group Pa
1 35 Mild cellular rejection None Klebsiella
pneumonia
2 96 No rejection ALG + MP (71) Renal failure




4 234 Toxoplasmosis ALG (94d) Toxoplasmosis
5 502 Mild cellular rejection Mild
graft atherosclerosis
Upb Tac and MTX (68, 238),
ATGAM+MP (392), MP (482)
Liver failure and
CMV infection
ALG, sheep antilymphocyte globulin; CMV, cytomegalovirus; MP, methyl prednisolone; Tac, tacrolimus; MTX,
methotrexate; ATGAM, equine anti-thymocyte globulin.
aGroup-C: controls. Group-NP: intravenous sheep antilymphocyte globulin (ALG) induction at 3 and + 5 days
perioperatively, daily oral tacrolimus (Tac), and twice weekly intravenous methotrexate (MTX) after
transplantation. Group-P: two courses of 4-week immunosuppressive therapy (1st course, oral Tac alone; 2nd course,
oral Tac and intravenous MTX) prior to transplantation and the same immunosuppressive therapy after
transplantation as for Group-NP.
Groups NP and P subjects had splenectomy at the time of heart transplantation.
bincrease dose.
Table 2.
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allotransplanted hosts. Xenoantibody did not appear to alter acute or chronic sur-
vival of baboon recipients managed with a clinically applicable regimen of immune
regulation. The two chronic survivors had well-functioning allografts that were free
of significant rejection injury. These findings have subsequently been confirmed
and elaborated on by Michler et al. [11].
5. Rhesus monkey to baboon orthotopic concordant xenoHTx
Orthotopic concordant xenotransplantation in a juvenile primate model was
examined [12, 13]. Eighteen donor rhesus monkeys weighing 2.4–3.8 kg (mean
2.9 kg) were matched with juvenile baboons, aged 9–19 months (mean 12.7 months)
and weighing 3.2–4.8 kg (mean 3.9 kg), using ABH blood type and mixed lympho-
cyte culture. In order to examine plasma level of tacrolimus (Tac) in infant baboons
and establish immunosuppressive regimen before starting orthotopic xenoHTx
experiments [14], seven of these baboons already received two courses of 4-week
immunosuppressive therapy prior to HTx. All baboons underwent splenectomy at
the time of HTx.
Twelve animals were divided into three groups; five baboons received no
immunosuppressive therapy (Group-C). Five baboons were pretreated (Group-P)
and the other seven (Group-NP) was not pretreated. Twelve baboons received
sheep antilymphocyte globulin (ALG; IV 15 mg/kg) induction for 3 days before the
operation and 5 days after xenoHTx and oral tacrolimus (Tac; 18 mg/kg) and
intravenous methotrexate (MTX; 0.1–5 mg IV twice weekly) daily after xenoHTx.
The baboons in Group-P received two courses of 4-week immunosuppressive ther-
apy prior to xenoHTx; the first course consisted with Tac (18 mg/kg p.o. daily)
alone and the second one consisted with Tac (12 mg/kg p.o. daily) and methotrexate
(MTX; 25 mg IV weekly). Pretreated baboons had drug-free intervals for 37 days
between two courses and for 83–110 days between the second course and xenoHTx.
Intravenous methotrexate, methylprednisolone, ALG, and their combination were
used as rescue therapy (Table 2).
Baboons in group-C had a mean survival of 8 days; all died as a result of classic
severe cellular rejection. Baboons in Group-NP had a mean survival of 51.3 days
(25–75 days), and those in Group-P had a mean survival of 198 days (35–502 days).
Two in Group-NP died during rescue therapy for rejection, and three in
Group-NP and two in Group-P died of cytomegalovirus (CMV) infection. One in
Group-NP died of massive micro-pulmonary embolism. The remaining two
in Group-P died of Klebsiella pneumoniae and renal failure aggravated by
ganciclovir, respectively.
The longest surviving baboon, named Max, had been a healthy, active, growing
baboon with normal cardiac function assessed by echocardiography and left
ventriculography and coronary arteries normal in size and distribution assessed by
coronary arteriograms at 1 year after xenoHTx. After these examinations, we tried
to convert him to oral medications, and his level of immunosuppression fluctuated
widely, which led to a late, powerful rejection response. This xenograft rejection
was reversed successfully using corticosteroids and ALG. The additional bolus
immunosuppression, however, permitted the development of generalized CMV
disease and eventually bacterial sepsis from which Max (Figure 1) ultimately died.
The animal’s autopsied xenograft was almost free of cellular rejection but with mild
coronary graft atherosclerosis [15].
Management of CMV infection in this splenectomized series of baboon recipi-
ents proved to be at least as difficult as controlling the immune response toward
their cardiac xenografts. However, Tac coupled with low-dose maintenance
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methotrexate and splenectomy has produced prolonged host survival in this
xenotransplantation model. Results suggest that concordant xenotransplantation
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transplantation. Group-P: two courses of 4-week immunosuppressive therapy (1st course, oral Tac alone; 2nd course,
oral Tac and intravenous MTX) prior to transplantation and the same immunosuppressive therapy after
transplantation as for Group-NP.
Groups NP and P subjects had splenectomy at the time of heart transplantation.
bincrease dose.
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Results of orthotopic cardiac xenotransplantation between immature baboon recipients and rhesus monkey
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6. Toward discordant xenoHTx
Although the high degree of evolutionary relatedness between human beings
and primates both suggests that xenotransplantation of primate organs and tissue
might be successful, particular concerns are raised by the use of primates, such as
baboons. The characteristics, for example, of intelligence and complex social inter-
actions of these closely related higher primates appear to be so like those of human
beings that use members of those species as sources for xenotransplantation which
might well be seen as ethically unacceptable [16]. The potential risk of extinction,
even to a species like the baboon that is not currently endangered, must be taken
seriously. The possible transmission of disease from higher primates to human
beings and the welfare of the animals should be concerned. From these concerns, it
is currently agreed that the use of primates would be ethically unacceptable.
Given the ethical concerns raised by the use of primates for xenotransplantation,
attention has turned to developing the pig as an alternative source of organs and
tissue, because the use of pigs for xenotransplantation raises fewer ethical concerns.
Attention has focused in particular on pigs, since their organs are comparable in size
to human ones, and they breed rapidly and could thus be used to supply transplant
material on a large scale. The use of pigs as a domestic animal that is farmed and
eaten is long established, and many would have fewer concerns about their use for
xenotransplantation than the use of primates. If pigs are used for xenotransplanta-
tion, they are likely to have been genetically modified so the human immune
response to the pig organs and tissue is reduced [16].
When a pig organ is transplanted into a human or nonhuman primate, an imme-
diate immune response occurs with hyperacute rejection (HAR). This has been
defined as destruction of the graft in less than 24 hours; however, it usually occurs
Figure 1.
Max, an immature baboon recipient of an orthotopic cardiac xenotransplant acquired from a donor rhesus
monkey.
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within the first hour. This is due to the binding of the preformed anti-pig antibodies
(Ab) to the endothelial cells of the graft. Ab deposits initiate a complement-mediated
response with endothelial injury, resulting in thrombosis, interstitial hemorrhage, and
edema, with subsequent graft dysfunction [17]. Later, it was determined that Ab bind
to the carbohydrate epitope, galactose–a1,3-galactose (Gal), expressed in the pig
vascular endothelium. This oligosaccharide is present in other mammals, except
humans and primates. These Ab are produced in response to viruses and microor-
ganisms that express Gal and colonize the gastrointestinal tract of primates [18].
7. Pig-to-baboon orthotopic discordant xenoHTx
The feasibility of transplanting across discordant xenogeneic barriers in an











1b None None 4.5 HAR Rejection
2 None None 18 HAR Rejection
Group-Da
1c Donor lung None 6.5 HAR Rejection
2 Donor lung None 10 HAR Rejection





None 99 Pneumonia Pneumonia
2 Large pig
lung
None 111 DXR Rejection
Group-D + Ea
1 Donor lung Blood replacement 117.5 DXR Brain death
2c Donor lung RBC/serum
replacement
100 DXR Rejection
3 Donor lung RBC/serum
replacement
111 DXR Rejection
4 Donor lung RBC/serum
replacement
123 DXR Rejection
5 Donor lung RBC/serum
replacement
174.5 DXR, CR Rejection
aGroup-C, controls; Group-D, donor lung perfusion; Group-LD, perfusion with another large pig lungs; Group-
D + E, donor lung perfusion, exsanguination, and replacement with whole blood pretreated or packed red blood cell
(RBC) and serum pretreated.
bNo immunosuppression therapy.
cKidney perfusion in case of suspected antibody-mediated rejection.
dThymic injection with donor myocardium (left atrium).
All subjects had pretransplant splenectomy. CMV, cytomegalovirus; RBC, red blood cell; HAR, hyperacute rejection;
DXR, delayed xenograft rejection; CR, cellular rejection.
Table 3.
Results of orthotopic cardiac xenotransplantation between juvenile baboon recipients and piglet donors.
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within the first hour. This is due to the binding of the preformed anti-pig antibodies
(Ab) to the endothelial cells of the graft. Ab deposits initiate a complement-mediated
response with endothelial injury, resulting in thrombosis, interstitial hemorrhage, and
edema, with subsequent graft dysfunction [17]. Later, it was determined that Ab bind
to the carbohydrate epitope, galactose–a1,3-galactose (Gal), expressed in the pig
vascular endothelium. This oligosaccharide is present in other mammals, except
humans and primates. These Ab are produced in response to viruses and microor-
ganisms that express Gal and colonize the gastrointestinal tract of primates [18].
7. Pig-to-baboon orthotopic discordant xenoHTx
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174.5 DXR, CR Rejection
aGroup-C, controls; Group-D, donor lung perfusion; Group-LD, perfusion with another large pig lungs; Group-
D + E, donor lung perfusion, exsanguination, and replacement with whole blood pretreated or packed red blood cell
(RBC) and serum pretreated.
bNo immunosuppression therapy.
cKidney perfusion in case of suspected antibody-mediated rejection.
dThymic injection with donor myocardium (left atrium).
All subjects had pretransplant splenectomy. CMV, cytomegalovirus; RBC, red blood cell; HAR, hyperacute rejection;
DXR, delayed xenograft rejection; CR, cellular rejection.
Table 3.
Results of orthotopic cardiac xenotransplantation between juvenile baboon recipients and piglet donors.
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laboratories during the early 1990s. Because HAR was at that time the single
most important factor in limiting discordant xenoHTx, early strategies were
directed toward eliminating or reducing baboon preformed xeno Ab to pig sugar
antigens [19, 20].
All recipient baboon underwent splenectomy 2 weeks before HTx. Donor hearts
were obtained from 12 newborn piglets of either sex age 2–7 days and weighing 1.8–
3.1 kg (mean 2.3  0.1 kg) and transplanted orthotopically with deep hypothermia
and circulatory arrest in recipient juvenile baboon age 252–459 days (mean
362 19 days) and weighing 2.4–3.5 kg (mean 2.9 0.1 kg). All animals received an
infusion of nafamostat mesylate (FUT-175) at a dose of 2 mg/kg/h for 2 h at the time
of reperfusion. The recipient baboon received 15 mg/kg CsA orally or 5 mg/kg
intravenously and 5 mg/kg 15-deoxyspergualin (DSG) intramuscularly, from the
day before HTx until death.
In two baboons, no antibody adsorption (AbA) using pig lungs was performed
for control (Group-C). In 10 baboons, the blood in the bypass circuit was perfused
into a pig lung to absorb baboon anti-pig antibody during circulatory arrest at the
time of HTx. In three baboons (Group-D), the donor lung was perfused, and in two
baboons (Group-LD), a lung larger than the donor pig (weighing 5–7 kg) was
perfused. In five baboons (Group-D + E), the donor lung was perfused, and exsan-
guination was also performed at the beginning of cardiopulmonary bypass (CPB),
and the baboon blood was replaced with pretreated whole blood (N = 1) or packed
red blood cell (RBC) and 50 ml of pretreated plasma (N = 4). The pretreated blood
(N = 1) and serum (N = 4) were made by perfusing with other large pig lung
(weighing 15 and 20 kg) before xenoHTx. Two baboons underwent pig kidney
perfusion using an extracorporeal shunt from the right femoral artery to vein, 5 and
6 days after xenoHTx, because antibody-mediated rejection was suspected.
Figure 2.
An immature baboon recipient of an orthotopic cardiac xenotransplant acquired from a donor pig, which
survived 6 days after xenotransplant.
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The two control animals survived 4.5 and 18 hours, and the pathological changes
of the grafts were compatible with HAR. The other animals survived 125  33 h
(10–375 hors). The longest surviving baboon who survived 375 hours was in Group-
D, but other two in Group-D died of HAR. All baboons in Group-LD and Group-
D + E survived more than 4 days after XenoHTx. One in Group-D died of CMV
infection and one in Group-LD died of pneumonia. One in Group-LD and four in
Group-D + E died of acute cellular rejection. In summary, examination and echo-
cardiography revealed no evidence of hyperacute rejection in baboons surviving
more than 1 day. The longest survivor (375 hours) died of CMV infection with
microscopic evidence of mild delayed HAR and graft coronary atherosclerosis. A
variable amount of delayed xenograft rejection (DXR) was observed histologically,
among the other recipient baboons (Table 3 and Figure 2) [20].
Another baboon which underwent large pig lung perfusion and is given
Tac + MTX without splenectomy survived 16 days, and the autopsied graft showed
mild DXR and moderate GCAS [20].
8. The role of anti-pig antibody in pig-to-baboon xenoHTx rejection
To investigate the role of anti-pig Ab in discordant xenograft rejection, these 12
baboons were divided into 2 groups: Group-S (n = 4) died within 24 hr. of HTx and
Group-L (n = 8) survived more than 24 hr. [19]. Mean survival period was
9.8  3.0 h in Group-S and 151  33 h in Group-L. Baboon anti-pig Ab was
measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and
daily after HTx. Anti-RBC Ab was measured by the titration method at tempera-
tures of 4 degrees C and 37 degrees C (RAb-4 and RAb-37). Anti-endothelial cell Ab
(EAb) and anti-white blood cell Ab (WAb) titers were measured with enzyme-
linked immunosorbent assay (ELISA). RAb titration > or = 1/4 and EAb and
WAb > or = 1/256 were determined to be seropositive. Seropositive rate of RAb-37
at the end of CPB (endCPB) in Group-L was significantly higher than that in
Group-S (8/8 vs. 1/4; P < 0.05). The seronegative rates of RBC-4 and EAb
(endCPB) in Group-L were higher than those in Group-S (7/8 vs. 1/4 and 6/8 vs.
1/4, respectively), but not significantly. There was no difference in seronegative
rate of WAb (endCPB) between both groups. More than fourfold decrease in RAb-4
and RAb-37 by AbA with a pig lung was observed in 5 and 7 of 8 baboons, while EAb
and WAb did not change by AbA. In all of Group-L, RAb-4 reverted to seropositive
within 3 days after HTx. In four of Group-L, RAb-37 became S(+), 1 or 2 days
before death by rejection. EAb became seropositive in all of Group-S, but five of
them survived more than 5 days after seroconversion. It was concluded that a pig
lung absorbed RAb-4 and RAb-37 may play a role in DXR.
After I came back to Japan, the role of RAb-37 on pig-to-baboon xenoHTx was
investigated using sequential heterotopic HTx [21]. Fifteen pig hearts were
obtained from pigs weighing 6.4–91 kg. Eleven hearts from pigs larger than the
recipient were used for perfusion, and four hearts from a pig of the same size as
the recipient for heterotopic transplant donor heart. Four female baboons
weighing 5.9–8.1 kg received Tac (12 mg.kg) and CAM (50 mg/kg) p.o. daily
2 weeks before and after xenoHTx. After perfusion with two or three large pig
hearts, a pig heart was heterotopically transplanted in the right neck of recipient
baboon. As the second and third recipient baboons died of hypotension during the
third pig heart perfusion and could not undergo heterotopic xenoHTx, the last
baboon underwent two pig heart perfusion and subsequent heterotopic xenoHTx.
All first perfused hearts and two second perfused hearts were hyperacutely
rejected within 30 minutes of perfusion, but the other two second and all third
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intravenously and 5 mg/kg 15-deoxyspergualin (DSG) intramuscularly, from the
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The two control animals survived 4.5 and 18 hours, and the pathological changes
of the grafts were compatible with HAR. The other animals survived 125  33 h
(10–375 hors). The longest surviving baboon who survived 375 hours was in Group-
D, but other two in Group-D died of HAR. All baboons in Group-LD and Group-
D + E survived more than 4 days after XenoHTx. One in Group-D died of CMV
infection and one in Group-LD died of pneumonia. One in Group-LD and four in
Group-D + E died of acute cellular rejection. In summary, examination and echo-
cardiography revealed no evidence of hyperacute rejection in baboons surviving
more than 1 day. The longest survivor (375 hours) died of CMV infection with
microscopic evidence of mild delayed HAR and graft coronary atherosclerosis. A
variable amount of delayed xenograft rejection (DXR) was observed histologically,
among the other recipient baboons (Table 3 and Figure 2) [20].
Another baboon which underwent large pig lung perfusion and is given
Tac + MTX without splenectomy survived 16 days, and the autopsied graft showed
mild DXR and moderate GCAS [20].
8. The role of anti-pig antibody in pig-to-baboon xenoHTx rejection
To investigate the role of anti-pig Ab in discordant xenograft rejection, these 12
baboons were divided into 2 groups: Group-S (n = 4) died within 24 hr. of HTx and
Group-L (n = 8) survived more than 24 hr. [19]. Mean survival period was
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WAb > or = 1/256 were determined to be seropositive. Seropositive rate of RAb-37
at the end of CPB (endCPB) in Group-L was significantly higher than that in
Group-S (8/8 vs. 1/4; P < 0.05). The seronegative rates of RBC-4 and EAb
(endCPB) in Group-L were higher than those in Group-S (7/8 vs. 1/4 and 6/8 vs.
1/4, respectively), but not significantly. There was no difference in seronegative
rate of WAb (endCPB) between both groups. More than fourfold decrease in RAb-4
and RAb-37 by AbA with a pig lung was observed in 5 and 7 of 8 baboons, while EAb
and WAb did not change by AbA. In all of Group-L, RAb-4 reverted to seropositive
within 3 days after HTx. In four of Group-L, RAb-37 became S(+), 1 or 2 days
before death by rejection. EAb became seropositive in all of Group-S, but five of
them survived more than 5 days after seroconversion. It was concluded that a pig
lung absorbed RAb-4 and RAb-37 may play a role in DXR.
After I came back to Japan, the role of RAb-37 on pig-to-baboon xenoHTx was
investigated using sequential heterotopic HTx [21]. Fifteen pig hearts were
obtained from pigs weighing 6.4–91 kg. Eleven hearts from pigs larger than the
recipient were used for perfusion, and four hearts from a pig of the same size as
the recipient for heterotopic transplant donor heart. Four female baboons
weighing 5.9–8.1 kg received Tac (12 mg.kg) and CAM (50 mg/kg) p.o. daily
2 weeks before and after xenoHTx. After perfusion with two or three large pig
hearts, a pig heart was heterotopically transplanted in the right neck of recipient
baboon. As the second and third recipient baboons died of hypotension during the
third pig heart perfusion and could not undergo heterotopic xenoHTx, the last
baboon underwent two pig heart perfusion and subsequent heterotopic xenoHTx.
All first perfused hearts and two second perfused hearts were hyperacutely
rejected within 30 minutes of perfusion, but the other two second and all third
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RAb-4 RAb-37 EAb-IgM EAb-IgG
Adult 582  579 296  291 288  189 853  264
Cord blood 144  181* 69/96* 21  8.3** 683  264
Infant <38 days old 80  58* 30  19*
Infant > = 38 days old 689  678*** 239  149***
RAb-4 and RAb-37: human anti-pig red blood cell antibody titer at temperature of 4°C and 37°C, respectively.
EAb-IgM and EAb-IgG: human anti-pig endothelial cell antibody (immunoglobulin M and G) titers, respectively.
*p < 0.01 vs. adult.
**p < 0.05 vs. adult.
***p < 0.01 vs. cord blood or infant younger than 38 days old.
Table 4.













1b F1 pig None 21 No No Severe HAR




None 104 Yes No Mild HAR
2 DAFb
transgenic pig
None 135 Yes Yes Mild HAR
3 DAFc
transgenic pig




Heart 211 Yes No Moderate HAR
2 DAFb
transgenic pig
Heart 310 Yes No Moderate HAR
3 d DAFb
transgenic pig












None 493 Yes Yes Mild to
moderate HAR
DAF, decay-accelerating factor; GnT-III, beta-D mannoside beta-1,4-N-acetylglucosaminyltransferase III; AXC,
aortic cross-clamping; CPB, cardiopulmonary bypass; HAR, hyperacute rejection; DXR, delayed xenograft rejection.
aGroup-C, controls; Group-DAF, transplanted DAF transgenic pig heart; Group-DAF + P, transplanted DAF
transgenic pig heart and perfused with another pig heart; Group-GnT-III, transplanted GnT-III transgenic pig heart.
bHetero DAF transgenic pig.
cHomo DAF transgenic pig.
Table 5.
Results of orthotopic cardiac xenotransplantation between rhesus monkey recipients and transgenic pig donors.
58
Xenotransplantation - Comprehensive Study
perfused hearts were not rejected within 2 hours after perfusion. The first and last
transplanted pig hearts stopped beating 6 days and 18 hours after xenoHTx.
Histological examination showed no rejection findings in the myocardium of the
graft taken at 1 hour after xenoHTx, but the explanted grafts after cardiac arrest
showed massive necrosis with ischemic change which suggested some kinds of
DXR. RAb-37 prior to perfusion in all baboons was 1: 256 or 1:512, but that at
1 hour after XenoHTx was less than 1:4 which was considered to be negative.
These findings suggested that RAb-37 may play an important role in DXR in pig-
to-baboon combination.
We also investigated the differences between newborn and adult natural het-
erophile anti-pig red blood cell IgM xenoantibodies as correlates of xenograft sur-
vival [22] (Table 4). Newborns and younger infants have significantly lower titers
of anti-pig RAb-4 and RAb-37 and anti-pig EAb-IgM than adult.
After coming back to Japan, Kawauchi M also investigated ontogeny of RAb-37
and HAR in 15 macaque monkeys [23]. Ten hearts from newborn Gottingen minia-
ture swine (6–12 days old) were heterotopically transplanted into 10 infant
macaque monkeys (52, 59, 75, 101, 108, 114, 129, 151, 181, and 192 days old) without
immunosuppressive therapy. RAb-37 prior to xenoHTx were gradually increased
according to the age of the monkeys. All six donor hearts in the recipients younger
than 4 months survived 6 hours, and then the animals were killed while the donor
hearts were beating. Donor hearts in four infant recipients ages 129, 151, 181, and
192 days were hyperacutely rejected at 19, 22, 29, and 9 minutes. The pig hearts in
the recipients younger than 4 months showed no findings of HAR.
These two findings may suggest that newborn and younger infants may be more
suitable recipient of discordant xenoHTx.
9. Transgenic pig-to-rhesus monkey orthotopic discordant xenoHTx
As Miyagawa et al. demonstrated the effect of the human beta-D mannoside
beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) gene in downregulating the
xenoantigen of pig heart grafts, using a pig to cynomolgus monkey transplantation
model suggests that this approach may be useful in clinical xenotransplantation
in the future [24]. Moreover, they showed the possibility that both the
decay-accelerating factor (DAF) and GnT-III double transgenic pig skin xenografts
could be used in place of human skin allografts in the cases of severe burns [25].
Then, after coming back to Japan, the author and Japanese colleagues
underwent orthotopic discordant xenoHTx using DAF and GnT-III transgenic pig
heart xenografts (unpublished data). Donor hearts were obtained from two F1 pigs,
six DAF transgenic pigs (five hetero DAF and one homo DAF), and three GNT-III
transgenic pigs and transplanted orthotopically in adult rhesus monkey with deep
hypothermia and circulatory arrest. All animals received no immunosuppressive
drugs.
In two baboons, a F1 pig heart was transplanted for control (Group-C). In three
baboons, the blood in the bypass circuit was perfused into a hetero DAF pig heart or
lung to absorb baboon anti-pig antibody during circulatory arrest at the time of
xenoHTx (Group-DAF + P).
In the one control animal, the graft stopped beating 21 minutes after aortic
unclamping before weaning from cardiopulmonary bypass (CPB). All other 10
rhesus monkeys could wean from CPB and undergo chest closure, but only one in
Group-DAF, one in Group-DAF + P, and two in Group-GNT-III could be removed
from a ventilator. Two grafts in Group-C and two perfused pig hearts showed
severe HAR. Other grafts showed various degree of HAR. These data suggested that
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RAb-4 RAb-37 EAb-IgM EAb-IgG
Adult 582  579 296  291 288  189 853  264
Cord blood 144  181* 69/96* 21  8.3** 683  264
Infant <38 days old 80  58* 30  19*
Infant > = 38 days old 689  678*** 239  149***
RAb-4 and RAb-37: human anti-pig red blood cell antibody titer at temperature of 4°C and 37°C, respectively.
EAb-IgM and EAb-IgG: human anti-pig endothelial cell antibody (immunoglobulin M and G) titers, respectively.
*p < 0.01 vs. adult.
**p < 0.05 vs. adult.
***p < 0.01 vs. cord blood or infant younger than 38 days old.
Table 4.
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DAF, decay-accelerating factor; GnT-III, beta-D mannoside beta-1,4-N-acetylglucosaminyltransferase III; AXC,
aortic cross-clamping; CPB, cardiopulmonary bypass; HAR, hyperacute rejection; DXR, delayed xenograft rejection.
aGroup-C, controls; Group-DAF, transplanted DAF transgenic pig heart; Group-DAF + P, transplanted DAF
transgenic pig heart and perfused with another pig heart; Group-GnT-III, transplanted GnT-III transgenic pig heart.
bHetero DAF transgenic pig.
cHomo DAF transgenic pig.
Table 5.
Results of orthotopic cardiac xenotransplantation between rhesus monkey recipients and transgenic pig donors.
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perfused hearts were not rejected within 2 hours after perfusion. The first and last
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transgene of DAF or GNT-III might not be enough to suppress HAR in adult rhesus
monkey which had high titers of anti-pig xenoantibodies.
10. Recent concerns about xenotransplantation in children
Xenotransplantation has been proposed as a method of reducing the espe-
cially acute shortage of organs for babies and children. Early clinical trials of
xenotransplantation will be a form of therapeutic research. Therapeutic research
must offer some prospect of genuine benefit for the patient, but it involves
greater uncertainties than treatment, and therefore greater caution must be
exercised. Many working parties concerning xenotransplantation, such as the
British Pediatric Association and the Medical Research Council, have advised
that therapeutic research should not involve children if it could equally well be
performed with adults. It would be difficult to justify the involvement of chil-
dren in major and risky xenotransplantation trials before some of the uncer-
tainties have been eliminated in trials involving adults. Therefore, the FDA and
WHO also recommend that the first xenotransplantation trials involve adults
rather than children.
Then, although the authors tried to continue animal experiment to start clinical
pediatric xenoHTx in the mid-2000s, we resigned.
11. Current status of pediatric heart transplantation in the world and
Japan
After the Bailey’s first xenoHTx, hundreds of neonates and small infants with
end-stage heart failure are living today because of primary or secondary HTx in the
world. The number of pediatric HTx has been increasing (Figure 3), and their
survival has been acceptable in every recipient age (Figure 4).
When the author came back to Japan in 1994, there was no Transplant Act in
Japan. In 1988, the Japan Medical Association professed that it would accept brain
death as human death. In 1990, the Provisional Commission for the Study on
Figure 3.
Pediatric heart transplants. Recipient age (in years) distribution by year of transplant.
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Brain Death and Organ Transplantation was set up in 1990. The draft of the
Organ Transplantation Law was proposed in 1994. Finally, on October 16, 1997,
the Organ Transplant Act took effect, which enabled brain dead organ donation
only if the person expressed in writing prior to death his/her intent to agree to
donate his/her organs. In addition, the Act states that “only persons 15 years and
above can express to donate.” Then, heart transplants to small children become
impossible.
So, we started to send children with end-stage heart failure to Dr. Bailey as
other pediatricians did (Figure 5) and continued to perform xenoHTx experi-
ments. But as mentioned above, we finished experiments due to the FDA and
WHO recommendation against pediatric xenotransplantation. Since 2003, the
author and members of Japanese Associations of Transplant patients made many
efforts to revise the Act, and finally the Act was revised in 2010. After then, the
Figure 5.
Pediatric heart transplant in Japan.
Figure 4.
Pediatric heart transplants. Kaplan–Meier survival (transplants: January 1982–June 2016).
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number of pediatric HTx has increased and finally exceeded that of HTx abroad
(Figures 5 and 6).
Unexpectedly, Dr. Bailey (Figure 7) died of cancer in May 2019.
Figure 7.
The panel of Professor Leonard Bailey’s memorial service.
Figure 6.
Pediatric heart transplantation abroad from Japan.
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Tissue-Specific Bioink from 
Xenogeneic Sources for 3D 
Bioprinting of Tissue Constructs
Sriya Yeleswarapu, Shibu Chameettachal, Ashis Kumar Bera 
and Falguni Pati
Abstract
3D bioprinting brings new aspirations to the tissue engineering and regenera-
tive medicine research community. However, despite its huge potential, its growth 
towards translation is severely impeded due to lack of suitable materials, technolog-
ical barrier, and appropriate validation models. Recently, the use of decellularized 
extracellular matrices (dECM) from animal sources is gaining attention as printable 
bioink as it can provide a microenvironment close to the native tissue. Hence, it 
is worth exploring the use of xenogeneic dECM and its translation potential for 
human application. However, extensive studies on immunogenicity, safety-related 
issues, and animal welfare-related ethics are yet to be streamlined. In addition, the 
regulatory concerns need to be addressed with utmost priority in order to expedite 
the use of xenogeneic dECM bioink for 3D bioprinted implantable tissues for 
human welfare.
Keywords: 3D bioprinting, xenogeneic tissues and organs, xenogeneic decellularized 
extracellular matrix (dECM), dECM bioink
1. Introduction
The field of tissue engineering centers on development of tissues that are 
capable to regenerate and has a capacity to restore the damaged organs both struc-
turally and functionally [1, 2]. Scaffolds that are developed to serve this purpose 
should be able to provide cell attachment sites and allow cell proliferation and 
migration while maintaining its structural and mechanical integrity [2]. Along with 
this, the placement and uniform distribution of cells in the scaffold play a major 
role to determine its functional efficiency [3]. This precise positioning of multiple 
cell types in an organized manner can be achieved with 3D bioprinting [4]. Plenty 
of natural materials, such as gelatin [5, 6], alginate [7–9], collagen [10, 11], and 
synthetic materials like polycaprolactone (PCL) [12–16] and polyethylene glycol 
(PEG) [17–22], come in handy while printing a structure. Although the above-
mentioned natural materials are biocompatible, disadvantages such as mechanical 
instability, limited degradability, restricted cell proliferation, and differentiation 
challenged researchers to investigate more on natural materials [23–25]. As a result, 
human organ/tissue specific extracellular matrix (ECM) emerged as a best source 
to develop a functional tissue in laboratory conditions [23, 26, 27]. Yet, the major 
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limitation for this best material is its availability [28–30]. The next alternative 
source of ECM is to use from other species that are anatomically, physiologically, 
and metabolically similar to the recipient such as nonhuman primates (like apes, 
monkeys, and porcine) [31–33]. However, due to the risk of infections from nonhu-
man primates to human patients and organs from apes, baboons are abandoned, 
and hence pig became a suitable candidate as an organ donor for humans [33]. 
There is growing interest of xenogeneic ECM material as printable bioink (biomate-
rial formulation used for bioprinting) in the field of bioprinting due to easy access 
and the availability in required quantity. A process termed decellularization allows 
maximum removal of cellular content while retaining the ECM components from 
the native animal tissue to reduce the chance of immune rejection when implanted 
in the patient [29]. The first ever reported in vivo study of decellularized tissue was 
reported in 1991 by Krejci et al. [34], where human decellularized skin was used 
in mouse model. In 1995, Badylak’s group used decellularized xenogeneic small 
intestinal submucosa for Achilles tendon repair [35]. Later, a number of decel-
lularized ECM (dECM)-based devices are introduced, e.g., human dermis, porcine 
urinary bladder, porcine small intestine submucosa, and porcine heart valves 
[36] (Figure 1; for details refer to Table 1). In the recent past, there are several 
preliminary reports demonstrating the use of animal-derived dECM in the form of 
bioinks for developing functional tissues [27, 37]. Not only high cellular viability, 
these dECM-based constructs also showed enhanced differentiation and prolifera-
tion of cells into specific cell types when embedded in tissue-specific ECM [23, 
27, 38]. Apart from the need to develop a fully functional construct, the foremost 
reason for not implanting these structures into human beings is due to high risk of 
xenotoxicity. Other species, being the source of material for the scaffold that has 
to be transplanted into human, have to undergo several stringent laws and clear all 
the clinical trials and ethical concerns. In this book chapter, discussion on the status 
of xeno-sourced dECM-based bioprinting, including the few reported preclinical 
studies, is included. The processing steps for dECM preparation and associated 
Figure 1. 
An upright triangle representing number of decellularied xeno-transplants that are being tested at various 
stages viz in vitro lab experiments, animal and human trials.
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benefits in terms of immuno-compatibility, possible immunological reactions dur-
ing xenotransplantation, importance of xenografts, ethical concerns, and regula-
tory restrictions are also discussed.
2. Immunogenicity against dECM
Xenotransplantation may be the best way to alleviate the burden of allograft 
organ shortage from the last decade. The most enormous barrier to xenotransplan-
tation is the immunological rejection which de-emphasizes this technique. The 
profound immunological rejection happens by both antibody-mediated immune 
response as well as cell-mediated innate or adaptive immune response. Several car-
bohydrate antigens have been identified that could act as targets for human natural 
Source Tissue Cell types Recipient Result Reference
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Various decellularized xeno derived organs that are used in in vitro, animal and human studies.
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antibodies to inhibit immune rejection; these include Galα1-3Galβ1-4GlcNAc 
(referred to as α1,3Gal), Hanganuziu-Deicher (H-D) antigen, Tn, Forssman anti-
gen, Sda antigen, etc. [39, 40]. Two antibody-mediated processes are hyperacute 
rejection (HAR) and acute humoral xenograft rejection (AHXR), which attack 
mainly the vascular system of graft tissue. HAR is mediated by natural antibodies 
against α-1,3Gal epitope, present in vascular endothelium of mammals except for 
humans, or their most recent ancestors, the Old World monkeys [31, 41]. α-1,3Gal 
epitope is expressed in other organisms, because of increased human interac-
tion with these animals; anti α1,3Gal is being developed in human sera. When it 
binds to its antigen determinant site of anti α1, 3Gal, it activates the complement 
system and coagulation system to reject the graft within minutes to hours. HAR is 
histologically characterized by the presence of interstitial hemorrhage edema and 
thrombosis in small blood vessels. The depletion of α1,3Gal antibody or comple-
ment inhibition may be the best strategies to prevent HAR. But early attempts to 
reduce antibody by injecting a competitive antagonist of α1,3Gal antigen were 
unsuccessful [42] because AHXR can reject graft with a very low concentration 
of α1,3Gal antibody after several days or weeks. On the other hand, non-alpha 
Gal antigens Hanganuziu-Deicher (H-D) antigen and Sda antigen are present in 
vascular endothelium and on the surface of erythrocyte of all mammals except 
humans. The antibody against these H-D and Sda antigens is responsible for HAR 
and AHXR reaction via activation of complement (classical pathway) and coagula-
tion system in α1,3Gal transferase gene knockout (GalT-KO) pigs [40, 43, 44]. The 
complement can also be activated via alternative pathway by islets transplantation 
and cause instant blood-mediated inflammatory reaction (IBMIR), resulting in an 
early rejection of transplanted islets [45]. The most successful approach to prevent 
antibody-mediated xenograft rejection is (i) transgenic pigs that express human 
complement regulatory protein that inhibits antibody-mediated complement 
activation [46] and (ii) pigs with a knockout α1,3Gal transferase gene [47, 48]. The 
elimination of α1,3Gal epitope extended the survival of xenograft to 2–6 months 
[43]. On the other hand, combination of both strategies at a time has increased the 
graft survival. Recently significant prolongation of graft survival was documented 
more than 900 days in a pig-to-baboon cardiac xenograft from α1,3Gal transferase 
knockout, which express human complement regulatory protein CD46 and human 
thrombomodulin (GTKO.hCD46.hTBM) [49, 50]. The strength of cellular rejection 
of xenotransplantation remains uncertain, because of difficulty in avoiding HAR 
and AHXR.
Xenografts are more prone to rejection when compared to allografts due to the 
antibodies produced by T-cells dependent activated B-cells. Inclusion of T-cell sup-
pressive treatment significantly prolonged the survival rate (>400 days) of xeno-
graft, where natural antibody-mediated immune rejection was suppressed [49–51]. 
The initial immune reaction by HAR and AHXR produced pathogen-associated 
molecular patterns (PAMPs) which activate the innate immune system, such as NK 
cells, macrophages, and neutrophils. Overcoming these barriers needs severe and 
sustained exposure to immune-suppressive drugs, which is very much harmful to 
host tissue.
All biologists are focusing on cells and intracellular contents and their regulation 
to escape from immune reaction, but the scenario has changed after Hauschka and 
Konigsberg’s work in 1966 [52]. It was reported that only the ECM can differenti-
ate myoblast to myotube formation. As the ECM has inbuilt tissue-specific matrix 
composition and topological cues, it may be an ideal scaffold for the use in tissue 
engineering. Both antibody-mediated and innate immune responses trigger by the 
specific receptor present on their respective target cells and inflammatory mol-
ecules like TNF, IFN, and different cytokines released upon activation of specific 
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cells. Decellularization is the best strategies to evade immune reaction by removing 
cells as well as receptors present on their surface membrane. Unfortunately, the 
implantation of decellularized allograft into a human produced the mixed type of 
result of compatibility and recipient immune response. In spite of all the hurdles, 
some early clinical success of ECM scaffold was achieved [53, 54], but a low level of 
immune reaction was identified by some group. The heart and lung xenotransplan-
tation working group in the National Heart, Lung, and Blood Institute (NHLBI) 
has identified xenogeneic immune response against ECM to be a major problem to 
use in clinical medicine [55]. Cryopreserved human allografts are extensively used 
in cardiac valve reconstruction; immunologic response of these allografts has been 
investigated by several groups to activate the anti-HLA antibody. Hawkins et al. 
reported that HLA class I and II antigens reduced by 99% in the decellularized 
human allograft, and postoperation reactive antibody levels of HLA class I or II did 
not increase in children up to 12 months [56]. The inhibition of the immunomodu-
latory effect of decellularized tissue is obtained mainly by the removal of predomi-
nantly alpha-gal epitope along with other non-gal antigen in vascular endothelium 
and by removal of MHC class I and II molecules during decellularization. Although 
the donor-derived MHC class I became undetectable at the time of decellulariza-
tion, it again reached measurable value following implantation (host-derived MHC 
class I) and is vascularized with host tissue [57, 58]. The underlying mechanism 
of decellularization on host immune response remains to be determined. Due to 
low or zero levels of MHC class I and II, T-cell proliferative response as well as 
B-cell activation is inhibited, and the anti-inflammatory effect can be seen in vitro, 
which results in the reduction of IL-2 and IFN-γ as well. As there is no MHC class 
antigen-presenting receptor, T cell does not recognize the foreign antigen, and 
T-cell-mediated immune response is suppressed. But the elevation of IL-10 fails to 
conclude the underlying mechanism because it has the only source from activated 
T cell, B cell, and macrophages [58]. It is reported that M2 phenotype in the graft 
prevents rejection of the xenogeneic donor tissue; however, the mechanism of 
macrophage activation to release IL-10 remains unknown. Till now, it is not well 
understood which protein and in which way decellularized xenogeneic material 
promotes immune reaction. The decellularized tissue may expose new protein, and 
the decellularization protocol may also have a significant impact on the response of 
human mononuclear cells [59]. Rieder et al. [60] reported that decellularized vascu-
lar wall elicited more immune cell proliferation than native equivalent, and hence, 
it proved the above hypothesis. It also hypothesized that opsonization would be the 
way of inflammation response and can occur through preformed antibody or bind-
ing of unspecific plasma protein to the surface. In genetically modified organism, 
(pig) alpha-gal epitope is knocked out, and it does not elicit immune response in 
decellularized tissue, but in unmodified xenogeneic tissue, some amount of alpha-
gal antigen may be retained, and that could be enough to stimulate immunogenic 
response. However, further study is needed to find out the mechanism of immune 
response with regard to decellularized matrices.
2.1 Strategies to resolve immune reaction against xenogeneic DECM
Xenogeneic dECM has a huge potential to be used in tissue engineering and 
regenerative medicine; some early enthusiastic studies in animal and clinical tri-
als using decellularized tissues resulted in severe inflammatory reaction, fibrous 
overgrowth, and tissue destruction [61–64]. Despite all these immunological reac-
tions, in recent years xenogeneic biomaterials are being used in abdominal surgery 
[65–67]. There have been some early studies, where glutaraldehyde cross-linking in 
native matrix inhibits immune response by the modification of surface area of tissues 
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that inhibit the interaction with peripheral blood mononuclear cell (PBMC) and in 
turn T-cell activation [68]. But the problem of glutaraldehyde fixation is that it can 
change the tissues’ topology and promote their degradation by calcification [69]. The 
natural cross-linking product quercetin, a plant flavonoid pigment, may be more 
effective, which increases mechanical strength and reduces immunogenicity [70].
3. Importance of xenografts in dECM-based bioprinting
Organs in the human body are extremely complex structures consisting of 
multiple cell types arranged in defined spatial organization, with varied ECM 
composition. It is due to this balanced and organized compositions that organs 
achieve perfect functionality [71]. Any disruption to this native structure alters the 
functionality of the organ drastically. The demand for organ transplantation is 
increasing exponentially due to the rise in traumatic injuries and changes in lifestyle, 
while the supply of organs increased marginally over time. The demand for organ 
transplantation is estimated to further rise with the advancements in diagnostics 
leading to early detection of diseases [72]. Researchers all over the world have been 
striving hard to find alternative strategies to reduce this gap for many years, using a 
combination of many materials along with cells [73]. As a result, researchers devel-
oped comparatively simple organs using tissue engineering approaches, such as 
artificial skin [74], cartilage [75], and trachea [76] that display a part or nearly full 
functionality of the particular tissue. Xenotransplantation is another promising 
approach that was started in early 1920s and has a potential to serve as a temporary 
measure to save patient’s life in the absence of allogenic organ [77]. Nevertheless, the 
barriers such as graft failure due to immune reaction [63] and infections from the 
graft to the patient prevent the acceptance of xenotransplantation as a treatment 
option. Consequently, an emerging technique, 3D bioprinting, revolutionized the 
field of tissue engineering and regenerative medicine exhibiting its potential to 
develop complicated organs [78]. To fabricate a scaffold, this technique uses materi-
als that are biocompatible and cells that are tissue-specific, while the best biomaterial 
to develop a tissue that eventually goes to human body is the material derived from 
that specific tissue, viz., ECM, as it can provide reseeded cells with local tissue 
environment [23]. This property of tissue-derived material can anchor cells and 
provides sufficient biochemical and mechanical cues allowing them to proliferate 
and differentiate to those tissue-specific lineages which ultimately aid in complex 
tissue formation [79, 80]. Ideally, autologous tissues are expected not to illicit an 
immune response after implantation, thus reducing the chance of organ rejection. 
However, due to the lack of sufficient autologous tissue, allogeneic tissues are chosen 
for transplantation. Allogeneic tissues also suffer from rejection from the host due to 
antibody-mediated rejection or T-cell movement into the allograft [81]. Genetic 
dissimilarity between donor and recipient turns out to be the main cause to induce 
immune response and eventually rejection of the graft [81]. Hence, the process of 
decellularization when applied on allogeneic tissues reduces the amount of genetic 
material, thereby allowing graft survival in the host [82]. But, the final yield of 
material after all the processing of tissue is very low and is insufficient for printing a 
higher volume 3D structure. Because of which, considering patient’s own tissue or 
tissue from the same species for development of bioink is not practical. The very next 
alternative that researchers explored was to obtain tissue source from other species 
and use its matrix as a bioink for tissue development [23]. The concept of using other 
species (porcine) tissue as a source of material for humans emerged due to the 
anatomical and physiological similarities between both the species [83, 84]. Apart 
from the cellular content, organs are rich in the noncellular component, i.e., 
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ECM [85]. In almost all the tissues, ECM proteins are produced by the resident cells 
[85, 86]. Many macrolevel molecules, growth factors, and fibrillar proteins in varied 
quantities constitute this considerable volume of the tissue [85]. Polysaccharides and 
proteins such as glycosaminoglycans (GAGs), hyaluronan, collagen, fibronectin, 
laminin, and elastin are the major ECM components in an organ [85]. These ECM 
components allow cell adhesion and cell migration, provide biochemical and 
mechanical properties, and impart elasticity that helps cells to obtain morphological 
orientation and physiological functionalities. Of all the ECM components men-
tioned, collagen is the most abundant protein which almost covers 30% of the 
protein content present in multicellular organisms [85, 86]. In vertebrates, as many 
as 28 different types of collagen are recognized with 46 distinct polypeptide chains, 
and the sources of collagen are abundantly available from marine animals to animals 
that live on land [87]. The main role of this profoundly available protein is to provide 
mechanical strength, maintain cellular adhesion, and support migration and other 
cellular functionalities that direct mature tissue formation [85]. To develop tissues 
like bone [88], skin substitutes [89], small intestine tissue [90], skeletal muscle 
tissue [91], collagen that is extracted from xenogeneic sources has been used exten-
sively in research works. Elastin is another ECM component that connects with 
collagen to provide elasticity to the tissue. It is due to this close association; elastic 
nature of tissue is being maintained. To develop constructs in vitro, along with the 
exposing cells to abundant proteins, enough mechanical properties are to be pro-
vided [85]. Hence, it is necessary to include elastin components into the engineered 
scaffold which imparts mechanical properties to the tissue. By combining the 
proteins, viz., different types of collagen and elastin, a reasonable amount of work 
has been done on blood vessel engineering, heart valve development, tissue-engi-
neered vascular grafts, musculoskeletal tissues, cartilage, and skin engineering [92]. 
The other fibrous protein that contributes for organization of ECM and is respon-
sible for cell functionality such as cellular attachment is fibronectin. Scaffolds that 
are functionalized with fibronectin enhanced properties such as cell adhesion [93, 
94], promoting elastin deposition [95]; cellular migration responsible for tumor 
metastasis [96, 97] has been reported in literature. When it comes to engineering a 
tissue in vitro using 3D bioprinting, the material should be biocompatible as well as 
print friendly. Components of ECM such as collagen, elastin, and fibrin were 
explored for them to be used as bioinks either separately or in combination with one 
another in 3D bioprinting technology. The potential of collagen as bioink was 
displayed for developing human skin model with keratinocytes and fibroblasts [98], 
cartilage tissue engineering [99], 3D collagen-based cell blocks that exhibited 
osteogenic activity [100], and osteochondral mimicking structures [101] and in bone 
regeneration applications [102]. The use of fibrinogen as a bioink was also reported 
for developing cartilage [103, 104] and vascular grafts [105]. The immune response 
to xenogeneic collagen in human models was reported to be not adverse, and in most 
of the cases, the presence of antibodies for xeno-derived collagen was due to by-
products during acceptance of implanted graft by host [106]. It is also reported 
in vitro experiments conducted with collagen and elastin derived from porcine and 
bovine did not trigger immune cells nor trigger proliferation of isolated B and T cells 
[107]. Nonetheless, to mimic native tissue environment for enhanced cellular 
functionality, a combination of all the proteins and macromolecules is required. 
Hence, instead of using all the macromolecules separately in varied amounts, 
researchers started using ECM of the tissue for tissue engineering and 3D bioprint-
ing applications (Figure 2), thereby providing all the necessary cues to the reseeded 
cells in essential amounts. For better acceptance of the 3D printed structure with 
ECM, decellularization of animal tissue is done to remove the maximum cellular 
content prior to 3D printing process. This reduces the chances of xenogeneic 
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that inhibit the interaction with peripheral blood mononuclear cell (PBMC) and in 
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dissimilarity between donor and recipient turns out to be the main cause to induce 
immune response and eventually rejection of the graft [81]. Hence, the process of 
decellularization when applied on allogeneic tissues reduces the amount of genetic 
material, thereby allowing graft survival in the host [82]. But, the final yield of 
material after all the processing of tissue is very low and is insufficient for printing a 
higher volume 3D structure. Because of which, considering patient’s own tissue or 
tissue from the same species for development of bioink is not practical. The very next 
alternative that researchers explored was to obtain tissue source from other species 
and use its matrix as a bioink for tissue development [23]. The concept of using other 
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components allow cell adhesion and cell migration, provide biochemical and 
mechanical properties, and impart elasticity that helps cells to obtain morphological 
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tioned, collagen is the most abundant protein which almost covers 30% of the 
protein content present in multicellular organisms [85, 86]. In vertebrates, as many 
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sible for cell functionality such as cellular attachment is fibronectin. Scaffolds that 
are functionalized with fibronectin enhanced properties such as cell adhesion [93, 
94], promoting elastin deposition [95]; cellular migration responsible for tumor 
metastasis [96, 97] has been reported in literature. When it comes to engineering a 
tissue in vitro using 3D bioprinting, the material should be biocompatible as well as 
print friendly. Components of ECM such as collagen, elastin, and fibrin were 
explored for them to be used as bioinks either separately or in combination with one 
another in 3D bioprinting technology. The potential of collagen as bioink was 
displayed for developing human skin model with keratinocytes and fibroblasts [98], 
cartilage tissue engineering [99], 3D collagen-based cell blocks that exhibited 
osteogenic activity [100], and osteochondral mimicking structures [101] and in bone 
regeneration applications [102]. The use of fibrinogen as a bioink was also reported 
for developing cartilage [103, 104] and vascular grafts [105]. The immune response 
to xenogeneic collagen in human models was reported to be not adverse, and in most 
of the cases, the presence of antibodies for xeno-derived collagen was due to by-
products during acceptance of implanted graft by host [106]. It is also reported 
in vitro experiments conducted with collagen and elastin derived from porcine and 
bovine did not trigger immune cells nor trigger proliferation of isolated B and T cells 
[107]. Nonetheless, to mimic native tissue environment for enhanced cellular 
functionality, a combination of all the proteins and macromolecules is required. 
Hence, instead of using all the macromolecules separately in varied amounts, 
researchers started using ECM of the tissue for tissue engineering and 3D bioprint-
ing applications (Figure 2), thereby providing all the necessary cues to the reseeded 
cells in essential amounts. For better acceptance of the 3D printed structure with 
ECM, decellularization of animal tissue is done to remove the maximum cellular 
content prior to 3D printing process. This reduces the chances of xenogeneic 
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rejection in human body. In the next section, the use of dECM as a bioink for 3D 
printing applications is discussed.
4. Current status of the xenografts application in bioprinting
The process of decellularization dates to 2000s, wherein organs such as skin, 
vascular tissue, and bladder were decellularized. In 2014, it was first shown that 
after decellularization process, the ECM that is devoid of cellular material could 
be used as a bioink for 3D printing applications [23]. In the recent past, almost 
all the organs have been subjected to the process of decellularization and used for 
3D bioprinting. With 3D bioprinting of decellularized organs such as the heart, 
liver, cartilage, adipose tissue, skeletal muscle, skin, etc., researchers have demon-
strated the potential of dECM-based constructs in terms of cell compatibility, cell 
Figure 2. 
Schematic representing the process of 3D bioprinting, in vitro maturation and transplantation of tissues 
developed from animal tissue derived decellularized extracellular matrix.
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attachment, migration, and proliferation. Decellularized heart matrix derived from 
porcine showed an enhanced expression of myosin heavy chain [23] and expression 
of transcription factors by cardiac progenitor cells [108]. The functionality of 3D 
engineered heart, developed from decellularized rat heart, was also demonstrated 
in one study [109]. Similarly, decellularized liver matrix from porcine exhibited 
consistent secretion of urea and albumin up to 14 days of culture [110] and higher 
levels of markers suggesting hepatocyte maturation [27]. Early adipogenic marker 
and lipoprotein lipase were notably observed in human-derived decellularized 
adipose tissue [23]. However, there is a need of further in vitro experiments on 
decellularized matrices, to completely replicate the complex geometry of the 
organs. With the current state of art, the in vitro models can be tested for immune 
response in animal models. For any biological material that is being implanted 
should contain as less as 50 ng/mg of DNA content for not eliciting the immune 
response in host body. To ensure this low level of nucleic acid content, the process 
of decellularization of xeno tissues must be stringent and harsh. Detergents such as 
SDS and Triton X served as chemical agents to remove the maximum DNA content 
from tissues in decellularization process. Using chemical treatment, acceptable level 
of DNA content was achieved in almost all the tissues decellularized so far. Apart 
from DNA nuclear material, Gal epitopes present in animals are also found to be 
responsible for acute implant rejection [23]. There are few reports from literature 
wherein 3D dECM scaffolds have been implanted in animal models to understand 
the host response. In one study, scaffolds that were fabricated using decellularized 
adipose tissue derived from porcine were implanted into mice. Due to significant 
reduction in DNA content and gal epitopes, the ECM grafts showed no signs of 
inflammation or necrosis. Also, there was formation of neo-adipose tissue with 
mature adipocytes supporting adipogenesis and acceptance of a xenograft [111]. 
Porcine-derived skin was also subjected to decellularization to show its potential 
in skin tissue engineering. Using chemical such as trypsin/EDTA and Triton X, 
the decellularized skin matrix was digested to form bioink, and a skin substitute 
was printed. This, when implanted into the wound of 10 mm in mice, accelerated 
wound healing was observed when compared to control groups. Further, immuno-
fluorescence staining showed early differentiation markers for epithelial tissue and 
CD-31 signifying re-epithelialization and vascularization, respectively [112]. The 
reported results exhibit the acceptance of xeno-derived dECM-based 3D bioprinted 
scaffolds by the host tissue. This is made possible due to the stringent chemicals and 
enzymes involved in decellularization process. Nevertheless, much more studies 
and experiments both in vitro and in vivo must be done for using these scaffolds as 
replacement of deceased parts in the human.
5. Regulatory facets of xeno dECM-based tissue transplantation
Although the prospective benefits are unquestionable, the use of xenoge-
neic products in human health care raises a number of issues; hence it has to be 
controlled strictly by the regulatory bodies to avoid complications. The duty of 
regulatory bodies is to regulate the indiscriminate use of animal-sourced material 
intended for human health application. The challenges include (1) the potential 
risk of transmission of infectious agents from source animals, (2) informed consent 
related issues, and (3) animal welfare issues [113].
From the preclinical testing, the regulations are made strict for the human 
welfare before use in clinical trials. In general, enough studies have to be performed 
for safety characterization of therapeutic agents including the efficacy or the activity 
and the toxicity or undesired effects to the host system. This type of potential clinical 
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attachment, migration, and proliferation. Decellularized heart matrix derived from 
porcine showed an enhanced expression of myosin heavy chain [23] and expression 
of transcription factors by cardiac progenitor cells [108]. The functionality of 3D 
engineered heart, developed from decellularized rat heart, was also demonstrated 
in one study [109]. Similarly, decellularized liver matrix from porcine exhibited 
consistent secretion of urea and albumin up to 14 days of culture [110] and higher 
levels of markers suggesting hepatocyte maturation [27]. Early adipogenic marker 
and lipoprotein lipase were notably observed in human-derived decellularized 
adipose tissue [23]. However, there is a need of further in vitro experiments on 
decellularized matrices, to completely replicate the complex geometry of the 
organs. With the current state of art, the in vitro models can be tested for immune 
response in animal models. For any biological material that is being implanted 
should contain as less as 50 ng/mg of DNA content for not eliciting the immune 
response in host body. To ensure this low level of nucleic acid content, the process 
of decellularization of xeno tissues must be stringent and harsh. Detergents such as 
SDS and Triton X served as chemical agents to remove the maximum DNA content 
from tissues in decellularization process. Using chemical treatment, acceptable level 
of DNA content was achieved in almost all the tissues decellularized so far. Apart 
from DNA nuclear material, Gal epitopes present in animals are also found to be 
responsible for acute implant rejection [23]. There are few reports from literature 
wherein 3D dECM scaffolds have been implanted in animal models to understand 
the host response. In one study, scaffolds that were fabricated using decellularized 
adipose tissue derived from porcine were implanted into mice. Due to significant 
reduction in DNA content and gal epitopes, the ECM grafts showed no signs of 
inflammation or necrosis. Also, there was formation of neo-adipose tissue with 
mature adipocytes supporting adipogenesis and acceptance of a xenograft [111]. 
Porcine-derived skin was also subjected to decellularization to show its potential 
in skin tissue engineering. Using chemical such as trypsin/EDTA and Triton X, 
the decellularized skin matrix was digested to form bioink, and a skin substitute 
was printed. This, when implanted into the wound of 10 mm in mice, accelerated 
wound healing was observed when compared to control groups. Further, immuno-
fluorescence staining showed early differentiation markers for epithelial tissue and 
CD-31 signifying re-epithelialization and vascularization, respectively [112]. The 
reported results exhibit the acceptance of xeno-derived dECM-based 3D bioprinted 
scaffolds by the host tissue. This is made possible due to the stringent chemicals and 
enzymes involved in decellularization process. Nevertheless, much more studies 
and experiments both in vitro and in vivo must be done for using these scaffolds as 
replacement of deceased parts in the human.
5. Regulatory facets of xeno dECM-based tissue transplantation
Although the prospective benefits are unquestionable, the use of xenoge-
neic products in human health care raises a number of issues; hence it has to be 
controlled strictly by the regulatory bodies to avoid complications. The duty of 
regulatory bodies is to regulate the indiscriminate use of animal-sourced material 
intended for human health application. The challenges include (1) the potential 
risk of transmission of infectious agents from source animals, (2) informed consent 
related issues, and (3) animal welfare issues [113].
From the preclinical testing, the regulations are made strict for the human 
welfare before use in clinical trials. In general, enough studies have to be performed 
for safety characterization of therapeutic agents including the efficacy or the activity 
and the toxicity or undesired effects to the host system. This type of potential clinical 
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risks constitutes an important component of an FDA regulation. Transfer of animal 
microorganisms to the recipient with the graft during xenograft transplantation is 
another major concern for regulatory authorities [114]. There are reports that HIV, 
hepatitis B and C, Creutzfeldt-Jakob disease, and rabies can be transmitted between 
humans during transplantation. It is also proved that contact between animals and 
humans during animal husbandry and from pets or food products can lead to zoo-
notic infections. So, the use of animal cells, tissues, and organs in any forms keeps 
the public health at risk with known and unknown infections. Hence it is advised to 
go for thorough screening for all kind of possible zoonotic infections by following 
the standard protocol [113]. Moreover, the risk of these microorganisms or virus 
getting adapted to human-to-human transmission is also a major factor that has to be 
considered, which might be a concern for general population [115]. When it comes to 
cross-species whole organ transplantation, there is unavoidable transfer of endog-
enous retrovirus that is existing in the genome of all porcine cells into the patient 
receiving the organ. However, there exists no documentation regarding the transfer 
of these viruses in humans who are exposed to pig organs [116], probably due to the 
lack of long-term observation.
Preclinical studies provide valuable insight into the safety issues before being 
used in the human volunteers. Animal welfare is a major concern during the appli-
cation of xenogeneic products in humans. Since animals’ welfare is a major ethical 
issue, it is considered by regulatory bodies before approving any product of animal 
origin for clinical use.
Also, during the clinical trial stages or in long term, the volunteers or the 
patients and the close contacts should be educated about the chance of infectious 
disease risks and about how to manage those risks. Moreover, such counseling 
should also be continued for long term as some infection may take years to get 
manifested. Also, lifelong surveillance is advised by FDA irrespective of the status 
of the implant or graft or other xenotransplantation product.
Conversely, 3D bioprinted in vitro organs and tissues that are being developed 
using dECM are expected not to pose potential threat to recipients. This is because 
the cell and nucleus materials are being removed from the tissue using harsh chemi-
cals during the process of decellularization. However, the regulatory bodies ensure 
that xenotransplantation is allowed only when there are evidences that show near-
zero chance of recipient getting infected and informed consent, and acceptance 
for lifelong postoperative care from the patient was collected [116]. Nevertheless, 
stringent regulations will be required from regulatory bodies to monitor the pros 
and cons for a longer duration.
6. Ethical and safety concerns
There are numerous challenges and hurdles being faced for translating xenoge-
neic products to the clinical level. Though the potential of tissue- or organ-derived 
bioink for 3D bioprinting is getting proved and accepted, to reach human level it 
must overcome ethical concerns apart from dealing with technological and regu-
latory challenges. The opinions expressed on ethics behind using xeno-derived 
material for humans are based on the source of material and the consequence after 
transplants, which are already mentioned in the regulatory facets [117]. There are 
few groups who argue that the primary idea of using animal organ into human is 
unethical, while few claiming that the detrimental outcomes after the transplant 
are unacceptable [118]. The apprehension on the outcomes of the xenotransplanta-
tion seems valid as there are reports in the literature suggesting that patients who 
received the animal organs survived only for a short span [77]. The use of animal 
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organ in patient started in the twentieth century. Organs such as liver, heart from 
baboon [119], and kidney from chimpanzee [120] were transplanted to patients who 
survived for a very short lifespan ranging from 20 to 195 days after the implantation 
[77]. Immune rejection is the primary reason for failure of the graft [77]. Apart 
from immune response from the host, there are insufficient scientific evidences 
about the risk of transmission of pathogens that are passive in animal species [117]. 
Though it is proven that these microorganisms that are existing in animal species are 
not harming them, it could be fatal when they enter other species [117]. It is ethical 
to have an informed consent from the patient, not only regarding the transplanta-
tion but also about all the further complications that could arise due to the foreign 
material being placed inside [117, 121]. With xeno-organ transplantation, the risk 
of animal virus and microorganisms entering human body is expected to rise [121]. 
Apart from this, there are a lot many unknown viruses that are hosted by animal 
species whose effects are not at all predictable [117]. Hence, the recipient should 
also be informed about the risks and preventions that he/she must take posttrans-
plantation, restricting his freedom [121, 122]. Further, to increase the success rate 
of transplants, recipients are constantly under the influence of immunosuppres-
sant drugs, which would enhance his chances of other infections [117]. However, 
immunological reactions are not reported much after using dECM 3D bioprinted 
constructs. Additionally, one has to justify whether the amount that is being spent 
on xenotransplantation research for translation to clinical level is really worth, as 
it can help a relatively smaller group of people. Furthermore, for animal welfare, 
there are animal-related ethical issues which are considered important similar to 
human ethical issues [123]. Some groups believe that, the use of animals to fulfill 
human needs is strongly unethical, while few accept that if the benefits surpass the 
degree of suffering of animals, then there is no harm to use animal organs for saving 
human life [124]. Almost all the vertebrates suffer and perceive pain in a similar way 
[121]. Producing transgenic animals for organ transplantation also received criti-
cism, as during this process, much more pain and suffering is imposed on animals 
due to multiple experiments in succession. In order to reduce the chance of viral 
transmissions, these transgenic animals are quarantined and kept in isolation [121]. 
Hence, the supports for animal welfare argue that the animals that undergo genetic 
engineering technique will be deprived of its natural habitat and are forced to live 
in a secluded place with pain and agony [117]. Will this suffering of an animal be 
the guarantee that its organ is successfully put into use remains as an unanswered 
question. Apart from ethics, religious feelings also come into play. A pig that is 
considered to have similar genetic and physiological traits similar to human [125] is 
considered unclean in many religions but is considered as a versatile model in bio-
medical research. On the other hand, if the benefits and safety of xenotransplanta-
tion is proven for human well-being, dealing with animal ethics could be vindicated. 
Nevertheless, how well the community approves and agrees to the use of transgenic 
animal organs for transplantation to serve humans is yet to be understood.
7. Future perspective
We believe that the severity of some disease conditions will be able to justify the 
use of xenogeneic therapeutic options, but the risk and benefits must be evaluated 
and concluded at the earliest. The most important concern, infectious disease trans-
mission, including the chance of latent viral infections, must be studied in a larger 
picture including all possible disease transmissions. Though studies are limited, 
severe immunological reactions are not reported by using decellularized bioinks 
till date indicating its future potential in regenerating organs and tissue. Large 
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cross-species whole organ transplantation, there is unavoidable transfer of endog-
enous retrovirus that is existing in the genome of all porcine cells into the patient 
receiving the organ. However, there exists no documentation regarding the transfer 
of these viruses in humans who are exposed to pig organs [116], probably due to the 
lack of long-term observation.
Preclinical studies provide valuable insight into the safety issues before being 
used in the human volunteers. Animal welfare is a major concern during the appli-
cation of xenogeneic products in humans. Since animals’ welfare is a major ethical 
issue, it is considered by regulatory bodies before approving any product of animal 
origin for clinical use.
Also, during the clinical trial stages or in long term, the volunteers or the 
patients and the close contacts should be educated about the chance of infectious 
disease risks and about how to manage those risks. Moreover, such counseling 
should also be continued for long term as some infection may take years to get 
manifested. Also, lifelong surveillance is advised by FDA irrespective of the status 
of the implant or graft or other xenotransplantation product.
Conversely, 3D bioprinted in vitro organs and tissues that are being developed 
using dECM are expected not to pose potential threat to recipients. This is because 
the cell and nucleus materials are being removed from the tissue using harsh chemi-
cals during the process of decellularization. However, the regulatory bodies ensure 
that xenotransplantation is allowed only when there are evidences that show near-
zero chance of recipient getting infected and informed consent, and acceptance 
for lifelong postoperative care from the patient was collected [116]. Nevertheless, 
stringent regulations will be required from regulatory bodies to monitor the pros 
and cons for a longer duration.
6. Ethical and safety concerns
There are numerous challenges and hurdles being faced for translating xenoge-
neic products to the clinical level. Though the potential of tissue- or organ-derived 
bioink for 3D bioprinting is getting proved and accepted, to reach human level it 
must overcome ethical concerns apart from dealing with technological and regu-
latory challenges. The opinions expressed on ethics behind using xeno-derived 
material for humans are based on the source of material and the consequence after 
transplants, which are already mentioned in the regulatory facets [117]. There are 
few groups who argue that the primary idea of using animal organ into human is 
unethical, while few claiming that the detrimental outcomes after the transplant 
are unacceptable [118]. The apprehension on the outcomes of the xenotransplanta-
tion seems valid as there are reports in the literature suggesting that patients who 
received the animal organs survived only for a short span [77]. The use of animal 
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organ in patient started in the twentieth century. Organs such as liver, heart from 
baboon [119], and kidney from chimpanzee [120] were transplanted to patients who 
survived for a very short lifespan ranging from 20 to 195 days after the implantation 
[77]. Immune rejection is the primary reason for failure of the graft [77]. Apart 
from immune response from the host, there are insufficient scientific evidences 
about the risk of transmission of pathogens that are passive in animal species [117]. 
Though it is proven that these microorganisms that are existing in animal species are 
not harming them, it could be fatal when they enter other species [117]. It is ethical 
to have an informed consent from the patient, not only regarding the transplanta-
tion but also about all the further complications that could arise due to the foreign 
material being placed inside [117, 121]. With xeno-organ transplantation, the risk 
of animal virus and microorganisms entering human body is expected to rise [121]. 
Apart from this, there are a lot many unknown viruses that are hosted by animal 
species whose effects are not at all predictable [117]. Hence, the recipient should 
also be informed about the risks and preventions that he/she must take posttrans-
plantation, restricting his freedom [121, 122]. Further, to increase the success rate 
of transplants, recipients are constantly under the influence of immunosuppres-
sant drugs, which would enhance his chances of other infections [117]. However, 
immunological reactions are not reported much after using dECM 3D bioprinted 
constructs. Additionally, one has to justify whether the amount that is being spent 
on xenotransplantation research for translation to clinical level is really worth, as 
it can help a relatively smaller group of people. Furthermore, for animal welfare, 
there are animal-related ethical issues which are considered important similar to 
human ethical issues [123]. Some groups believe that, the use of animals to fulfill 
human needs is strongly unethical, while few accept that if the benefits surpass the 
degree of suffering of animals, then there is no harm to use animal organs for saving 
human life [124]. Almost all the vertebrates suffer and perceive pain in a similar way 
[121]. Producing transgenic animals for organ transplantation also received criti-
cism, as during this process, much more pain and suffering is imposed on animals 
due to multiple experiments in succession. In order to reduce the chance of viral 
transmissions, these transgenic animals are quarantined and kept in isolation [121]. 
Hence, the supports for animal welfare argue that the animals that undergo genetic 
engineering technique will be deprived of its natural habitat and are forced to live 
in a secluded place with pain and agony [117]. Will this suffering of an animal be 
the guarantee that its organ is successfully put into use remains as an unanswered 
question. Apart from ethics, religious feelings also come into play. A pig that is 
considered to have similar genetic and physiological traits similar to human [125] is 
considered unclean in many religions but is considered as a versatile model in bio-
medical research. On the other hand, if the benefits and safety of xenotransplanta-
tion is proven for human well-being, dealing with animal ethics could be vindicated. 
Nevertheless, how well the community approves and agrees to the use of transgenic 
animal organs for transplantation to serve humans is yet to be understood.
7. Future perspective
We believe that the severity of some disease conditions will be able to justify the 
use of xenogeneic therapeutic options, but the risk and benefits must be evaluated 
and concluded at the earliest. The most important concern, infectious disease trans-
mission, including the chance of latent viral infections, must be studied in a larger 
picture including all possible disease transmissions. Though studies are limited, 
severe immunological reactions are not reported by using decellularized bioinks 
till date indicating its future potential in regenerating organs and tissue. Large 
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population studies are required to rule out the possibilities of rejection. A well-
defined animal source is also required as species close to humans are not preferred. 
The animal husbandry conditions must be defined and should start dedicated farms 
isolated from other animals and be monitored regularly to avoid unexpected or 
non-listed diseases. Moreover, an unquestionable monitoring system for animal 
welfare conditions is also important during the raise in the use of xeno-products in 
human.
8. Conclusion
The tissue-derived decellularized extracellular matrice bioink is the latest trend 
in the field of 3D bioprinting. The 3D bioprinted constructs from xenogeneic dECM 
are yet to be studied and analyzed extensively. However, the immune response to 
xenogeneic collagen, the major dECM-derived bioink component, in human models 
is not induced by any complicated immune reactions in the host. Though studies 
are in progress, the 3D bioprinted constructs with xenogeneic dECM bioink are 
least studied for safety and efficacy despite immune reactivity studies. The animal 
welfare-related issue is untouched. The initial studies using xenogeneic decellular-
ized matrices are tempting; therefore it is worth to speculate that 3D bioprinting 
with xenogeneic dECM can revolutionize the field of regenerative medicine.
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Abstract
The liver is a complex organ that requires constant perfusion for the delivery 
of nutrients and oxygen and the removal of waste in order to survive. Efforts to 
recreate or mimic the liver microstructure via a ground-up approach are essential 
for liver tissue engineering. A decellularization/recellularization strategy is one 
of the approaches aiming at the possibility of producing a fully functional organ 
with in vitro-developed construction for clinical applications to replace failed 
livers, such as end-stage liver disease (ESLD). However, the complexity of the liver 
microarchitecture along with the limited suitable hepatic component, such as the 
optimization of the extracellular matrix (ECM) of the biomaterials, the selection 
of the seed cells, and development of the liver-specific three-dimensional (3D) 
niche settings, pose numerous challenges. In this chapter, we have provided a 
comprehensive outlook on how the physiological, pathological, and spatiotemporal 
aspects of these drawbacks can be turned into the current challenges in the field, 
and put forward a few techniques with the potential to address these challenges, 
mainly focusing on a decellularization-based liver regeneration strategy. We 
hypothesize the primary concepts necessary for constructing tissue-engineered 
liver organs based on either an intact (from a naïve liver) or a partial (from a 
pretreated liver) structure via simulating the natural development and regenera-
tive processes.
Keywords: tissue engineering, decellularization, recellularization, thrombogenicity, 
hemocompatibility, partial hepatectomy transplantation
1. Introduction
The liver is the largest internal organ in the human body, accounting for approx-
imately 2–5% of the total body volume [1, 2]. Physiologically, the liver possesses 
over 500 different functions [3] and any severe damage could be life-threatening, 
such as that caused by ESLD, including acute liver failure and chronic liver disease.
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In modern times, the failure of solid organs, such as ESLD caused by injury or 
disease, has become a major challenge in clinics [4]. According to the U.S. Centers 
for Disease Control and Prevention (https://www.cdc.gov/), in 2014, 38,170 people 
died of ESLD. Currently, orthotopic liver transplant (OLT) is an ideal therapy for 
ESLD. However, a shortage of liver organ donors severely limits OLT usage. The 
Department of Health and Human Services in the United States has estimated that 
(https://optn.transplant.hrsa.gov) 22 people on the National Transplant Waiting 
List die each day, while one person is added to the waiting list every 10 min. 
Additionally, people fortunate enough to receive an organ transplantation have 
to suffer from the lifelong use of immunosuppressants against chronic rejection. 
Therefore, new technologies are eagerly needed to create a transplantable liver [5]. 
Tissue engineering is a mixed field that aims to fabricate functional organs in vitro 
[6]. Over the decades, great progress has been achieved in the laboratory, and 
even some livers have been used in clinics [7]. Tissue engineering by using a decel-
lularization/recellularization strategy, which maintains the architecture, vascular 
system, and ECM components, has been shown to be a promising tool for solid 
organs, such as liver.
Liver tissue engineering by using decellularization/recellularization strategy 
(Figure 1) involves biomimicking the architecture and physiological features of 
the native liver. The procedure generally needs three major components: a scaf-
folding platform, seed cells, and a 3D microenvironment. Despite the numerous 
advances over the years, it is still an enormous challenge to fabricate a liver organ 
[8]. Generating liver organ-specific 3D structure scaffold to keep as much as 
original biochemical, physiochemical, and biomechanical ECM microenvironment 
is the one of the main hurdles in liver engineering field [9]. Such physiological 3D 
structure also plays a remarkable role in influencing seeded cell long-term survival 
and complex liver tissue mass formation [10]. To achieve this, scientists have been 
working with different scaffolding systems for liver tissue engineering. Studies have 
shown that a construction strategy based on a combination of a decellularized naïve 
liver matrix and recellularization with seed cells has led to constructs that match 
human organs in size and structure. However, the present constructs still only fulfill 
Figure 1. 
The decellularization/recellularization strategy in liver tissue engineering. Mammals donor-derived livers 
undergo a process of decellularization to obtain decellularized liver scaffolds (DLS) (step a–c), and then 
recellularized seed cells are placed onto the scaffolds (step d–f). Finally, the recellularized scaffolds are placed 
into 3D culture conditions in a bioreactor to construct liver-like tissues or organs with an overall structure and 
vasculature (step g).
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partial functions of the liver. The preservation of a functional ECM during decel-
lularization, cellular differentiation [11], and a lack of endothelial-lying vascular 
networks limits the long-term functional integration of constructs after in vivo 
transplantation. As techniques continue develop, some methods with the potential 
to overcome these challenges should be explored in the near future, which will fur-
ther boost the development of a tissue-engineered liver with improved functions. 
In this chapter, we have tried to focus on the possibility of liver tissue engineering 
by using a decellularization/recellularization strategy and to describe the current 
advancements made in the field to address a possible clinical transplantation.
2. Decellularization-based scaffold biomaterials
The term “biomaterials” traditionally means a nonliving substance used for 
a medical purpose. As the technology of biomaterials developed, the definition 
expanded to include substances to control the biological environment of cells and 
tissues for increased compatibility with a host to allow for colonization, prolifera-
tion, and differentiation of cells while maintaining their specific morphologies, 
configurations and avoiding immunological rejection. Based on the increasing 
knowledge of ECM biology, scaffold biomaterials can be grouped as synthetic 
materials, natural materials, or a decellularized matrix [12]. Moreover, modifica-
tions have been made to enhance the biologically active signals of scaffolds, leading 
to improved cell attachment, survival, and tissue formation [13, 14].
Biomaterials with required properties have been well studied from synthetic 
materials. For instance, a nanofibrous matrix made of poly and poly-embedded 
growth factors was transplanted into animals and restored cardiac regeneration 
by promoting vascularization [15]. Zawaneh et al. have reported the design of an 
injectable synthetic and biodegradable polymeric biomaterial consisting of poly-
ethylene glycol and a polycarbonate of dihydroxyacetone that is easily extruded 
through narrow-gage needles, biodegrades into inert products, and is well tolerated 
by soft tissues [16]. Those chemically and biologically modified synthetic materi-
als could result in a better way to mimic and control seed cell responses [17, 18]. 
Another advantage of synthetic materials is their easier to predict and control the 
degradation of synthetic scaffolds. However, despite this wealth of knowledge, the 
ability of synthetic biomaterials to support cell attachment, or induce phenotypic 
expression is much lower than that of natural biomaterials [19–21]; thus, natural 
biomaterials have been extensively studied [22].
Natural biomaterials include collagen, alginate, and chitosan. These types of 
biomaterials are inherently able to facilitate for seed cell attachment, proliferation, 
and functional differentiation, thus they hold significant promise for liver tissue 
engineering [23, 24]. However, traditional natural materials have poor inherent 
bioactivity, acidic byproducts, etc., and alone cannot rebuild the complex architec-
ture of solid organs like liver. Other limitations include their unpredictable degrada-
tion kinetics; generally, weak mechanical strength, and risk of evoking an immune 
response [25], etc. also need to be considered.
Decellularized scaffolds (matrices) being natural biomaterials, which are 
deprived of cellular components while maintaining their original architecture and 
vascular system, have been widely studied and used in more complex tissue engi-
neering [26]. In the case of liver tissue engineering, the use of decellularization/
recellularization strategy was inspired by a pioneer study of heart tissue engineer-
ing from the Ott group in 2008 [27]. After that, liver tissue engineered by using 
this approach has been fabricated [28–30]. Compared to those derived from other 
synthetic or natural biomaterial scaffolds, the decellularized liver scaffold (DLS) 
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mostly preserves the native complex liver ECM components, spatial microstruc-
ture, and perusable vascular architecture [31, 32] as more “biocompatible ways” 
for seed cells attaching and reorganizing on a complex 3D level [33]. Therefore, the 
DLS might have more favorable advantages than other scaffolds for clinical appli-
cation although the biocompatibility signal between ECM of the DLS and seed 
cells is still unclear. Scientists have recellularized stem cells onto the natural 3D 
DLS and have found that these culturing cells not only survive better in the scaf-
fold structure than their culturing in 2D environment but also differentiate into 
functional cells as well [34]. Zhang et al. seeded adult mouse liver hepatic stem/
progenitor cells onto the DLS that generated from naïve liver (nDLS) and cultured 
the complex in bioreactor, which formed a liver-like construction. Importantly, 
the nDLS/cell construction was able to repair a cirrhotic liver and even replace the 
failure liver [35].
Although many studies have been performed in the DLS field for liver tissue 
engineering [36–40], unfortunately, because of the nDLS being a lack of “active 
microenvironmental” support in existing ECM components, the optimization 
of the nDLS biomaterials become an important procedure for improving the 
skill of liver tissue engineering. Many protocols have been applied to modify the 
non-bioactive decellularized scaffolds. The application of a variety of growth 
factors [41] to promote the survival, proliferation, and differentiation of cells, like 
insulin-like growth factor 1 thought to promote hepatic cell differentiation from 
bone marrow-derived mesenchymal stem cells, vascular endothelial growth fac-
tor applied to enhance the vascularization of tissue-engineered tissues or organs. 
Additionally, the complex synergistic and antagonistic actions between different 
kinds of growth factors in vivo, more attention should be paid to the combined and 
sequential application of different growth factors. Consideration of optimizing the 
ECM of nDLS foir its behave like “naïve liver regenerative niche” might be a nice 
way to induce liver-like tissue formation spontaneously both in vitro and in vivo. 
Based on this, recently, Yang et al. has presented a very interesting experiment: 
the authors generated an acellular liver scaffold from pretreated naïve liver. They 
pretreated a naïve liver by performing a 30–55% partial hepatectomy, and the 
liver was maintained in vivo for 3–5 days until acute liver regeneration occurred, 
which allowed for the generation of the scaffold from the regenerative liver (rDLS) 
(Figure 2). These rDLS retain a variety of higher level of supporting growth factors 
for liver spontaneous regeneration as compared to that of nDLS, including their 
collagens, growth factors (HGF, TGF-α, IL-6, b-FGF, VEGF), glycosaminoglycans, 
antithrombotic proteins, and other matrix proteins [42]. Since the novel rDLS pos-
sesses a natural liver regenerative microenvironment, so-called “bioactive” ECM, 
it has shown more efficiency than nDLS in promoting primary hepatocyte survival 
and antithrombotic activity. Notably, when recellularized the rDLS with intrahe-
patic stem/progenitor cells and cultured them in 3D environment, a more likely 
liver organ was formatted as compared to the nDLS recellularized with the same 
stem/progenitor cells, after transplanted into recipients [42]. This pioneer study 
demonstrated that “bioactive” scaffolds of the rDLS obtained from a regenerative 
liver possess an advanced natural “active state niche” as compared to nDLS (“still 
state niche”) for promoting primary hepatocyte survival, resistance to thrombosis, 
and liver-like organ construction. Other forms of bioactive factors are also involved 
in liver tissue engineering, like microRNAs, etc. [43, 44]. Furthermore, it needs to 
be mentioned that the advantage of highly conserved each specific ECM protein of 
decellularized scaffold among species of which the ECM are recognizable within 
and between species largely without immune rejection [45, 46] when properly pro-
cessed to remove cellular antigens that would induce an immune rejection without 
damaging the ECM.
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3.  Seed cells response to the natural three-dimensional-decellularized 
liver biomaterial scaffold
Cellular components are an integral part of any tissue engineering. In the case of 
the liver, it is important to find appropriate cells, such as hepatocytes or stem cells 
and to seed them into biomaterial scaffolds to regenerate liver tissues or organs [47]. 
Appropriate seed cells contain parenchymal such as hepatocytes, cholangiocytes, and 
supportive cells like liver sinusoidal endothelial cells, Kupffer cells, hepatic stellate 
cells, and pit cells [48]. Hepatocytes account for 60–65% of a liver’s cell population [1, 
2, 49], which is important for liver tissue engineering. If it is difficult to obtain patient-
derived hepatocytes, along with challenging isolation, culture, and the low yields of 
these cells in vitro [50], stem cells are required for liver tissue engineering [51, 52].
Stem cells are generally grouped as embryonic stem cells (ESCs), somatic stem 
cells (SSCs), and inducible pluripotent stem cells (iPS) [53]. ESCs have a higher 
regenerative capacity and can be manipulated to differentiate into other cell types 
[54, 55]. For liver tissue engineering, ESCs are considered beneficial for the pur-
pose of cell differentiation. For instance, epithelial cells differentiate from ESCs, 
which could cover the interior of vessels (arteries, veins, and capillaries) of DLS, 
and the interior of vessels is one of the major players of the angiogenesis process in 
physiological and pathological conditions involved in thrombus resistant effects. 
Due to the ethical problems with ESCs, tetratomics and expanded adult human 
hepatocytes [56], iPS are described as an alternative for adult human hepatocyte 
differentiation [57–61]. More studies about iPS are under active investigation at 
present [62], but dozens of publications regarding iPS-derived hepatic lineages have 
varied from report to report, making it difficult to compare the relative successes 
of the various modified protocols in enhancing hepatocyte differentiation [63, 64]. 
Moreover, cultured human hepatocytes often upregulate inappropriate immature 
markers, such as alpha-fetal protein (AFP). Consequently, any comparisons made 
to these altered adult hepatocytes may make the candidate immaturely appear 
more strongly functional than they truly are. Indeed, an examination of published 
accounts reveals that many protocols lead to fetal hepatocyte-like cells, but in some 
Figure 2. 
Generation of a porcine decellularized liver scaffold from naïve livers and livers that had undergone partial 
hepatectomy (PHx). (A) Perfusion procedure for liver organ decellularization. (B) Blood-vessel tree of a 
decellularized scaffold from a naïve liver (nDLS). (C) Blood vessel tree of a decellularized scaffold from a 
partial hepatectomy (PHx) liver (rDLS).
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antithrombotic proteins, and other matrix proteins [42]. Since the novel rDLS pos-
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it has shown more efficiency than nDLS in promoting primary hepatocyte survival 
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cases, the characterization reported is not sufficient to determine the fetal versus 
mature nature of the resulting differentiated hepatic cells. Given the seemingly fetal 
nature of iPS-derived hepatic cells produced to date, it is apparent that additional, 
careful modification of differentiation protocols is still required for further inves-
tigation before clinical implementation. Somatic stem cells could overcome the 
obstacles caused by ECSs, thereby making them more appropriate for liver tissue 
engineering [65, 66].
SSCs are composed of intrahepatic SSCs and extrahepatic SSCs. Bone mar-
row-, umbilical-, and fat tissue-derived mesenchymal stem cells are well accepted 
extrahepatic SSCs [67–69], while oval cells, especially neuro-glial antigen 2 (Ng2)-
expressing cells (Ng2+HSP), are currently identified as intrahepatic stem/progeni-
tor cells. Isolation of the Ng2+HSP should be completed by using a specific protocol 
[70]. Other sources of SSC behaviors seeded in the DLS have also influenced liver 
tissue engineering. Several studies have demonstrated that liver-derived mesenchy-
mal stem cell (MSC)-like cells can differentiate into hepatocytes and cholangiocytes 
in nDLS and that the functional differentiation of MSCs in certain situations could 
be an alternative approach for an engineered liver organ transplantation in the 
treatment or replacement of ESLD [35, 71]. Our recently studied animal models 
have revealed that intrahepatic MSC-like SSCs repaired injured livers better than 
extrahepatic MSCs [unpublished]. Contrary to past hypotheses, extrahepatic bone 
marrow-derived MSCs do not seem to directly differentiate themselves into hepato-
cytes, in particularly in vivo, compared to local (liver) MSC-like cells, such as above 
mentioned the Ng2+HSP. As the Ng2+HSP has been demonstrated to have a role in 
tissue repair [70] and failed liver replacement [35] in liver cirrhosis murine model, 
we recently further demonstrated that the intrahepatic Ng2+HSP cells are capable 
of more efficiency than extrahepatic BM-MSCs in self-renewal and hepatocyte and 
cholangiocyte differentiations (unpublished) (Figure 3). Interestingly, by using 
the Ng2+HSP, Zhang et al. have successfully reconstituted a liver construct in vitro 
Figure 3. 
Murine intrahepatic and extrahepatic mesenchymal stem cells (MSCs). (A) Cultured and 
immunofluorescently stained of intrahepatic neuro-glial antigen 2 (Ng2)-expressing mesenchymal stem cell 
(MSC)-like stem/progenitor cells (Ng2+HSP). (B) Cultured and immunofluorescently stained identical bone 
marrow (BM)-derived-MSCs (BM-MSCs), as visualized by optical microscopy, scale bar = 100 μM.
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that is very similar to a naïve liver organ [35]. In addition, the immuno-modulatory, 
anti-inflammatory, antiapoptotic, and angiogenic properties of the intrahepatic 
MSC-like Ng2+HSP in the liver still need to be further investigated for liver tissue 
engineering.
4. Decellularization/recellularization strategy-based liver construction
With the development of decellularization approaches, such as the detergent 
perfusion technique, whole decellularized scaffolds from liver organs have been 
produced DLS with an ECM structure and bioactive components being used 
fabricate bioengineered liver tissues, thus serving as a platform for liver organ 
bioengineering. Within the past several decades, numerous accomplishments 
have been driven by the development of these construction strategies. To date, 
decellularization-based liver construction strategies are constantly advancing such 
as maintaining complete hepatic vessel networks [72].
Despite the well-conserved macroscopic structure of a liver organ obtained by 
using decellularization, it is still difficult to avoid some disruption to the ECM com-
position and ultrastructure through decellularization, which leads to impairment 
of the natural 3D microenvironment, for example, an impairment of glycosami-
noglycans within the ECM by enzymes [73] can cause altered stiffness. Therefore, 
improved measures for preserving the integrity of the ECM during the decellular-
ization process are required [74, 75]. An functional engineered liver tissue usually 
uses stem cells or progenitor cells that need to differentiate into multiple kinds of 
repair cells, which is a challenge to directly seed cells to colonize in relevant sites of 
DLS to induce their differentiation into specific cell types. Whether an engineer-
ing formed liver organ can successfully fulfill its functions depends not only on its 
physically decellularized scaffold structure but also on an effective recellularization. 
Therefore, how to populate seed cells like differentiated hepatocytes from different 
kinds of seed cells or stem cells themselves onto the DLS needs to be carefully con-
sidered. In particular, how to manipulate the DLS to enhance the targeted specific 
colonization of cells to specific areas of DLS such as perfused endothelial cells 
[76–78], has drawn much attention. To ensure the long-term survival of an engi-
neered liver by allowing exchanges of oxygen, nutrients, and disposal of metabolic 
waste [79], a functional vascular network and thrombosis after transplantation also 
needs to be considered. Despite the conservation of the general vascular structure 
by DLS, the formation of a functional vascular network remains a challenge for liver 
organ construction. The mainstream strategy to fabricate an engineered liver organ 
with a functional vascular network includes also the procedure of prevasculariza-
tion. The initial approaches have been successfully used in spontaneous lineage of 
endothelial cells in DLS vascular networks after recellularization with stem cells 
[80–82] to challenge thrombosis after transplantation when exposed to blood, thus 
leading to localized organ failures [83]. There are two nice approaches showed that 
endothelialization of vasculature and immobilization of heparin on nDLS could 
reduce its incidence of thrombosis [84]. More recently, from a pretreated naïve liver 
obtained rDLS, exhibited except for strong promoting primary hepatocyte survival 
but also antithrombosis more effect [biomaterials 2018]. Notably, after transplanta-
tion guiding the rDLS/cells complex forms complex liver-like tissues (geometries) 
more effective on rDLS than on nDLS (Figure 4), meanwhile combined with better 
organization of endothelial lineage in rDLS than in nDLS [42]. This suggests that 
rDLS possesses an advanced “bioactive natural regeneration state niche” relative to 
the nDLS, which preserves a “still state niche.” Therefore, the spontaneous manipu-
lation of the ECM on DLS is a more promising strategy for decellularization-based 
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that is very similar to a naïve liver organ [35]. In addition, the immuno-modulatory, 
anti-inflammatory, antiapoptotic, and angiogenic properties of the intrahepatic 
MSC-like Ng2+HSP in the liver still need to be further investigated for liver tissue 
engineering.
4. Decellularization/recellularization strategy-based liver construction
With the development of decellularization approaches, such as the detergent 
perfusion technique, whole decellularized scaffolds from liver organs have been 
produced DLS with an ECM structure and bioactive components being used 
fabricate bioengineered liver tissues, thus serving as a platform for liver organ 
bioengineering. Within the past several decades, numerous accomplishments 
have been driven by the development of these construction strategies. To date, 
decellularization-based liver construction strategies are constantly advancing such 
as maintaining complete hepatic vessel networks [72].
Despite the well-conserved macroscopic structure of a liver organ obtained by 
using decellularization, it is still difficult to avoid some disruption to the ECM com-
position and ultrastructure through decellularization, which leads to impairment 
of the natural 3D microenvironment, for example, an impairment of glycosami-
noglycans within the ECM by enzymes [73] can cause altered stiffness. Therefore, 
improved measures for preserving the integrity of the ECM during the decellular-
ization process are required [74, 75]. An functional engineered liver tissue usually 
uses stem cells or progenitor cells that need to differentiate into multiple kinds of 
repair cells, which is a challenge to directly seed cells to colonize in relevant sites of 
DLS to induce their differentiation into specific cell types. Whether an engineer-
ing formed liver organ can successfully fulfill its functions depends not only on its 
physically decellularized scaffold structure but also on an effective recellularization. 
Therefore, how to populate seed cells like differentiated hepatocytes from different 
kinds of seed cells or stem cells themselves onto the DLS needs to be carefully con-
sidered. In particular, how to manipulate the DLS to enhance the targeted specific 
colonization of cells to specific areas of DLS such as perfused endothelial cells 
[76–78], has drawn much attention. To ensure the long-term survival of an engi-
neered liver by allowing exchanges of oxygen, nutrients, and disposal of metabolic 
waste [79], a functional vascular network and thrombosis after transplantation also 
needs to be considered. Despite the conservation of the general vascular structure 
by DLS, the formation of a functional vascular network remains a challenge for liver 
organ construction. The mainstream strategy to fabricate an engineered liver organ 
with a functional vascular network includes also the procedure of prevasculariza-
tion. The initial approaches have been successfully used in spontaneous lineage of 
endothelial cells in DLS vascular networks after recellularization with stem cells 
[80–82] to challenge thrombosis after transplantation when exposed to blood, thus 
leading to localized organ failures [83]. There are two nice approaches showed that 
endothelialization of vasculature and immobilization of heparin on nDLS could 
reduce its incidence of thrombosis [84]. More recently, from a pretreated naïve liver 
obtained rDLS, exhibited except for strong promoting primary hepatocyte survival 
but also antithrombosis more effect [biomaterials 2018]. Notably, after transplanta-
tion guiding the rDLS/cells complex forms complex liver-like tissues (geometries) 
more effective on rDLS than on nDLS (Figure 4), meanwhile combined with better 
organization of endothelial lineage in rDLS than in nDLS [42]. This suggests that 
rDLS possesses an advanced “bioactive natural regeneration state niche” relative to 
the nDLS, which preserves a “still state niche.” Therefore, the spontaneous manipu-
lation of the ECM on DLS is a more promising strategy for decellularization-based 
Xenotransplantation - Comprehensive Study
102
liver tissue. In the future, the objective of a decellularization-based liver construc-
tion strategy could be based on generating a 3D decellularized biomaterial scaffold 
with natural “regenerative bioactive niche” for the seed cell attachment, prolifera-
tion and differentiation of cells, and developing a transplantable “new” liver in vitro 
that maintains the structures and functions of a naïve liver.
In summary, compared with other strategies that can only fabricate partial 
structures, a decellularization/recellularization-based liver tissue engineering 
strategy enables the construction of the liver structures with complete blood vessel 
network at a clinically relevant scale, thus becoming a more promising approach 
for liver tissue engineering. However, in order to provide a promising route for 
developing a functional bioartificial liver with potential applications for humans by 
Figure 4. 
Comparison of the murine liver-lobule-like tissue construction formation between rDLS and nDLS after 
portal-renal arterialized auxiliary heterotopic liver transplantation. (A) Schematic of the procedure. The 
left green cycle indicates the DLS, and the right green cycle indicates the end-to-end anastomosis of the PV 
(scaffold)-L-RA (recipient). The green arrows in the panels indicate the right-RA. The right bottom cartoon 
shows the end-to-side anastomosis of the IVC (scaffold)-IVC (recipient). (Ba–d) Exposure of the right-side 
kidney (the square indicates the kidney) (a). Nephrectomy of the right-side kidney (the square indicates the 
lack of kidney) (b). The cell-loaded DLS where the kidney was removed (the bold arrow indicates the PV, 
thin arrow indicates the IVC, and the green arrow indicates a right renal artery (right-RA)). The left-side 
renal artery (L-RA) was connected to the PV with cross-clamping of the PV and the IVC of the recellularized 
scaffold (c). The noncell loaded DLS was connected to the recipient by the same procedure as the cell-loaded 
DLS where the kidney was removed (d). (Ca–c) DLS seeded with Ng2+HSP cells formed a liver-lobule-like 
construct in rDLS (a and b) after approximately 20–40 days (a, indicated as a cycle), for two lobes with better 
blood patency (b), represented with a white arrow; there was no visible blood flow in the nDLS loaded with 
Ng2+HSP cells for the same time (c). (D) Blood flow velocity (flow, arbitrary unit, AU) was measured in rDLS 
and nDLS at 45 min within 100 s after the operation by a near-infrared-LDF system, scale bar = 50 μM.
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such strategy, several questions must be answered: (1) Is the use of a decellularized 
liver matrix the only possible solution? (2) What kinds of cells need to be chosen for 
recellularization? Extrahepatic cells? or possibly resident stem/progenitors cells? 
(3) What is the optimal decellularized liver scaffold (DLS)? (4) What is the length 
of time for incubation in a bioreactor? (5) Would the technique be applicable to a 
human liver with its extensively sinusoidal surface?
5. Conclusion and challenges
Clearly, decellularization/recellularization through the development of in vitro 
and in vivo tissue and organ models for liver bioengineering are advancing strate-
gies. This, combined with multidisciplinary team-workers performing focused, 
systematic studies to address critical questions, is essential for the success of this 
strategy. The following critical issues might need to be addressed before clinical 
applications: (1) preservation and modification of a functional ECM structure to 
better mimic the regenerative niche; (2) selection of effective seed cell sources for 
recellularization; (3) modification of blood-vessel networks for “endothelialized 
DLS”; (4) long-term survival by preventing from thrombosis and functions after 
transplantation; and (5) immune rejection. In the coming years, many new tech-
niques will be explored, which are expected to have the potential to address these 
challenges.
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kidney (the square indicates the kidney) (a). Nephrectomy of the right-side kidney (the square indicates the 
lack of kidney) (b). The cell-loaded DLS where the kidney was removed (the bold arrow indicates the PV, 
thin arrow indicates the IVC, and the green arrow indicates a right renal artery (right-RA)). The left-side 
renal artery (L-RA) was connected to the PV with cross-clamping of the PV and the IVC of the recellularized 
scaffold (c). The noncell loaded DLS was connected to the recipient by the same procedure as the cell-loaded 
DLS where the kidney was removed (d). (Ca–c) DLS seeded with Ng2+HSP cells formed a liver-lobule-like 
construct in rDLS (a and b) after approximately 20–40 days (a, indicated as a cycle), for two lobes with better 
blood patency (b), represented with a white arrow; there was no visible blood flow in the nDLS loaded with 
Ng2+HSP cells for the same time (c). (D) Blood flow velocity (flow, arbitrary unit, AU) was measured in rDLS 
and nDLS at 45 min within 100 s after the operation by a near-infrared-LDF system, scale bar = 50 μM.
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such strategy, several questions must be answered: (1) Is the use of a decellularized 
liver matrix the only possible solution? (2) What kinds of cells need to be chosen for 
recellularization? Extrahepatic cells? or possibly resident stem/progenitors cells? 
(3) What is the optimal decellularized liver scaffold (DLS)? (4) What is the length 
of time for incubation in a bioreactor? (5) Would the technique be applicable to a 
human liver with its extensively sinusoidal surface?
5. Conclusion and challenges
Clearly, decellularization/recellularization through the development of in vitro 
and in vivo tissue and organ models for liver bioengineering are advancing strate-
gies. This, combined with multidisciplinary team-workers performing focused, 
systematic studies to address critical questions, is essential for the success of this 
strategy. The following critical issues might need to be addressed before clinical 
applications: (1) preservation and modification of a functional ECM structure to 
better mimic the regenerative niche; (2) selection of effective seed cell sources for 
recellularization; (3) modification of blood-vessel networks for “endothelialized 
DLS”; (4) long-term survival by preventing from thrombosis and functions after 
transplantation; and (5) immune rejection. In the coming years, many new tech-
niques will be explored, which are expected to have the potential to address these 
challenges.
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in Pigs as a Basis for Preclinical 
Studies on Human Cell Therapy
Shin Enosawa and Eiji Kobayashi
Abstract
Along with a growing interest in regenerative medicine, pigs are becoming a 
popular model for preclinical studies on human cell therapy. Due to pharmaceuti-
cal species difference and inability to self-medicate, specific modification and care 
are necessary in immunosuppressive regimen for pigs. Here, we summarize recent 
literature on immunosuppression in pigs for experimental transplantation. Based 
on literature and our own experiences, a practical protocol has been proposed in 
this report. In early studies of allogeneic organ transplantation, recipient pigs were 
administered cyclosporine or tacrolimus, and mycophenolate mofetil at slightly 
higher dose than that in human cases, because of relatively poor effectiveness of the 
drugs in pigs. Steroids may be effective but sometimes can cause debilitating side 
effects. Cell transplantation studies follow the basic protocol, but it remains to be 
clarified whether the smaller graft mass, even if it is xenogeneic, requires the same 
scale of immunosuppression as organ transplantation. To obtain reliable results, 
the use of gastrostomy tube and blood trough level monitoring are highly recom-
mended. Nonpharmaceutical immunosuppression such as thymic intervention and 
the use of severe combined immunodeficient pigs have also been discussed.
Keywords: pig, experimental transplantation, immunosuppression, human cell 
therapy, regenerative medicine
1. Introduction
The number of preclinical studies conducted using pigs has been increasing, 
especially in the field of cell therapy [1]. The merits of using pigs include (1) size 
advantages that enable to mimic clinical procedures; (2) availability of various 
experimental pigs such as miniature, microminiature, and gene-engineered strains; 
and (3) worldwide trend of discouragement of using dogs as research models.
However, immunosuppressive treatment has not been established well in pigs. 
Initially, pigs were used as models for performing allogeneic organ transplanta-
tion; now, the hope is to use them as xenogeneic organ donors. In the latter case, 
immunosuppressive protocols have been designed for primate recipients, while 
the number of reports mentioning immunosuppressive protocols for xenogeneic 
transplantation in pigs is unexpectedly few. In addition, insufficient medications 
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1. Introduction
The number of preclinical studies conducted using pigs has been increasing, 
especially in the field of cell therapy [1]. The merits of using pigs include (1) size 
advantages that enable to mimic clinical procedures; (2) availability of various 
experimental pigs such as miniature, microminiature, and gene-engineered strains; 
and (3) worldwide trend of discouragement of using dogs as research models.
However, immunosuppressive treatment has not been established well in pigs. 
Initially, pigs were used as models for performing allogeneic organ transplanta-
tion; now, the hope is to use them as xenogeneic organ donors. In the latter case, 
immunosuppressive protocols have been designed for primate recipients, while 
the number of reports mentioning immunosuppressive protocols for xenogeneic 
transplantation in pigs is unexpectedly few. In addition, insufficient medications 
are occasionally found in studies conducted by researchers who are not accustomed 
to organ transplantation.
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We summarize here the pharmaceutical immunosuppressive regimens in 
experimental transplantation of organs, tissues, and cells in pigs (Table 1), as well 
as highlight the usefulness of thymic intervention and severe combined immunode-
ficient (SCID) pigs. Finally, we propose an appropriate introductory protocol that 
will fit human cell and tissue transplantation.
Study design Pigs Immunosuppression
In vitro culture, IC50 
estimation [2]
Unknown Cys, Tac, Aza, Rap, MMF, MP
Orthotopic allogeneic small 
bowel transplantation [3, 4]
Large White × 
Landrace, 26.4 ± 4.7 kg
Tac 0.43 ± 0.14 mg/kg/day, po (keep trough 
5–15 ng/ml), MMF 10 mg/kg × 2/day, po
Trough level determination 
[5]
Yorkshire × Landrace, 
22–30 kg








Cys 40 mg/kg/day, po (keep trough 
100–300 ng/ml) or Tac 1.5 mg/kg/day, po (keep 
trough 4–8 ng/ml), MMF 500 mg/day, MP and 
P (tapered)
Orthotopic allogeneic 





Cys 10–13 mg/kg/day, iv (keep trough 
400–800 ng/ml) [8, 9] or Tac 0.15 or 0.30 mg/
kg/day, iv (keep trough 20–40 or 45–80 ng/
ml) [10]
Heterotopic allogeneic 





MMF 1.5 g × 2 /day, iv or Cys 10–13 mg/kg/day, 




Landrace, 6 kg Tac 0.5 mg/kg/day, im
Human bone marrow 
mesenchymal stem 




Cys 5 mg/kg/day, route unknown
Human umbilical 
mesenchymal stem cell 
transplantation to cardiac 
muscle [15, 16]
Yorkshire, size and age 
unknown
Cys 4–10 mg/kg/day, po, 1–2/day, some cases 
treated with steroids
Human iPS cell-derived 
cardiomyocyte sheet to 
endocardium [18]
Minipig, 20–25 kg Tac 0.75 mg/kg/day, MMF 500 mg/day, Pl 
20 mg/day
Human ES cell-derived 
retinal sheet to retina [19]
Yucatan minipig Cys, po, details unknown
Orthotopic allogeneic 





Thymectomy and donor thymus 
transplantation
Human hepatocyte 











Thymectomy and splenectomy, and Tac 0.5 mg/
kg/day, MMF 60 mg/kg/day, prednisolone 
20 mg/day, po
Abbreviations: half maximal inhibitory concentration (IC50); major histocompatibility complex (MHC); cyclosporine 
(Cys); tacrolimus (Tac); azathioprine (Aza); rapamycin (rap); mycophenolate mofetil (MMF); methylprednisolone 
(MP); prednisone (P); prednisolone (Pl); per os (po); intravenous injection (iv); intramuscular injection (im).
Table 1. 
Summary of immunosuppressive protocols.
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2.  Role of species differences in the effectiveness of 
immunosuppressants in vitro
The half maximal inhibitory concentration (IC50) of major immunosuppres-
sants was reported to be higher in mitogen response of pig lymphocytes than that in 
human lymphocytes [2]. The IC50 of cyclosporine, tacrolimus, and azathioprine was 
19.1 times [1.72 μg/ml (pig) vs. 0.09 μg/ml (human)], 13.0 times [2.99 ng/ml (pig) 
vs. 0.23 ng/ml (human)], and 11.0 times [1.43 μg/ml [pig] vs. 0.13 μg/ml (human)] 
higher in pigs than in human lymphocytes, respectively. The species differences 
decreased in case of rapamycin and mycophenolate mofetil (MMF); IC50 values of 
rapamycin and MMF were 2.28 times [2.05 ng/ml (pig) vs. 0.90 ng/ml (human)] 
and 1.45 times [10.75 ng/ml (pig) vs. 7.42 ng/ml (human)] higher in pigs than in 
humans, respectively. In contrast, the IC50 value of methylprednisolone in pigs was 
only 0.41 times [0.11 μg/ml (pig) vs. 0.27 μg/ml (human)] the value in humans. 
These results suggest that the blood concentration of calcineurin inhibitors should 
be kept higher in pigs than in humans to suppress blast formation of lymphocytes in 
transplantation studies.
3. Immunosuppressive medications in allogeneic transplantation
In allogeneic orthotopic small bowel transplantation, high-dose tacrolimus 
monotherapy and low-dose tacrolimus-MMF combination therapy were compared 
using Large White-Landrace pig strain as donors and recipients (both weigh-
ing approximately 26 kg) [3, 4]. Tacrolimus dose was controlled to keep trough 
at 15–25 ng/ml (high-dose group) or 5–15 ng/ml (low-dose group). The average 
dosage amount of tacrolimus in the high single dose group was 0.3 mg/kg/day 
intramuscularly from the day of operation to day 6 and 0.61 ± 0.26 mg/kg/day 
via gastrostomy after day 7. In the low-dose combination group, recipients were 
administered 0.1 mg/kg of tacrolimus intramuscularly on the day of operation and 
0.43 ± 0.14 mg/kg/day (average) of tacrolimus and 10 mg/kg twice a day of MMF 
via gastrostomy. All recipients in the high single dose group died within 46 days, 
while 7 out of the 10 recipients in the low-dose combination group survived for 
more than 60 days; the nontreated controls died within 15 days [3]. The subgroup 
study of tacrolimus-MMF combined group revealed that the recipients with low 
trough level of tacrolimus showed better survival, suggesting that higher trough 
level increases side effects of infection [4]. In general, the protocol consisting of cal-
cineurin inhibitors (cyclosporine or tacrolimus) and MMF suppresses the immune 
responses of T and B cells, respectively, and the combination treatment leads to 
effective immunosuppression with low side effects.
A pharmacokinetic study recommended the oral administration of 0.25 mg/kg of 
tacrolimus and 500 mg of MMF at 12 h intervals to pigs weighing 22–30 kg [5]. MMF 
dose was calculated to be around 20 mg/kg at each administration. The trough level 
of tacrolimus was kept at 5–15 ng/ml.
When orthotopic forelimb transplantation was performed between outbred 
pigs weighing 13–24 kg, recipients were administered cyclosporine or tacrolimus 
and MMF orally once a day [6, 7]. The desired trough levels were 100–300 ng/ml in 
case of cyclosporine and 3–8 ng/ml for tacrolimus. A total of 500 mg of MMF was 
administered, i.e., 21–38 mg/kg. They also used steroids; 500 mg of methylpred-
nisolone was injected intravenously during the operation, and 2.0 mg/kg/day of 
prednisone was given on the first postoperative day and then tapered by 0.5 mg/kg/
day every 3 days to a maintenance dose of 0.1 mg/kg/day until the end of observa-
tion period (90 days) [6] or for the first 30 days [7].
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We summarize here the pharmaceutical immunosuppressive regimens in 
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kg/day, iv (keep trough 20–40 or 45–80 ng/
ml) [10]
Heterotopic allogeneic 





MMF 1.5 g × 2 /day, iv or Cys 10–13 mg/kg/day, 
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cardiomyocyte sheet to 
endocardium [18]
Minipig, 20–25 kg Tac 0.75 mg/kg/day, MMF 500 mg/day, Pl 
20 mg/day
Human ES cell-derived 
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Table 1. 
Summary of immunosuppressive protocols.
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2.  Role of species differences in the effectiveness of 
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dose was calculated to be around 20 mg/kg at each administration. The trough level 
of tacrolimus was kept at 5–15 ng/ml.
When orthotopic forelimb transplantation was performed between outbred 
pigs weighing 13–24 kg, recipients were administered cyclosporine or tacrolimus 
and MMF orally once a day [6, 7]. The desired trough levels were 100–300 ng/ml in 
case of cyclosporine and 3–8 ng/ml for tacrolimus. A total of 500 mg of MMF was 
administered, i.e., 21–38 mg/kg. They also used steroids; 500 mg of methylpred-
nisolone was injected intravenously during the operation, and 2.0 mg/kg/day of 
prednisone was given on the first postoperative day and then tapered by 0.5 mg/kg/
day every 3 days to a maintenance dose of 0.1 mg/kg/day until the end of observa-
tion period (90 days) [6] or for the first 30 days [7].
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The Massachusetts General Hospital group uses genetically defined mini pigs, 
swine leukocyte antigen (SLA)gg (class Ic/class IId) donors, and SLAdd (class Id/class 
IId) recipients [8–11]. In orthotopic kidney transplantation, 10–13 mg/kg of cyclo-
sporine once a day, administered with a catheter to the external jugular vein, kept 
the trough level at 400–800 ng/ml [8, 9]. The first 12-day administration resulted 
in the survival of well-functioning major histocompatibility complex (MHC) class 
I-disparate kidney grafts for over 90 days regardless of use of steroids. In another 
study [10], continuous intravenous injection of 0.15 or 0.30 mg/kg/day of tacrolimus 
treatment kept the drug level at 20–40 or 45–80 ng/ml, respectively, and the first 
12-day administration resulted in well-functioning kidney grafts that survived for 
over 5 months. In addition, the high-dose regimen achieved successful engraftment of 
MHC class Ic/class IIc-mismatched kidney. The same group also compared the sepa-
rate effect of cyclosporine and MMF on the survival of class I-disparate heterotopic 
heart graft [11]. The treatment protocol of cyclosporine was the same as above [8] 
and MMF was administered at 1.5 g twice a day through a catheter into the external 
jugular vein to keep the trough level at 3–5 μg/ml. The survival days of the test heart 
grafts were 53 ± 7.5 days (mean ± SD) and over 124 days in cyclosporine and MMF 
groups, respectively. The graft vascular changes were also mild in the MMF group.
4. Immunosuppressive medications in xenogeneic transplantation
Because pigs are hoped to be a xenogeneic donor, the major objectives in pig 
experiments include establishing xenogeneic antigen-free pigs and developing 
strategies for long-term survival in nonhuman primates [12]. In such studies, 
immunosuppression is almost equivalent to human clinics using tacrolimus, MMF, 
and antibody remedies. Pig recipients in xenotransplantation appear in the preclini-
cal studies of human cell and tissue therapy.
In a short-term experiment of intrahepatic transplantation of human hepatocyte 
cell line, 0.5 mg/kg of tacrolimus was injected intramuscularly for 7 days [13]. 
When pigs received xenogeneic human-lined hepatocytes, the recipients survived 
D-galactosamine-induced hepatic injury. Human albumin appeared in the recipient 
serum 2 days after transplantation but disappeared at day 7, suggesting that the cells 
survived only for a few days.
Intramyocardial transplantation of mesenchymal stem cells had been actively 
investigated in not only basic research but also clinical practice. Because of the 
size advantage, pigs were used for preclinical studies to explore proof of concept 
by mimicking clinical procedure. Human bone marrow-derived mesenchymal 
stem cells labeled with radioactive indium (111In) were transplanted in porcine 
myocardium via catheter inserted from a femoral artery and traced by whole body 
scanning for 6 days [14]. Recipient pigs were orally treated with 5 mg/kg of cyclo-
sporine from 3 days before to 6 days after cell transplantation. Immunosuppressed 
pigs retained the radioactivity far longer than nontreated controls. In another study, 
pigs received human umbilical mesenchymal stem cells in artificial cardiac infarct 
area and were administered 5 mg/kg of cyclosporine orally twice a day, from the 
day before to 8 weeks after cell transplantation [15]. In a similar study, 10 mg/kg 
of cyclosporine was administered orally, twice a day from 3 days before to 8 weeks 
after the cell transplantation [16]. As a more sophisticated approach, cardiomyocyte 
sheet transplantation is being undertaken [17, 18]. When cell sheets consisting of 
human induced pluripotent stem (iPS) cell-derived myocytes were transplanted 
onto the epicardium of minipigs (weighing 20–25 kg) mimicking clinical trial, 
0.75 mg/kg/day of tacrolimus, 500 mg/day of MMF, and 20 mg/day of prednisolone 
were administered from 5 days before to 8 weeks after the transplantation [18].
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Transplantation of human embryonic stem cell-derived retinal pigmented 
epithelium was also performed in pigs [19]. Although immunosuppression was 
precarious, cyclosporine was added in the feed and their blood level 2 h after 
administration was only 1 pg/ml, and the graft tissue was detectable after 3 months. 
Because retina is known as an immune-privileged site, additional immunosuppres-
sion may not be necessary.
5.  Nonpharmaceutical immunosuppression: thymic intervention and 
SCID pigs
Studies on genetically defined minipigs by Massachusetts General Hospital 
group emphasize the role of thymus in the establishment and maintenance of 
immunological tolerance. As quoted above [8], the 12-day administration of 
cyclosporine induced the long-term engraftment of MHC class I-disparate kid-
neys, but not if the thymus was removed. They also stated that old recipients tend 
to be difficult to establish tolerance [9]. These observations lead to the concept 
of tolerance induction by thymic transplantation. In this, unlike conventional 
thymic tissue transplantation, the donor thymus is transplanted by vascular 
anastomosis that assures immediate and perfect function of the thymus. Three 
weeks after the complete removal of thymus, the recipient was transplanted with 
MHC fully-disparate donor thymus in the neck region and infused continuously 
with 0.15 mg/kg/day of tacrolimus (trough level, 30–40 ng/ml) for 12 days. After 
3–4 months, the recipient accepted a kidney from the thymus donor without 
immunosuppression [20].
Previously, we reported the effectiveness of thymectomy on the acceptance of 
xenogeneic human hepatocytes and artificial vascular tubes [21, 22]. Upon hepa-
tocyte transplantation, the blood human albumin levels were higher in neonatally-
thymectomized microminiature pigs than in nonthymectomized controls [21]. In 
another study, thymus and spleen were removed from Göttingen minipigs aged 
6–7 months (≥ 15 kg), followed by the administration of 0.5 mg/kg/day of tacro-
limus, 60 mg/kg/day of MMF, and 20 mg/day of prednisolone [22]. Seven days 
after the removal, an artificial vascular tube made from human fibroblasts was 
transplanted in between a carotid artery and a jugular vein to form an arteriovenous 
shunt. While the shunt was obstructed completely by thrombus 2 weeks after the 
operation in pigs without the removal of thymus and spleen, the shunt was func-
tional in pigs with thymectomy and splenectomy, even though the immunosuppres-
sive treatment administered was equal.
Finally, we would like to refer briefly to the availability of SCID pigs in preclini-
cal study on human cell therapy. According to a well-constructed review [23], there 
are 11 SCID pig strains so far; one was naturally found and others were genetically 
modified. The mutated genes in these strains are ARTEMIS (a gene encoding a 
nuclear protein that is involved in V(D)J recombination and DNA repair), inter-
leukin 2 receptor gamma chain (IL2RG), recombination-activating genes (RAG)1, 
and RAG2. Three strains have double mutations, namely RAG1 and 2, RAG2 and 
IL2RG, and ARTEMIS and IL2RG. In accordance with gene function, each strain 
lacks specific immune-competent cell lineages such as T, B, and natural killer (NK) 
cells. Human cell transplant experiments were reported as iPS cell teratoma forma-
tion [24] and ovarian cancer engraftment [25], both of which did not focus on 
preclinical study on human cell therapy. SCID pigs need the highest antibacterial 
care because of their vulnerability to infection. Indeed, they have been reported 
to survive for only 6 months at the longest [23]. In addition, as general features 
of mutant pigs, there are diversities in phenotypic severity and small litter size. If 
Xenotransplantation - Comprehensive Study
116
The Massachusetts General Hospital group uses genetically defined mini pigs, 
swine leukocyte antigen (SLA)gg (class Ic/class IId) donors, and SLAdd (class Id/class 
IId) recipients [8–11]. In orthotopic kidney transplantation, 10–13 mg/kg of cyclo-
sporine once a day, administered with a catheter to the external jugular vein, kept 
the trough level at 400–800 ng/ml [8, 9]. The first 12-day administration resulted 
in the survival of well-functioning major histocompatibility complex (MHC) class 
I-disparate kidney grafts for over 90 days regardless of use of steroids. In another 
study [10], continuous intravenous injection of 0.15 or 0.30 mg/kg/day of tacrolimus 
treatment kept the drug level at 20–40 or 45–80 ng/ml, respectively, and the first 
12-day administration resulted in well-functioning kidney grafts that survived for 
over 5 months. In addition, the high-dose regimen achieved successful engraftment of 
MHC class Ic/class IIc-mismatched kidney. The same group also compared the sepa-
rate effect of cyclosporine and MMF on the survival of class I-disparate heterotopic 
heart graft [11]. The treatment protocol of cyclosporine was the same as above [8] 
and MMF was administered at 1.5 g twice a day through a catheter into the external 
jugular vein to keep the trough level at 3–5 μg/ml. The survival days of the test heart 
grafts were 53 ± 7.5 days (mean ± SD) and over 124 days in cyclosporine and MMF 
groups, respectively. The graft vascular changes were also mild in the MMF group.
4. Immunosuppressive medications in xenogeneic transplantation
Because pigs are hoped to be a xenogeneic donor, the major objectives in pig 
experiments include establishing xenogeneic antigen-free pigs and developing 
strategies for long-term survival in nonhuman primates [12]. In such studies, 
immunosuppression is almost equivalent to human clinics using tacrolimus, MMF, 
and antibody remedies. Pig recipients in xenotransplantation appear in the preclini-
cal studies of human cell and tissue therapy.
In a short-term experiment of intrahepatic transplantation of human hepatocyte 
cell line, 0.5 mg/kg of tacrolimus was injected intramuscularly for 7 days [13]. 
When pigs received xenogeneic human-lined hepatocytes, the recipients survived 
D-galactosamine-induced hepatic injury. Human albumin appeared in the recipient 
serum 2 days after transplantation but disappeared at day 7, suggesting that the cells 
survived only for a few days.
Intramyocardial transplantation of mesenchymal stem cells had been actively 
investigated in not only basic research but also clinical practice. Because of the 
size advantage, pigs were used for preclinical studies to explore proof of concept 
by mimicking clinical procedure. Human bone marrow-derived mesenchymal 
stem cells labeled with radioactive indium (111In) were transplanted in porcine 
myocardium via catheter inserted from a femoral artery and traced by whole body 
scanning for 6 days [14]. Recipient pigs were orally treated with 5 mg/kg of cyclo-
sporine from 3 days before to 6 days after cell transplantation. Immunosuppressed 
pigs retained the radioactivity far longer than nontreated controls. In another study, 
pigs received human umbilical mesenchymal stem cells in artificial cardiac infarct 
area and were administered 5 mg/kg of cyclosporine orally twice a day, from the 
day before to 8 weeks after cell transplantation [15]. In a similar study, 10 mg/kg 
of cyclosporine was administered orally, twice a day from 3 days before to 8 weeks 
after the cell transplantation [16]. As a more sophisticated approach, cardiomyocyte 
sheet transplantation is being undertaken [17, 18]. When cell sheets consisting of 
human induced pluripotent stem (iPS) cell-derived myocytes were transplanted 
onto the epicardium of minipigs (weighing 20–25 kg) mimicking clinical trial, 
0.75 mg/kg/day of tacrolimus, 500 mg/day of MMF, and 20 mg/day of prednisolone 
were administered from 5 days before to 8 weeks after the transplantation [18].
117
Controllable Immunosuppression in Pigs as a Basis for Preclinical Studies on Human Cell Therapy
DOI: http://dx.doi.org/10.5772/intechopen.89521
Transplantation of human embryonic stem cell-derived retinal pigmented 
epithelium was also performed in pigs [19]. Although immunosuppression was 
precarious, cyclosporine was added in the feed and their blood level 2 h after 
administration was only 1 pg/ml, and the graft tissue was detectable after 3 months. 
Because retina is known as an immune-privileged site, additional immunosuppres-
sion may not be necessary.
5.  Nonpharmaceutical immunosuppression: thymic intervention and 
SCID pigs
Studies on genetically defined minipigs by Massachusetts General Hospital 
group emphasize the role of thymus in the establishment and maintenance of 
immunological tolerance. As quoted above [8], the 12-day administration of 
cyclosporine induced the long-term engraftment of MHC class I-disparate kid-
neys, but not if the thymus was removed. They also stated that old recipients tend 
to be difficult to establish tolerance [9]. These observations lead to the concept 
of tolerance induction by thymic transplantation. In this, unlike conventional 
thymic tissue transplantation, the donor thymus is transplanted by vascular 
anastomosis that assures immediate and perfect function of the thymus. Three 
weeks after the complete removal of thymus, the recipient was transplanted with 
MHC fully-disparate donor thymus in the neck region and infused continuously 
with 0.15 mg/kg/day of tacrolimus (trough level, 30–40 ng/ml) for 12 days. After 
3–4 months, the recipient accepted a kidney from the thymus donor without 
immunosuppression [20].
Previously, we reported the effectiveness of thymectomy on the acceptance of 
xenogeneic human hepatocytes and artificial vascular tubes [21, 22]. Upon hepa-
tocyte transplantation, the blood human albumin levels were higher in neonatally-
thymectomized microminiature pigs than in nonthymectomized controls [21]. In 
another study, thymus and spleen were removed from Göttingen minipigs aged 
6–7 months (≥ 15 kg), followed by the administration of 0.5 mg/kg/day of tacro-
limus, 60 mg/kg/day of MMF, and 20 mg/day of prednisolone [22]. Seven days 
after the removal, an artificial vascular tube made from human fibroblasts was 
transplanted in between a carotid artery and a jugular vein to form an arteriovenous 
shunt. While the shunt was obstructed completely by thrombus 2 weeks after the 
operation in pigs without the removal of thymus and spleen, the shunt was func-
tional in pigs with thymectomy and splenectomy, even though the immunosuppres-
sive treatment administered was equal.
Finally, we would like to refer briefly to the availability of SCID pigs in preclini-
cal study on human cell therapy. According to a well-constructed review [23], there 
are 11 SCID pig strains so far; one was naturally found and others were genetically 
modified. The mutated genes in these strains are ARTEMIS (a gene encoding a 
nuclear protein that is involved in V(D)J recombination and DNA repair), inter-
leukin 2 receptor gamma chain (IL2RG), recombination-activating genes (RAG)1, 
and RAG2. Three strains have double mutations, namely RAG1 and 2, RAG2 and 
IL2RG, and ARTEMIS and IL2RG. In accordance with gene function, each strain 
lacks specific immune-competent cell lineages such as T, B, and natural killer (NK) 
cells. Human cell transplant experiments were reported as iPS cell teratoma forma-
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to survive for only 6 months at the longest [23]. In addition, as general features 
of mutant pigs, there are diversities in phenotypic severity and small litter size. If 
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these difficulties can be overcome, SCID pigs will be useful experimental animals 
for preclinical study on human cell therapy.
6. Conclusion
Due to the lack of identifiable sign of rejection, immunosuppression in cell 
transplant experiment is hard to control. Successful protocol is established only 
based on case-by-case experiences. Here, we suggest an introductory regimen 
of immunosuppression in human cell and tissue transplantation into pigs using 
tacrolimus and MMF. Preliminary doses are 0.5 mg/kg of tacrolimus orally and 
40 mg/kg of MMF orally, and the administration should start 3 and 5 days before 
transplantation, respectively. Drugs can be administered by mixing in the powdered 
feed before transplantation; however, after transplantation, it should be given 
through a gastrostomy tube to assure the dosage in order to not be affected by 
appetite. Periodical examination of drug trough levels is indispensable and should 
be reflected in subsequent dose. Steroids should be carefully tested because their 
immunosuppressive dose has a risk of side effects such as gastrointestinal ulcer and 
systemic over immunosuppression. In addition, unavailability of exogenous steroid 
monitoring makes dosage control difficult. If surgical skill is available, the combi-
nation of thymectomy and splenectomy is recommended. Since the graft mass of 
cell and tissue transplantation is far smaller and not fully vascularized than organs, 
the recipients may need less immunosuppression. Data accumulation and optimiza-
tion are desired in this field.
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of immunosuppression in human cell and tissue transplantation into pigs using 
tacrolimus and MMF. Preliminary doses are 0.5 mg/kg of tacrolimus orally and 
40 mg/kg of MMF orally, and the administration should start 3 and 5 days before 
transplantation, respectively. Drugs can be administered by mixing in the powdered 
feed before transplantation; however, after transplantation, it should be given 
through a gastrostomy tube to assure the dosage in order to not be affected by 
appetite. Periodical examination of drug trough levels is indispensable and should 
be reflected in subsequent dose. Steroids should be carefully tested because their 
immunosuppressive dose has a risk of side effects such as gastrointestinal ulcer and 
systemic over immunosuppression. In addition, unavailability of exogenous steroid 
monitoring makes dosage control difficult. If surgical skill is available, the combi-
nation of thymectomy and splenectomy is recommended. Since the graft mass of 
cell and tissue transplantation is far smaller and not fully vascularized than organs, 
the recipients may need less immunosuppression. Data accumulation and optimiza-
tion are desired in this field.
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Abstract
The shortage of organs for transplantation is of critical importance worldwide. 
Xenotransplantation or xeno-embryonic organ transplantation can stably supply 
organs and is considered to be an established alternative treatment. Regenerative 
medicine is another option, and recent advances in stem cell research have enabled 
the reproduction of miniature organs, called organoids, derived in vitro from 
human induced pluripotent stem cells. However, the in vitro production of large 
and complex organs that can efficiently function in vivo is not yet accomplished. 
We proposed a novel strategy for xenotransplantation in which a chimeric kidney is 
constructed by injecting human nephron progenitor cells into a porcine embryonic 
kidney, thereby eliminating pig nephron progenitor cells and allowing transplanta-
tion into a human and long-term survival. In this chapter, we discussed advantages 
and pitfalls of xenotransplantation and xeno-embryonic kidney transplantation. 
Recent attempts of human organoids and blastocyst complementation were 
reviewed. Finally, we proposed our novel xeno-regenerative therapeutic strategy.
Keywords: kidney regeneration, xeno-embryonic kidney transplantation, 
organogenic niche method, nephron progenitor cell replacement system, induced 
pluripotent stem cells
1. Introduction
Currently, the only definitive treatment for end-stage organ failure is transplan-
tation. However, the global scarcity of organs is a critical challenge, necessitating 
that novel alternatives be developed. Xenotransplantation is a revolutionary therapy 
that can supply organs stably. In recent years, gene editing techniques, such as 
CRISPR/Cas9, have been developed to produce animals that generate organs at 
low risk of rejection and infection. Given that our understanding of xenogenic 
immune barriers has expanded, xenotransplantation may have a promising outlook. 
Presently, the strong antigenicity of xenogenic organs is the main barrier to xeno-
transplantation and has resulted in the development of methods of xeno-embryonic 
transplantation that use less antigenic organs. Although embryonic organs are 
prematurely transplanted, they can mature in vivo in a self-sustaining manner to 
perform their function. Xeno-embryonic organs, therefore, have some utility as a 
scaffold for the regeneration of human organs.
Regenerative medicine is anticipated to be a promising alternative when tackling 
the problem of a shortfall in organ availability. Recent advances in stem cell research 
have enabled the reproduction of miniature organs called organoids, which are 
derived in vitro from human induced pluripotent stem cells (iPSCs). However, we 
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have not yet achieved in vitro reproduction of large and complex organs that func-
tion efficiently in vivo. Because kidneys comprise a three-dimensional and complex 
combination of various cell types that must perform homeostatic and endocrine 
functions, in vitro regeneration of the kidneys is particularly challenging compared 
with other organs. To overcome this challenge, we sought to use xeno-embryonic 
kidneys as a scaffold for development of human progenitor cells. By transplanting 
exogenous nephron progenitor cells (NPCs) into the metanephric mesenchyme of a 
xenogenic fetus, we aimed to regenerate whole neo-kidneys from the transplanted 
NPCs via their xenogenic development program. Specifically, we propose a novel 
xenotransplantation strategy wherein a chimeric kidney is constructed by injecting 
human NPCs into a porcine embryonic kidney and transplanted into a human after 
eliminating pig NPCs.
In this chapter, we discussed advantages and pitfalls of xenotransplantation and 
xeno-embryonic kidney transplantation. Recent attempts of human organoids and 
blastocyst complementation were reviewed. Finally, we proposed our novel xeno-
regenerative therapeutic strategy.
2. Kidney xenotransplantation
Xenotransplantation is a revolutionary therapy used to solve the problem of 
organ shortage. The concept has existed for more than 100 years, with the first 
kidney xenotransplantation performed in 1906. In this procedure, a pig kidney was 
heterotopically transplanted into a patient with renal failure but had to be removed 
after 3 days because of vessel thrombosis [1]. Subsequent attempts at renal xeno-
grafting failed, and the practice was abandoned. However, xenotransplantation re-
emerged as an option following the development of powerful immunosuppressive 
agents. In 1964, the kidney of a chimpanzee was successfully transplanted into a 
patient with renal failure and functioned for 9 months before the patient ultimately 
died of pneumonia [2]. Nonhuman primates were often used as a xenograft source 
at this time because the similarities between species produced good outcomes. 
However, this practice was abandoned because of the relative scarcity of nonhu-
man primate sources, concerns about disease transmission, and ethical issues. By 
contrast, pigs are almost limitlessly available as a transplant source, and their kid-
neys are similar in size and physiological function to those of humans. At present, 
porcine kidneys are therefore considered a suitable xenotransplantation source [3].
Nevertheless, using porcine kidneys in xenotransplantation presents some 
problems that must be addressed. The most critical problem is the presence of 
α-galactose-1,3-galactose (Gal). This galactose moiety is added to cell surface 
sugars in swine by α-1,3-galactosyltransferase (GalT), whereas primates, including 
humans, do not inherit GalT and possess anti-Gal antibodies as natural antibodies 
[4]. When a pig kidney is transplanted into a primate, anti-Gal antibodies bind to 
the Gal antigen expressed on porcine vascular endothelial cells, activate human 
complement, and cause hyperacute vascular rejection that immunosuppressants 
alone cannot prevent. Recently, genetically modified pigs with low risk of rejection 
potential were created with gene editing technology; a representative example is 
the GalT-knockout (KO) pig [5]. Given that these transgenic pigs do not express 
Gal, the anti-Gal antibody in primates does not react with them. Pigs expressing 
human complement regulatory proteins (e.g., human CD55 and CD46) that sup-
press human complement activation have also been reported [6, 7]. Other attempts 
have been made to overcome the risk of coagulation dysfunction by introducing 
human coagulation-regulatory genes, such as thrombomodulin, into pigs [8]. 
Moreover, pigs are now available that have various combinations of these genetic 
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modifications, and research is ongoing as to the optimal combination for transplan-
tation. Actually, it is technically possible to produce pigs with multiple KO genes 
and multiple transgenes simultaneously [9, 10]. One such example is the double 
gene KO pig including GalT-KO that expresses three human complement regulatory 
genes and two anti-inflammatory genes; however, this combination might not yet 
be complete [10].
Improved immunosuppressive regimens are also contributing to the progress 
seen in xenotransplantation of pig kidneys. There has been particular interest in 
blockade inhibiting the CD40/CD154 pathway, with anti-CD40 or anti-CD154 
antibody therapy contributing significantly to a prolongation of renal xenograft 
survival [11, 12]. In 2019, a GalT-KO kidney expressing CD55 was transplanted from 
pig to rhesus macaque and had the longest survival of life-sustaining xenograft to 
date (499 days) [13]. However, although hyperacute rejection by Gal antibodies 
has been largely overcome, late antibody-mediated injury by non-Gal antibodies 
remains a problem. Another problem that needs to be resolved is recipient death 
from infection due to strong immunosuppression [12].
The possibility of zoonotic infection cannot be ignored in xenotransplantation. 
Given that pigs can be bred in pathogen-free environments, the risk of acquiring 
zoonotic infections is lower than that of primates. However, the risk of porcine 
endogenous retrovirus (PERV) that integrates along chromosomes cannot be 
removed by this approach. In previous research, it was reported that PERV can 
infect human cells in vitro [14]. In 2015, CRISPR/Cas9 succeeded in knocking out 
62 copies of the PERV pol gene in porcine cells [15], and in 2017, a PERV-free pig 
was produced [16].
As shown in this section, the measures taken against rejection and infection 
mean that kidney xenotransplantation is rapidly approaching clinical reality.
3. Xeno-embryonic kidney transplantation
The use of xeno-embryonic transplantation may broaden the organ pool. This 
approach seems to benefit from a lower risk of rejection compared with adult organ 
transplantation, making a potentially invaluable therapeutic resource. Although an 
embryonic organ is transplanted prematurely, it can mature in a self-sustaining way 
in vivo to become functional. Xeno-embryonic organs may be particularly useful as 
a scaffold for the regeneration of human organs.
Metanephroi have generally been used for embryonic kidney transplantation [17] 
because this form is already committed to becoming a kidney. When transplanted 
into a recipient, the metanephroi is free to differentiate and mature into a whole kid-
ney. The transplanted metanephroi promotes angiogenesis, encouraging host blood 
vessel infiltrating, thus resulting in glomeruli that are composed of host-derived 
vasculature [18]. The developed metanephroi produces urine, and anastomosing 
the ureter of the metanephroi and the ureter of the host has been shown to prolong 
the survival time of host anephric rats [19]. Moreover, the developed metanephroi 
acquires endocrine function, producing both renin and erythropoietin [20, 21].
Conveniently, the metanephroi is a fetal organ that may have low immunoge-
nicity, potentially making it especially suitable for transplantation. Contrasting 
with adult grafts that already have the donor vessels, the avascular metanephroi is 
only vascularized by host vessels after it is transplanted. Thus, humoral immunity 
to donor endothelial cells is less likely to occur when using the metanephroi for 
transplantation [22]. Additionally, we can expect a reduced expression of donor 
antigens, such as HLA class I and II, on a developing metanephroi graft when 
compared to an adult graft [23].
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modifications, and research is ongoing as to the optimal combination for transplan-
tation. Actually, it is technically possible to produce pigs with multiple KO genes 
and multiple transgenes simultaneously [9, 10]. One such example is the double 
gene KO pig including GalT-KO that expresses three human complement regulatory 
genes and two anti-inflammatory genes; however, this combination might not yet 
be complete [10].
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ney. The transplanted metanephroi promotes angiogenesis, encouraging host blood 
vessel infiltrating, thus resulting in glomeruli that are composed of host-derived 
vasculature [18]. The developed metanephroi produces urine, and anastomosing 
the ureter of the metanephroi and the ureter of the host has been shown to prolong 
the survival time of host anephric rats [19]. Moreover, the developed metanephroi 
acquires endocrine function, producing both renin and erythropoietin [20, 21].
Conveniently, the metanephroi is a fetal organ that may have low immunoge-
nicity, potentially making it especially suitable for transplantation. Contrasting 
with adult grafts that already have the donor vessels, the avascular metanephroi is 
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to donor endothelial cells is less likely to occur when using the metanephroi for 
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antigens, such as HLA class I and II, on a developing metanephroi graft when 
compared to an adult graft [23].
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The ultimate size of the developed metanephroi appears to be imprinted during 
the early stages of embryonic development. Considering human clinical applica-
tion, pigs are an ideal resource for metanephric transplantation as with adult 
kidney xenotransplantation. In the case of allogenic porcine transplantation, the 
metanephroi on embryonic day 28 (E28) has been successfully transplanted into 
a nonimmunosuppressed recipient pig and shown to differentiate into a mature 
kidney without rejection [24]. Allogenic adult kidney grafts are easily rejected 
without immunosuppression. Transplants originating from pig embryos on E27 to 
E28 all exhibited significant growth and full differentiation, while those harvested 
on E20 and E25 failed to develop and only differentiated into few glomeruli and 
tubules, together with other derivatives, such as blood vessels, cartilage, and bone 
[25]. This indicates that metanephroi that are too immature may be incompletely 
pre-programmed and may differentiate into nonrenal structures. However, age-
dependent graft growth and survival in allogenic rats was shown to be optimal 
from E15 and worsened progressively for metanephroi obtained on E16 to E21. The 
developed metanephroi obtained on E15 showed maturation of renal elements and 
no sign of rejection, whereas those obtained on E20 had a poor renal architecture 
and a dense lymphocytic infiltrate [26]. Importantly, there appears to be an optimal 
window for harvesting metanephroi to obtain good transplantation outcomes.
Successful xeno-metanephric transplantation has been reported previously. In 
an important study, E28 pig metanephroi or adult kidneys were transplanted into 
recipient rats with and without immunosuppression. Those transplanted into 
nonimmunosuppressed rats showed tissue rejection, whereas those transplanted 
into hosts treated with CTLA-4-Ig underwent growth and differentiation. By 
contrast, adult kidney grafts showed disturbed morphology, necrotic tissue, 
and a high degree of lymphocyte infiltration, even when hosts were treated with 
CTLA-4-Ig [25].
The immune advantage of metanephroi over developed adult kidneys has been 
demonstrated by direct comparison of xenotransplantation into host animals 
treated with immunosuppressants. Next, it will be necessary to study the xeno-
transplantation of pig metanephroi into nonhuman primates.
In the case of xenotransplantation of pig islets, embryonic islet tissues are 
regarded as a choice for xenotransplantation with several advantages including 
reduced immunogenicity, long-term proliferative potential, and revascularization 
by host endothelium. However, the embryonic implants exhibit a delayed insulin 
response to glucose in vivo (>3 months) and limited effect on improvement of 
blood glucose level [27]. Fetal and neonatal pig islets have the higher expression 
of GAL and will be more susceptible to xenorejection than adult pig islets [28, 29]. 
Therefore, adult pig is regarded as the primary donor source of islet xenografts, 
which can supply an adequate amount of viable islet cells and start functioning 
immediately after implantation.
4. Kidney organoids derived from pluripotent stem cells (PSCs)
The field of stem cell research is growing at a rapid pace. The reproduction of 
organoids derived from human iPSCs in vitro is already possible in several organs, 
including the optic cup, intestines, and liver [30–32]. Although embryologic 
kidney development is complicated, the reproduction of kidney organoids has 
been reported. Kidneys arise from metanephroi, which develop via the reciprocal 
interaction between the metanephric mesenchyme, containing NPCs and stromal 
progenitor cells, and the ureteric bud. Takasato et al. reported simultaneously 
inducing metanephric mesenchyme and ureteral buds from human iPSCs to 
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produce kidney organoids. The generated organoids contained nephrons associated 
with a collecting duct network surrounded by renal interstitium and endothelial 
cells [33]. Taguchi et al. also reported the successful differentiation of human 
iPSCs into NPCs and ureteric buds in vitro, by repeating the development of the 
metanephric kidney [34, 35]. Additionally, they reconstructed kidney organoids 
with higher-order structures, containing embryonic branching morphogenesis, by 
reaggregating NPCs and ureteric buds derived from mouse PSCs and stromal pro-
genitor cells from mouse embryos. However, a method for differentiating human 
iPSCs into stromal progenitor cells is yet to be established. Furthermore, neither 
of the developed kidney organoids have a urine drainage system, and both are too 
small to function in vivo. Therefore, generating functional kidneys in vitro remains 
a challenge before this research has translational potential.
5. Blastocyst complementation
As an alternative to in vitro directed differentiation of iPSCs, previous studies 
have considered methods of regenerating solid organs from transplanted exogenous 
cells to function in vivo by borrowing a xenogenic development program. One such 
method is blastocyst complementation. When PSCs are transplanted into blasto-
cysts, which are early animal embryos, chimeras containing blastocysts and PSCs 
are formed. When PSCs are injected into blastocysts that have undergone genetic 
manipulation not to generate a target organ, the missing organ is formed from 
the injected PSCs by systemic chimera formation. Using the method of blastocyst 
complementation, kidneys derived from mouse iPSCs have been regenerated in sall1 
knockout mice that lack kidneys [36]. Successful kidney regeneration has also been 
derived from mouse iPSCs in sall1 knockout rats [37]. Therefore, this generation 
mechanism appears to have interspecies compatibility. The renal lineage cells were 
derived from the injected PSCs, whereas nonrenal lineages such as blood vessels 
and stromal cells in kidneys were chimeric for both blastocyst cells and PSCs. 
Recently, mouse PSC-derived vascular endothelial cells were regenerated into Flk-1 
knockout mice, lacking a key gene for vascular endothelial development [38]. By 
simultaneously disrupting Flk-1 and genes required for genesis of the target organ, 
rejection-free organs could be generated from patient-specific iPSCs. The size of 
the regenerated organ will be affected by the size of the host animal blastocyst. 
Successful allogenic blastocyst complementation has been shown to regenerate large 
organs in pancreas-deficient pigs [39].
Given that human iPSCs fundamentally lack the ability to form chimeras, blasto-
cyst complementation cannot be applied directly to humans. Inducing the expres-
sion of anti-apoptotic genes could give some chimera-forming ability to human 
iPSCs [40, 41], but the long-term safety would require clarification because these 
are also recognized oncogenes. Another issue is that basing this method on systemic 
chimera formation leads to the serious ethical concern of chimera formation in host 
gametes or neural tissue other than the target organs. The introduction of the het-
erologous cells during insemination must be thoroughly considered for the loss of 
the personal identity of a living being [42]. If these problems can be resolved, such a 
method that can produce organs that function in vivo would be highly significant.
6. Organogenic niche method and NPC replacement system
We have developed an organogenic niche method that utilizes a xenogenic devel-
opment program. In this method, exogenous organ progenitor cells are transplanted 
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opment program. In this method, exogenous organ progenitor cells are transplanted 
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into the region of the xenogenic fetus where the target organ develops. The trans-
plantation of progenitor cells into host tissue matched by developmental stage may 
be critical for efficient cell grafting. In our experiments, we first injected human 
mesenchymal stem cells (hMSC) expressing glial cell line-derived neurotrophic fac-
tor into the embryonic rat site where budding of the ureteric bud occurred. Second, 
the transplanted host rat embryo was grown in a whole-embryo culture system [43]. 
Third, the transplanted hMSCs were integrated into the metanephroi and differen-
tiated into tubular epithelial cells, interstitial cells, and glomerular epithelial cells 
[44]. Fourth, we transplanted the developed metanephroi into recipient rats. Using 
this approach, the metanephroi integrated with the vessels of recipient rats and the 
vascularized nephrons (derived from hMSCs) regenerated. The neo-kidney derived 
from hMSCs also produced urine by filtering the host blood, and the level of urea 
nitrogen and creatinine in the urine was higher than that of the host serum [45], 
and it also secreted human erythropoietin in response to host anemia [46]. Thus, we 
successfully regenerated human cell-derived neo-kidneys with in vivo function. As 
described, instead of PSCs, we used stem cells or progenitor cells that have limited 
potency. These cells were only locally transplanted into embryos at mid-to-late 
gestational ages, thereby ensuring that chimera formation only occurs in the kidney 
and avoiding any potential ethical concerns.
Existing native host cells inhibit the engraftment of transplanted donor cells. 
We recently developed a new method combining an organogenic niche with elimi-
nating host NPCs to increase the efficiency of donor cell engraftment [47]. In this 
method, we used transgenic mice in which the diphtheria toxin receptor (DTR) 
was specifically expressed on Six2-positive NPCs (Six2-iDTR transgenic mouse). 
Rodents such as mice and rats naturally lack the DTR, so Six2-positive NPCs 
selectively undergo apoptosis with the administration of diphtheria toxin. When 
donor mouse NPCs are transplanted into host mouse metanephroi, they became 
chimeric with the existing native host NPCs, and contribution rate of the donor 
cells was 30% of cap mesenchyme cells. Administering diphtheria toxin eliminated 
the host mouse NPCs and allowed 100% replacement with donor mouse NPCs 
that could generate neo-nephrons [47] (Figure 1). In this way, we succeeded in 
achieving full replacement with heterogeneous donor rat NPCs. Importantly, we 
revealed that nephrons derived from rat NPCs could connect to the host mouse 
collecting ducts, even when nephrons and collecting ducts were heterogeneous. 
Next, we examined the possibility of in vivo regeneration of interspecies kidneys 
Figure 1. 
Schematic of the drug-induced cell elimination system to exchange native NPCs with exogenous NPCs.
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using NPC replacement. In subsequent research, we successfully regenerated rat 
nephrons using the Six2-iDTR mouse metanephroi as a scaffold in recipient rats 
receiving immunosuppressive therapy. We showed that neo-kidneys were vascular-
ized by blood vessels originating from the recipient rats using the species-specific 
antibody for detection. Furthermore, we injected fluorescent-labeled dextran into 
the recipient rats, and the accumulation of dextran in Bowman’s space of neo-
glomeruli and in the lumen of neo-tubules was confirmed. Our findings confirmed 
that neo-kidneys were incorporated into blood circulatory system of recipients, 
resulting in functional neo-glomeruli filtration [48].
In the future, we aim to use this system of kidney regeneration with pig fetuses 
as the bioreactor and human iPSC-derived NPCs as the cell source. It is not difficult 
to supply a cell source because protocols for inducing NPCs from human iPSCs 
have already been developed [33, 34]; additionally, expansion of NPC culture is 
possible [49, 50]. A fundamental problem with our proposals is that human cells 
permanently express DTR and can undergo apoptosis when treated with diphtheria 
toxin. Therefore, the DTR system cannot be applied directly to humans. Recently, 
we developed a new transgenic model to ablate NPCs using an alternative drug that 
does not affect human cells (unpublished data).
7. Stepwise peristaltic ureter system
Although transplanted metanephroi can produce urine, they lack a urine 
excretion pathway, gradually become hydronephrotic, and cease functioning. 
Neo-kidneys regenerated using metanephroi as a bioreactor may also follow the 
same mechanism. Recently, we developed a urine excretion strategy for embryonic 
kidneys generated by stem cell methods.
The ultimate size of a metanephric graft is determined by the size of the source 
animal. Pigs are therefore considered a suitable resource from this perspective. To 
eliminate the potential for rejection, we transplanted metanephroi from cloned pig 
fetuses into syngenic hosts. All transplanted metanephroi differentiated success-
fully into mature kidneys, growing to 5–7 mm in length by 3 weeks. After 5 weeks, 
metanephroi grew to more than 1 cm and retained urine in the developed ureters, 
and after 8 weeks, they grew to about 3 cm and started to develop hydronephrosis 
as urine production increased [51]. Ureteral primordia start peristalsis during the 
embryonic stage and normally excrete urine into the bladder, and this sustained 
urine excretion may be important for normal development.
To delay the onset of hydronephrosis and to promote the growth of metanephric 
grafts, we transplanted metanephroi with ureters and a bladder (MNB) into a 
recipient animal. After 4 weeks, hydronephrosis occurred in the group with normal 
metanephroi transplants but not in the group with MNB transplants. In the MNB 
group, urine retention in the bladder was observed. Histopathologic examination 
also showed more pronounced tubular luminal dilation and interstitial fibrosis, and 
greater reductions in the number of glomeruli, in the metanephroi group than with 
the MNB group. Moreover, urine volumes and urinary levels of urea nitrogen and 
creatinine were higher in the MNB group than in the metanephroi group.
Furthermore, we demonstrated the generation of a urine excretion channel 
in MNB by using the stepwise peristaltic ureter (SWPU) system. Briefly, at an 
appropriate time, we connected the host ureter to the MNB graft containing urine 
produced by the metanephroi. The SWPU system allowed for continuous urine 
drainage from the developed bladder of the MNB into the recipient bladder via the 
recipient ureter. Even 8 weeks after transplantation, the MNB showed no hydrone-
phrosis and had maintained mature renal structures, such as glomeruli and renal 
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Furthermore, we demonstrated the generation of a urine excretion channel 
in MNB by using the stepwise peristaltic ureter (SWPU) system. Briefly, at an 
appropriate time, we connected the host ureter to the MNB graft containing urine 
produced by the metanephroi. The SWPU system allowed for continuous urine 
drainage from the developed bladder of the MNB into the recipient bladder via the 
recipient ureter. Even 8 weeks after transplantation, the MNB showed no hydrone-
phrosis and had maintained mature renal structures, such as glomeruli and renal 
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Figure 2. 
Schematic of our novel xeno-regenerative therapeutic strategy for kidney regeneration.
tubules. The levels of urea nitrogen and creatinine were much higher in the urine 
from the MNB than in the sera of recipients. Finally, the SWPU system significantly 
prolonged the lifespan of anephric rats in the MNB group compared with the 
nontransplanted group.
In a previous study, researchers demonstrated that they could create a urinary 
pathway by directly connecting the ureter of the transplanted metanephroi to the 
ureter of the host (ureteroureterostomy) to prolong the short-term survival of 
anephric rats [19]. However, the SWPU system is more efficient than ureteroure-
terostomy in terms of preventing hydronephrosis and allowing maturation of the 
metanephroi. Surgery for the SWPU system is also easier than that for uretero-
ureterostomy because the bladder of the MNB expands with urinary retention. 
Furthermore, we can join two metanephroi to a host ureter using the SWPU system, 
whereas it is difficult to connect two metanephroi to the host ureter. In a previous 
study, it was reported that the survival time in anephric rats correlated with the total 
volume of the grown metanephroi [52]. It is possible that the SWPU system is more 
effective than the conventional method in prolonging survival time for this reason.
Assuming that MNBs can be used as a scaffold for kidney regeneration before 
transplantation into patients with renal failure, we investigated the effects of host 
renal failure on the structure and activity of the transplanted MNB. Uremic condi-
tions were reproduced using a 5/6 renal infarction rat model, and 4 weeks after 
transplantation, the developed bladder was successfully anastomosed to the host 
ureter. At 8 weeks after transplantation, histological analysis showed the presence 
of mature glomeruli and tubules in the groups with and without renal failure. There 
were also no differences between these groups in terms of survival in anephric 
host rats, indicating that the grafts were responsible for prolonging host survival, 
even under renal failure conditions [53]. The results of this study demonstrate 
that a transplanted MNB can grow and function effectively, even under uremic 
conditions.
The use of MNB as a kidney regeneration scaffold can provide new treatment 
for patients with renal failure. We assume that the SWPU system will be applicable 
to human neo-kidneys regenerated via the NPC replacement system, using a pig 
MNB as a scaffold to establish the urinary excretion pathway. In brief, human 
iPSC-derived NPCs may be injected into the metanephroi of porcine fetuses that 
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are genetically manipulated to have an NPC elimination system. Human nephrons 
may then regenerate in porcine metanephroi by eliminating the porcine NPCs 
and replacing them with human NPCs. The MNB that has human kidneys will be 
transplanted into patients with end-stage renal disease, and an excretion pathway 
will be constructed. In this case, the regenerated kidneys will be of human origin, 
but the ureters and bladder of MNB will be of porcine origin (Figure 2). Although 
further investigation is required, we assume that replacing nephrons, which are the 
main targets to rejection, could decrease antigenicity.
8.  Regenerative potential of iPSCs derived from patients with renal 
failure
The use of iPSCs generated from patients holds promise for tailored therapy that 
uses patient-derived cells, tissues, or organs. In clinical settings, it is desirable to 
use patient-derived iPSCs as the cell source for neo-kidneys to circumvent immune 
rejection. However, because uremia can reduce the function of stem cells, it may be 
problematic to use stem cells derived from patients in renal failure. Previous studies 
have shown that uremia causes many toxic effects, including reduced proliferation 
capacity, abnormalities of differentiation, and angiogenic dysfunction in stem cells 
[54, 55]. We previously reported that gene and protein expression of p300-/CBP-
associated factor was significantly suppressed and that in vivo angiogenesis activa-
tion was decreased in hMSCs derived from patients with end-stage renal disease 
(ESRD) [56]. However, there have been no reports about the biological properties 
of iPSCs derived from patients with ESRD. In our recent study, iPSCs derived from 
patients with ESRD could differentiate into NPCs as efficiently as iPSCs derived 
from healthy controls. Moreover, NPCs derived from patients with ESRD showed 
the potential to become mature and vascularized nephrons in vivo, similar to the 
process in healthy control [57]. These findings suggest that iPSCs from patients 
with ESRD may still be a useful cell source for kidney regeneration.
9. Conclusions
In this chapter, we have described several potential alternatives to allotransplan-
tation, focusing on our novel xeno-regenerative therapeutic strategy for kidney 
regeneration. Although there are issues to be overcome with the treatment alterna-
tives that are being developed, recent advances in genetic recombination technol-
ogy and stem cell research may make them available in clinical practice. We have 
addressed the development of genetically modified pigs that possess an NPC elimi-
nation system and have performed experiments with NPCs derived from human 
iPSCs. To date, each step of our proposed strategy for kidney regeneration has 
been accomplished successfully in rodent models. This includes the regeneration of 
kidneys derived from transplanted NPCs via NPC replacement, the transplantation 
of regenerated kidneys into host animals, and the construction of a urine excre-
tion pathway (i.e., the SWPU system). Looking to the future, we aim to complete a 
series of studies to allow transplantation from pig to human, which should facilitate 
the translation of our strategies to clinical settings.
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Abstract
Pigs are valuable and essential large animal models for human medical applica-
tions, including for stem cell therapy. Moreover, substantial effort has been made 
to directly engraft genetically engineered pig organs in the human body and to use 
pigs as in vivo bioreactors for the growth and development of human cells, tissue, 
or organs. However, engraftment of human cells in pigs has not yet been achieved. 
Although severe combined immunodeficient pigs have been developed, which can 
accept human biological materials, these pigs do not have practical value at present 
owing to difficulty in their care. To overcome these current limitations, we have 
proposed the generation of operational immunodeficient pig models by simply 
removing the thymus and spleen, enabling the long-term accommodation of human 
tissue. In this review, we summarize research progress on xenotransplantation 
animal models that accept human cells, tissues, or organs.
Keywords: regenerative therapy, transplant, bioreactor, immune tolerance
1. Introduction
Organ transplantation is often the only possible treatment for a patient with 
organ failure. The organs are donated from either living or deceased donors, and 
thus the number of transplantable organs is limited and insufficient to meet the 
clinical demand. Consequently, some illegal or unethical transplantations along 
with transplant commercialism and tourism have emerged, representing a world-
wide problem.
The discovery of the potential of pluripotent stem cells (PSCs), including 
embryonic stem cells (ESCs) and induced PSCs (iPSCs), to regenerate tissues or 
organs offers new hope to overcome this situation. Human ESCs [1] and iPSCs [2] 
are now widely used to generate tissues or organs, and techniques for the in vitro 
production of specific cell types have been developed [3]. However, these strategies 
still have several limitations for clinical application, including the size, maturity, 
function, and risk of tumor formation after transplantation [4].
To solve these problems, large animal models for the transplantation of human 
PSC-derived cells, tissues, or organs are required. In this review, we summarize 
the animal models currently used in the development for xenotransplantation and 
highlight the efficacy and prospects of pig models to accept human tissues or organs.
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1. Introduction
Organ transplantation is often the only possible treatment for a patient with 
organ failure. The organs are donated from either living or deceased donors, and 
thus the number of transplantable organs is limited and insufficient to meet the 
clinical demand. Consequently, some illegal or unethical transplantations along 
with transplant commercialism and tourism have emerged, representing a world-
wide problem.
The discovery of the potential of pluripotent stem cells (PSCs), including 
embryonic stem cells (ESCs) and induced PSCs (iPSCs), to regenerate tissues or 
organs offers new hope to overcome this situation. Human ESCs [1] and iPSCs [2] 
are now widely used to generate tissues or organs, and techniques for the in vitro 
production of specific cell types have been developed [3]. However, these strategies 
still have several limitations for clinical application, including the size, maturity, 
function, and risk of tumor formation after transplantation [4].
To solve these problems, large animal models for the transplantation of human 
PSC-derived cells, tissues, or organs are required. In this review, we summarize 
the animal models currently used in the development for xenotransplantation and 
highlight the efficacy and prospects of pig models to accept human tissues or organs.
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2. Xenotransplantation in small animals (mouse and rat)
Immunosuppression is a key requirement for an animal to accept human tissues 
or organs, as a functional immune system will result in the host animals rejecting 
the human grafts. The nude mouse was the first immunosuppressed animal model 
developed in 1962 [5]. Nude mice lack T cells and can therefore accept human 
tumor cells. Subsequently, severe combined immunodeficient (SCID) mice were 
developed in 1983, which lack both B cells and T cells [6]. McCune et al. [7] suc-
cessfully transplanted a human fetal thymus, liver cells, and lymph node into SCID 
mice, resulting in the differentiation of human T cells and B cells. However, the rate 
of engraftment of human cells in these mice was low due to maintenance of their 
natural killer (NK)-T cell activity. Gerling et al. [8] developed NOD/SCID mice by 
crossbreeding SCID mice with NOD mice, a diabetes model due to autoimmunity 
in the pancreas, which also show low NK-T cell activity and macrophage function 
[9]. Combining the low activity of NK-T cells and macrophages in NOD mice with 
the lack of B cells and T cells in SCID mice, the use of NOD/SCID mice improved 
the engraftment rate of hematopoietic stem cells [10]. Ito et al. [11] produced NOG 
mice as a crossbreed of NOD/SCID mice and gamma(c)(null) mice, which com-
pletely lack NK-T cells, and achieved a dramatically improved engraftment rate of 
human hematopoietic cells.
We previously reported the successful transplantation of rat cells into SCID 
mice [12]. Isolated hepatocytes obtained from the rat liver were injected into 
urokinase-type plasminogen activator (uPA)/SCID mice, in which urokinase-type 
plasminogen accumulates specifically in the native liver causing the damaged 
liver. The mice served as bioreactors to allow the transplanted rat hepatocytes to 
proliferate in the mouse host, resulting in more than 95% of cells in the mouse 
liver being of rat origin. Oldani et al. [13] successfully developed a mouse-rat 
chimeric liver, which was transplanted in rats. They injected hepatocytes isolated 
from Lewis rats into C57Bl/6Fah−/−Rag2−/−Il2rg−/− mice to create chimeric livers, 
which were transplanted into rats with or without immunosuppression. Without 
immunosuppression, the recipient rats died from acute rejection, whereas rats 
with immunosuppression survived for more than 112 days and maturation of rat 
bile ducts was observed 4 months after transplantation. We also demonstrated 
that the nude rat model could serve as an in vivo bioreactor. Liver grafts from 
Syrian hamsters were transplanted into nude rats that administered several immu-
nosuppressive agents, including tacrolimus and mycophenolate mofetil (MMF). 
After auxiliary xenogenic partial liver transplantation, regeneration of the liver 
graft was observed, and its weight increased from pre-transplant to 7 days after 
transplantation [14].
These immunodeficient mouse models, including SCID, NOD/SCID, and NOG 
mice, are useful for research on regenerative medicine using human PSCs, allowing 
for evaluation of teratoma formation to confirm the differentiation of the cells into 
the three germ layers [1]. In addition, these models are widely utilized for evalua-
tion of tumorigenicity in human PSC-derived cells after transplantation [4], since 
human PSC-derived cells or tissues have a risk of tumor formation from contami-
nation of undifferentiated PSCs [15, 16]. Small animals such as mice and rats are 
widely applied as models in cell transplantation research owing to their ease of 
handling. However, small animals have limitations in terms of the number of cells 
that can be transplanted and evaluation of therapeutic efficacy, that is, a human 
clinical application might require the transplantation of several hundreds of million 
cells, which is impossible to accomplish in small animals. Moreover, large animal 
models are required for accurate evaluation of the efficacy of cell transplantation. 
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Furthermore, large animal models are expected to play roles as bioreactors for 
functionally mature human tissues or organs.
3. Xenotransplantation in middle and large animals (monkey and pig)
Chong et al. [17] transplanted human ESC-derived cardiomyocytes into the 
hearts of pig-tailed macaques as a nonhuman primate model. The main advan-
tage of this model is that the hearts are much larger (37–52 g) than those of mice 
(0.15 g), rats (1 g), and guinea pigs (3 g), which allowed for the transplantation 
of 1 × 109 cells into the infarcted myocardium and subsequent engraftment. The 
macaques were administered methylprednisolone, cyclosporine, and abatacept 
(a CTLA4 immunoglobulin) to prevent immune rejection. The efficacy of human 
ESC-derived cardiomyocytes in the infarcted hearts of pig-tailed macaques was 
demonstrated, and maturation of the transplanted ESC-derived cardiomyocytes 
was observed [18]. However, compared to an adult human, pig-tailed macaques 
are still relatively small (5.2–12.6 kg), and the heart is much smaller than that of a 
human (300 g).
Pigs are a suitable animal for preclinical studies and in vivo reactors in terms 
of their size and anatomy that correspond well to those of humans. To establish an 
immunosuppressed state that allows for transplantation of human PSC-derived 
cells or tissues into host pigs without rejection, SCID pigs were also developed [19]. 
Suzuki et al. [19] generated cloned pigs by serial nuclear transfer using fibroblasts 
with disruption of the X-linked interleukin 2 receptor subunit gamma (IL2RG) 
gene, as this mutation is known to cause X-linked SCID in humans. The SCID pigs 
accepted human cells, indicating their potential in preclinical studies and as in vivo 
reactors with human PSCs. However, raising these pigs is a technical challenge; 
among the 31 cloned piglets produced, only four survived for over 1 year. In addi-
tion, SCID pigs must be raised under meticulous hygiene conditions, which impose 
a further cost for their establishment and maintenance. Therefore, it is not practical 
to use SCID pigs as models in preclinical studies and in vivo reactors.
Total thymectomy is an alternative strategy to create immunosuppressed pigs 
that can accept human cells. Binns et al. [20] first proposed the concept of achiev-
ing immunosuppression by performing thymectomy in neonatal pigs in 1972. 
Microminiature pigs (MMPs) are smaller than domestic or ordinary miniature 
pigs and are thus suitable model animals for preclinical studies [21]. To develop 
immunodeficient MMPs, we performed thymectomy in neonatal pigs, which were 
transplanted with human hepatocytes that could engraft in the pig liver without 
any immunosuppressive agents [22]. To further improve the immunodeficient pig 
model, we performed splenectomy along with the thymectomy in 6–7-month-old 
miniature pigs and administered several immunosuppressive agents, including 
tacrolimus, MMF, and prednisolone, via a stomach tube [23]. This so-called opera-
tional immunodeficient miniature pig (OIDP) model allowed for the successful 
implantation of artificial human vascular tubes created by a three-dimensional 
bioprinting. Moreover, the human tube was inserted between the carotid artery and 
jugular vein to act as a shunt, and blood flow was observed for 3 months without 
immune rejection.
As mentioned above, establishment of a chimera is a potential strategy for 
growing human tissues or organs in large animals. Matsunari et al. [24] demon-
strated that blastocyst complementation can be applied to large animals by creat-
ing chimeric pigs. Specifically, they generated embryos from clones of porcine 
somatic cells, which showed an apancreatic phenotype, and their complementation 
Xenotransplantation - Comprehensive Study
138
2. Xenotransplantation in small animals (mouse and rat)
Immunosuppression is a key requirement for an animal to accept human tissues 
or organs, as a functional immune system will result in the host animals rejecting 
the human grafts. The nude mouse was the first immunosuppressed animal model 
developed in 1962 [5]. Nude mice lack T cells and can therefore accept human 
tumor cells. Subsequently, severe combined immunodeficient (SCID) mice were 
developed in 1983, which lack both B cells and T cells [6]. McCune et al. [7] suc-
cessfully transplanted a human fetal thymus, liver cells, and lymph node into SCID 
mice, resulting in the differentiation of human T cells and B cells. However, the rate 
of engraftment of human cells in these mice was low due to maintenance of their 
natural killer (NK)-T cell activity. Gerling et al. [8] developed NOD/SCID mice by 
crossbreeding SCID mice with NOD mice, a diabetes model due to autoimmunity 
in the pancreas, which also show low NK-T cell activity and macrophage function 
[9]. Combining the low activity of NK-T cells and macrophages in NOD mice with 
the lack of B cells and T cells in SCID mice, the use of NOD/SCID mice improved 
the engraftment rate of hematopoietic stem cells [10]. Ito et al. [11] produced NOG 
mice as a crossbreed of NOD/SCID mice and gamma(c)(null) mice, which com-
pletely lack NK-T cells, and achieved a dramatically improved engraftment rate of 
human hematopoietic cells.
We previously reported the successful transplantation of rat cells into SCID 
mice [12]. Isolated hepatocytes obtained from the rat liver were injected into 
urokinase-type plasminogen activator (uPA)/SCID mice, in which urokinase-type 
plasminogen accumulates specifically in the native liver causing the damaged 
liver. The mice served as bioreactors to allow the transplanted rat hepatocytes to 
proliferate in the mouse host, resulting in more than 95% of cells in the mouse 
liver being of rat origin. Oldani et al. [13] successfully developed a mouse-rat 
chimeric liver, which was transplanted in rats. They injected hepatocytes isolated 
from Lewis rats into C57Bl/6Fah−/−Rag2−/−Il2rg−/− mice to create chimeric livers, 
which were transplanted into rats with or without immunosuppression. Without 
immunosuppression, the recipient rats died from acute rejection, whereas rats 
with immunosuppression survived for more than 112 days and maturation of rat 
bile ducts was observed 4 months after transplantation. We also demonstrated 
that the nude rat model could serve as an in vivo bioreactor. Liver grafts from 
Syrian hamsters were transplanted into nude rats that administered several immu-
nosuppressive agents, including tacrolimus and mycophenolate mofetil (MMF). 
After auxiliary xenogenic partial liver transplantation, regeneration of the liver 
graft was observed, and its weight increased from pre-transplant to 7 days after 
transplantation [14].
These immunodeficient mouse models, including SCID, NOD/SCID, and NOG 
mice, are useful for research on regenerative medicine using human PSCs, allowing 
for evaluation of teratoma formation to confirm the differentiation of the cells into 
the three germ layers [1]. In addition, these models are widely utilized for evalua-
tion of tumorigenicity in human PSC-derived cells after transplantation [4], since 
human PSC-derived cells or tissues have a risk of tumor formation from contami-
nation of undifferentiated PSCs [15, 16]. Small animals such as mice and rats are 
widely applied as models in cell transplantation research owing to their ease of 
handling. However, small animals have limitations in terms of the number of cells 
that can be transplanted and evaluation of therapeutic efficacy, that is, a human 
clinical application might require the transplantation of several hundreds of million 
cells, which is impossible to accomplish in small animals. Moreover, large animal 
models are required for accurate evaluation of the efficacy of cell transplantation. 
139
Pigs as Models of Preclinical Studies and In Vivo Bioreactors for Generation of Human Organs
DOI: http://dx.doi.org/10.5772/intechopen.90202
Furthermore, large animal models are expected to play roles as bioreactors for 
functionally mature human tissues or organs.
3. Xenotransplantation in middle and large animals (monkey and pig)
Chong et al. [17] transplanted human ESC-derived cardiomyocytes into the 
hearts of pig-tailed macaques as a nonhuman primate model. The main advan-
tage of this model is that the hearts are much larger (37–52 g) than those of mice 
(0.15 g), rats (1 g), and guinea pigs (3 g), which allowed for the transplantation 
of 1 × 109 cells into the infarcted myocardium and subsequent engraftment. The 
macaques were administered methylprednisolone, cyclosporine, and abatacept 
(a CTLA4 immunoglobulin) to prevent immune rejection. The efficacy of human 
ESC-derived cardiomyocytes in the infarcted hearts of pig-tailed macaques was 
demonstrated, and maturation of the transplanted ESC-derived cardiomyocytes 
was observed [18]. However, compared to an adult human, pig-tailed macaques 
are still relatively small (5.2–12.6 kg), and the heart is much smaller than that of a 
human (300 g).
Pigs are a suitable animal for preclinical studies and in vivo reactors in terms 
of their size and anatomy that correspond well to those of humans. To establish an 
immunosuppressed state that allows for transplantation of human PSC-derived 
cells or tissues into host pigs without rejection, SCID pigs were also developed [19]. 
Suzuki et al. [19] generated cloned pigs by serial nuclear transfer using fibroblasts 
with disruption of the X-linked interleukin 2 receptor subunit gamma (IL2RG) 
gene, as this mutation is known to cause X-linked SCID in humans. The SCID pigs 
accepted human cells, indicating their potential in preclinical studies and as in vivo 
reactors with human PSCs. However, raising these pigs is a technical challenge; 
among the 31 cloned piglets produced, only four survived for over 1 year. In addi-
tion, SCID pigs must be raised under meticulous hygiene conditions, which impose 
a further cost for their establishment and maintenance. Therefore, it is not practical 
to use SCID pigs as models in preclinical studies and in vivo reactors.
Total thymectomy is an alternative strategy to create immunosuppressed pigs 
that can accept human cells. Binns et al. [20] first proposed the concept of achiev-
ing immunosuppression by performing thymectomy in neonatal pigs in 1972. 
Microminiature pigs (MMPs) are smaller than domestic or ordinary miniature 
pigs and are thus suitable model animals for preclinical studies [21]. To develop 
immunodeficient MMPs, we performed thymectomy in neonatal pigs, which were 
transplanted with human hepatocytes that could engraft in the pig liver without 
any immunosuppressive agents [22]. To further improve the immunodeficient pig 
model, we performed splenectomy along with the thymectomy in 6–7-month-old 
miniature pigs and administered several immunosuppressive agents, including 
tacrolimus, MMF, and prednisolone, via a stomach tube [23]. This so-called opera-
tional immunodeficient miniature pig (OIDP) model allowed for the successful 
implantation of artificial human vascular tubes created by a three-dimensional 
bioprinting. Moreover, the human tube was inserted between the carotid artery and 
jugular vein to act as a shunt, and blood flow was observed for 3 months without 
immune rejection.
As mentioned above, establishment of a chimera is a potential strategy for 
growing human tissues or organs in large animals. Matsunari et al. [24] demon-
strated that blastocyst complementation can be applied to large animals by creat-
ing chimeric pigs. Specifically, they generated embryos from clones of porcine 
somatic cells, which showed an apancreatic phenotype, and their complementation 
Xenotransplantation - Comprehensive Study
140
with allogenic blastomeres resulted in the development of a functional pancreas. 
Wu et al. [25] reported a successful pig-human chimera that was created by 
introducing human PSCs into fertilized pig eggs. Therefore, when combined 
with blastocyst complementation, human organs can be created in a human-pig 
chimera; however, these methods are associated with serious ethical and legal 
problems. Alternatively, the introduction of human-derived cells to pig fetuses 
can lead to immune tolerance, allowing for the acceptance of human PSC-derived 
tissues or organs.
4. Immune tolerance induction for xenotransplantation
Immune tolerance is defined as a lack of an immune response against particular 
antigens. In general, the immune system has tolerance to self-antigens and only 
responds to non-self-antigens, which is a challenge for transplantation, as the 
grafted cells or tissues are rejected and not able to survive in the host body. The 
phenomenon of immune tolerance was first described in 1945 in which anastomosis 
in the placenta was observed in twin calves, and they accepted each other’s skin 
grafts [26]. Hasek et al. [27] subsequently confirmed this phenomenon in chicken 
and duck by producing parabiosis in fertilized eggs. In 1953, Medawar et al. [28] 
established actively acquired tolerance by implanting a live antigen in the fetuses 
of mice or embryonic chicks. Using this method, Binns et al. [29] also tried to 
create immune tolerance in pigs by implanting bone marrow cells or lymphocytes 
from another pig into fetal pigs, resulting in prolonged survival of skin graft in the 
treated pigs.
In addition to these examples, induction of immune tolerance to human cells 
or tissues has been attempted in other animals. Kenneth et al. [30] transplanted 
human mesenchymal stem cells into fetal sheep early in gestation. Despite the 
xenogeneic condition, the human mesenchymal stem cells engrafted and survived 
in multiple tissues for up to 13 months after transplantation. These strategies of 
injecting human cells into a fetus were proven to result in immune tolerance to 
human cells after birth.
As MMPs have emerged as suitable candidates for immune tolerance induc-
tion to accept human cells, tissues, and organs owing to their useful applications 
in preclinical studies and in vivo reactors, it may be possible to create MMPs with 
immune tolerance to human cells by injecting a human antigen into pig fetuses 
without requiring the need to create human-pig chimeras [31].
5. Conclusions
Our newly developed OIDPs can accept human cells, tissues, and organs derived 
from human PSCs. These models will allow for long-term observation after the 
transplantation of human PSC-derived cells or tissues to better evaluate the safety 
and efficacy of the procedure. Moreover, if human cells, tissues, and organs are 
transplanted into piglets, they will grow in vivo along with the growth of the host 
pig. These grafts will then mature and be of suitable size with appropriate function 
for human application. Therefore, pigs can be suitable models for preclinical studies 
and serve as in vivo bioreactors for developing human tissues or organs (Figure 1). 
Transplantable MMPs without immunosuppressive agents are expected to be 
developed in the near future as promising and valuable animal models for research-
ers, which can dramatically promote regenerative medicine and organ transplant 
therapies with human PSCs.
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Figure 1. 
Schema of pigs as models of preclinical studies and in vivo bioreactors. (A) Adult operational immunodeficient 
miniature pigs (OIDPs) are useful for preclinical studies in regenerative medicine with human PSCs, enabling 
evaluation of the safety and efficacy of cell transplantation. In particular, after transplantation of human 
PSC-derived spheroids or organoids into the OIDPs, the risk of tumorigenicity can be evaluated. (B) Fetal 
or neonatal OIDPs are also useful as in vivo bioreactors, facilitating the efficient in vivo growth of immature 
human tissues. After immature human PSC-derived tissues or organs are transplanted into OIDPs, they will 
mature along with the growth of the host.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Recently, remarkable progress has been made in the area of preclinical 
xenotransplantation experiments. Surprisingly, a heterotopic heart from the gene-
editing pig continued to beat for almost 2.5 years, when implanted in the monkey 
abdomen, and a pig life-supporting kidney could also function for over 1.3 years in 
monkeys. Concerning islets, islets from gene-editing pigs could work for more than 
one year in monkeys. It is noteworthy that one group reported a survival of adult wild-
type pig islets of over 600 days. On the other hand, the progress in these preclinical 
trials strongly affected not only the xenotransplantation study itself but regeneration 
studies to use pigs as a scaffold to foster human induced pluripotent stem cells.
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